<!DOCTYPE html>
<html lang="en" xml:lang="en" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta charset="utf-8"/>
<meta content="SAS 9.4" name="generator"/>
<title>SAS Output</title>
<style>
/*<![CDATA[*/
.body.c > table, .body.c > pre, .body.c div > table,
.body.c div > pre, .body.c > table, .body.c > pre,
.body.j > table, .body.j > pre, .body.j div > table,
.body.j div > pre, .body.j > table, .body.j > pre,
.body.c p.note, .body.c p.warning, .body.c p.error, .body.c p.fatal,
.body.j p.note, .body.j p.warning, .body.j p.error, .body.j p.fatal,
.body.c > table.layoutcontainer, .body.j > table.layoutcontainer { margin-left: auto; margin-right: auto }
.layoutregion.l table, .layoutregion.l pre, .layoutregion.l p.note,
.layoutregion.l p.warning, .layoutregion.l p.error, .layoutregion.l p.fatal { margin-left: 0 }
.layoutregion.c table, .layoutregion.c pre, .layoutregion.c p.note,
.layoutregion.c p.warning, .layoutregion.c p.error, .layoutregion.c p.fatal { margin-left: auto; margin-right: auto }
.layoutregion.r table, .layoutregion.r pre, .layoutregion.r p.note,
.layoutregion.r table, .layoutregion.r pre, .layoutregion.r p.note,
.layoutregion.r p.warning, .layoutregion.r p.error, .layoutregion.r p.fatal { margin-right: 0 }
article, aside, details, figcaption, figure, footer, header, hgroup, nav, section { display: block }
html{ font-size: 100% }
.body { margin: 1em; font-size: 13px; line-height: 1.231 }
sup { position: relative; vertical-align: baseline; bottom: 0.25em; font-size: 0.8em }
sub { position: relative; vertical-align: baseline; top: 0.25em; font-size: 0.8em }
ul, ol { margin: 1em 0; padding: 0 0 0 40px }
dd { margin: 0 0 0 40px }
nav ul, nav ol { list-style: none; list-style-image: none; margin: 0; padding: 0 }
img { border: 0; vertical-align: middle }
svg:not(:root) { overflow: hidden }
figure { margin: 0 }
table { border-collapse: collapse; border-spacing: 0 }
.layoutcontainer { border-collapse: separate; border-spacing: 0 }
p { margin-top: 0; text-align: left }
h1.heading1 { text-align: left }
h2.heading2 { text-align: left }
h3.heading3 { text-align: left }
h4.heading4 { text-align: left }
h5.heading5 { text-align: left }
h6.heading6 { text-align: left }
span { text-align: left }
table { margin-bottom: 1em }
td, th { text-align: left; padding: 3px 6px; vertical-align: top }
td[class$="fixed"], th[class$="fixed"] { white-space: pre }
section, article { padding-top: 1px; padding-bottom: 8px }
hr.pagebreak { height: 0px; border: 0; border-bottom: 1px solid #c0c0c0; margin: 1em 0 }
.stacked-value { text-align: left; display: block }
.stacked-cell > .stacked-value, td.data > td.data, th.data > td.data, th.data > th.data, td.data > th.data, th.header > th.header { border: 0 }
.stacked-cell > div.data { border-width: 0 }
.systitleandfootercontainer { white-space: nowrap; margin-bottom: 1em }
.systitleandfootercontainer > p { margin: 0 }
.systitleandfootercontainer > p > span { display: inline-block; width: 100%; white-space: normal }
.batch { display: table }
.toc { display: none }
.proc_note_group, .proc_title_group { margin-bottom: 1em }
p.proctitle { margin: 0 }
p.note, p.warning, p.error, p.fatal { display: table }
.notebanner, .warnbanner, .errorbanner, .fatalbanner,
.notecontent, .warncontent, .errorcontent, .fatalcontent { display: table-cell; padding: 0.5em }
.notebanner, .warnbanner, .errorbanner, .fatalbanner { padding-right: 0 }
.body > div > ol li { text-align: left }
.beforecaption > h4 { margin-top: 0; margin-bottom: 0 }
.c { text-align: center }
.r { text-align: right }
.l { text-align: left }
.j { text-align: justify }
.d { text-align: right }
.b { vertical-align: bottom }
.m { vertical-align: middle }
.t { vertical-align: top }
.accessiblecaption {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.aftercaption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.batch > col, .batch > colgroup > col, .batch > colgroup, .batch > tr, .batch > * > tr, .batch > thead, .batch > tbody, .batch > tfoot { border: none; }
.batch {
    background-color: #ffffff;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: 'SAS Monospace', 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    padding: 7px;
    }
.beforecaption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.body {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    margin-left: 8px;
    margin-right: 8px;
}
.bodydate {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    text-align: right;
    vertical-align: top;
    width: 100%;
}
.bycontentfolder {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.byline {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.bylinecontainer > col, .bylinecontainer > colgroup > col, .bylinecontainer > colgroup, .bylinecontainer > tr, .bylinecontainer > * > tr, .bylinecontainer > thead, .bylinecontainer > tbody, .bylinecontainer > tfoot { border: none; }
.bylinecontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.caption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.cell, .container {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.contentfolder, .contentitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.contentproclabel, .contentprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.contents {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
    margin-left: 8px;
    margin-right: 8px;
}
.contentsdate {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.contenttitle {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.continued {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
    width: 100%;
}
.data {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.dataemphasis {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.dataemphasisfixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.dataempty {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.datafixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.datastrong {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.datastrongfixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.date {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.document, .errorbanner, .errorcontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.errorcontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.extendedpage {
    background-color: #ffffff;
    border-style: solid;
    border-width: 1pt;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
    text-align: center;
}
.fatalbanner, .fatalcontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.fatalcontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.folderaction {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.footer {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footeremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.footeremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.footerempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footerfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.footerstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footerstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.frame {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.graph > col, .graph > colgroup > col, .graph > colgroup, .graph > tr, .graph > * > tr, .graph > thead, .graph > tbody, .graph > tfoot { border: none; }
.graph {
    background-color: #ffffff;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.header {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headeremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.headeremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.headerempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headerfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.headersandfooters, .headerstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headerstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.index, .indexaction {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.indexitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.indexprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.indextitle, .linecontent, .list, .list10, .list2, .list3, .list4, .list5, .list6, .list7, .list8, .list9, .listitem, .listitem10, .listitem2, .listitem3, .listitem4, .listitem5, .listitem6, .listitem7, .listitem8, .listitem9, .note, .notebanner, .notecontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.notecontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.output > col, .output > colgroup > col, .output > colgroup, .output > tr, .output > * > tr, .output > thead, .output > tbody, .output > tfoot { border: none; }
.output {
    background-color: #cccccc;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.pageno {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
    text-align: right;
    vertical-align: top;
}
.pages {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
    margin-left: 8px;
    margin-right: 8px;
}
.pagesdate {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.pagesitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.pagesproclabel, .pagesprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.pagestitle, .paragraph {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.parskip {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.prepage, .proctitle {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.proctitlefixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooter {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooteremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowfooteremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowfooterempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooterfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.rowfooterstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooterstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheader {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderemphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowheaderemphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowheaderempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.rowheaderstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.systemfooter, .systemfooter10, .systemfooter2, .systemfooter3, .systemfooter4, .systemfooter5, .systemfooter6, .systemfooter7, .systemfooter8, .systemfooter9 {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: bold;
}
.systemtitle, .systemtitle10, .systemtitle2, .systemtitle3, .systemtitle4, .systemtitle5, .systemtitle6, .systemtitle7, .systemtitle8, .systemtitle9 {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: medium;
    font-style: normal;
    font-weight: bold;
}
.systitleandfootercontainer > col, .systitleandfootercontainer > colgroup > col, .systitleandfootercontainer > colgroup, .systitleandfootercontainer > tr, .systitleandfootercontainer > * > tr, .systitleandfootercontainer > thead, .systitleandfootercontainer > tbody, .systitleandfootercontainer > tfoot { border: none; }
.systitleandfootercontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.table > col, .table > colgroup > col, .table > colgroup, .table > tr, .table > * > tr, .table > thead, .table > tbody, .table > tfoot { border: none; }
.table {
    background-color: #cccccc;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.titleandnotecontainer > col, .titleandnotecontainer > colgroup > col, .titleandnotecontainer > colgroup, .titleandnotecontainer > tr, .titleandnotecontainer > * > tr, .titleandnotecontainer > thead, .titleandnotecontainer > tbody, .titleandnotecontainer > tfoot { border: none; }
.titleandnotecontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.titlesandfooters, .usertext, .warnbanner, .warncontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.warncontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
/*]]>*/
</style>
</head>
<body class="c body">
<div style="padding-bottom: 8px; padding-top: 1px">
<div id="IDX" class="systitleandfootercontainer" style="border-spacing: 1px">
<p><span class="c systemtitle">Lipids data set 2</span> </p>
</div>
<div style="padding-bottom: 8px; padding-top: 1px">
<table class="table" style="border-spacing: 1px" aria-label="Data Set REF.LIPIDS_SORTED_2">
<caption aria-label="Data Set REF.LIPIDS_SORTED_2"></caption>
<colgroup><col/><col/><col/></colgroup>
<thead>
<tr>
<th class="r header" scope="col">sub_ref_no</th>
<th class="header" scope="col">Title</th>
<th class="header" scope="col">Main_Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td class="r data">1</td>
<td class="data">HDL and type 2 diabetes: the chicken or the egg?</td>
<td class="data">Based on the current literature, a bidirectional correlation between HDL dysfunction and type 2 diabetes exists, leading to a perpetual self-feeding cycle (Fig. 1). It is increasingly evident that not all HDL disturbances are causatively associated with the development and progression of type 2 diabetes. Most recent clinical and epidemiological data indicate that an optimal range of plasma HDL-C concentrations exists in humans. Even though very high HDL-C levels appear to correlate with dysfunctional HDL, this does not necessarily preclude a substantial benefit when raising ones HDL-C from very low levels to levels within the optimal range. The notion that HDL proteome dictates its lipidome and subsequently HDL particle functionality [11] suggests that alterations in the HDL metabolic pathway have substantial influence on its properties and functions. However, the interrelation between HDL lipidome, proteome and particle functionality is a missing part of the puzzle, which remains as yet unsolved. HDL, the sleeping beauty of lipoproteins, is waiting for its prince to awake her therapeutic potential. Understanding HDL functionality and the factors affecting it in diabetic individuals remains a crucial step towards better glucose homeostasis. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The significance of HDL-C optimal ranges
1. A bidirectional correlation between HDL dysfunction and type 2 diabetes exists.
2. An optimal range of plasma HDL-C concentration exists in humans.
3. Raising one’s HDL-C levels from very low to levels within the optimal range may translate to benefit.
4. HDL proteome dictates its lipidome and HDL particle functionality.
5. Understanding HDL functionality in diabetic individuals remains a crucial step towards better glucose homeostasis. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">2</td>
<td class="data">The role of miR-320 in glucose and lipid metabolism disorder-associated diseases</td>
<td class="data">Although glucose and lipid metabolism disorder-associated diseases have been recognized for many years, the effective prevention and treatment strategies remain elusive. In this article, we first reviewed that miR-320 might be a potential biomarker for metabolic diseases, such as obesity, diabetes, and its complications, which provided a new diagnostic strategy for these diseases. Then, we systematically described the effects of miR-320 on glucose and lipid metabolism disorder-associated diseases. For clinical application, multiple studies suggested that the aberrant expression of miRNAs played essential roles in various diseases, which provided a new therapeutic strategy [149]. Here, we reviewed the diagnostic and therapeutic strategies for glucose and lipid metabolism disorder-associated diseases by targeting miR-320. Moreover, we provided a summary table to better illustrate the various miRNAs indicated in the text (Table 1).  XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">3</td>
<td class="data">HDL Particle Subspecies and Their Association With Incident Type 2 Diabetes: The PREVEND Study</td>
<td class="data">In this large population based-cohort study, we discerned the association of HDL size and various HDL subclasses (small, medium, and large HDL particles) and subspecies (H1P-H7P) determined with a novel NMR-based algorithm with incident T2D in the general population. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We found that larger HDL size and higher H4P concentrations were inversely associated with T2D development, whereas H2P levels were positively associated with T2D development after multiple adjustments. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In secondary analyses, large HDL particles and H6P were also inversely associated with T2D in fully adjusted analyses, in subjects with BMI &lt; 30 kg/m2. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In obese subjects, in contrast, such independent associations were not observed. Furthermore, higher concentrations of large HDL and H6P were associated with incident T2D in women. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The inverse association of HDL-C with T2D development as shown in earlier epidemiological studies has been translated into a potential protective influence of HDL-C against incident T2D (4-6). Consequently HDL-C has been included in risk scores of T2D prediction drawn from the Framingham Offspring Study Diabetes Mellitus and the Diabetes Prediction Model risk scores (3, 5). XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX HDL does not represent a single lipoprotein fraction (commoly assessed by the HDL-C concentration) but includes a diverse group of particles which may differ in their alleged antidiabetic roles (9-12, 36) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the current study, HDL-C was positively associated with large and medium HDL, as well as with HP3, HP4, HP6, and HP7, and inversely with small HDL as well as with HP1, HP2, and HP5. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A potentially important novel observation of our study is the inverse association of large HDL and the positive association small HDL with incident T2D remained after adjustment for age, sex, and HDL-C. This suggest that such associations of NMR-assayed HDL sub-fractions may be clinically meaningful beyond measurement of HDL-C per se. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The association between different HDL particle sub-classes (small, medium, and large) and HDL size with incident T2D has been studied recently, including application of NMR methodology. Higher concentrations of large HDL and greater HDL size were suggested to be inversely associated with incident T2D (8, 17-19). XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, the association between medium and small HDL particles and incident T2D was evaluated only in a limited number of studies (16-18). These previous studies were conducted in different populations with varying ethnicities, and the HDL variables studied were not uniformly adjusted for covariates (16-19) XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Interestingly, the current study expanded the investigation of HDL with incident T2D by assessing its association with 7 different HDL subspecies and demonstrated for the first time the positive and inverse associations of H2P and H4P, respectively, with incident T2D in adjusted analyses. Furthermore, the association between the larger subspecies H6P and H7P and incident T2D were independent of metabolic factors but not of HOMA-IR, triglycerides, and LDL-C. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In comparison, we recently documented an inverse association of H6P with development of post-transplantation diabetes in renal transplant recipients (22). A salient feature of HDL subclasses and subspecies distribution and their associations with T2D could be explained by their relationships with BMI and insulin resistance as confirmed in the current study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Insulin resistance is appreciated to be associated with fewer large HDL particles and a decrease in HDL particle size (15, 16, 37, 38). XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Of further interest, the correlation between phospholipid content of HDL subfractions separated by gel filtration chromatography and HDL subspecies as quantified by NMR spectroscopy was reported recently (37, 39). Fractions with low phospholipid content appeared very similar to H7P and H6P, respectively, as assessed by NMR, while the fraction with high phospholipid content appeared very similar to H2P as assessed by NMR (37). Fractions with a low phospholipid content were inversely correlated with HOMA-IR (37). Moreover, HDL remodeling consequent to insulin resistance and T2D results in HDL particles with fewer cholesteryl esters (40, 41). XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Taken together, these findings make it necessary to adjust for adiposity and/or insulin resistance when evaluating the association of HDL  subfractions and subspecies with newly developed T2D. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX HDL particles may convey protective effects on β-cells in vitro, allegedly by mediating cellular cholesterol efflux (CEC) and possibly also by its antioxidative function (42, 43). A  positive correlation between CEC and large and medium HDL particles and HDL size, and an inverse correlation between CEC and small HDL particles were reported using J774 macrophages (44, 45). Although in another study CEC was only associated with the HDL particle concentration (46), this may link impaired HDL function to adiposity and/or insulin resistance coinciding with smaller HDL particles (23, 47). XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Another key process that could link T2D development with HDL function is the proprotein convertase subtilisin/kexine type 9 (PCSK9) pathway which may affect β-cell function by regulating cellular cholesterol homeostasis (48). PCSK9 also regulates sphingosine-1-phosphate, an important mediator of HDL function (49). XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, the antioxidative function of HDL, an HDL metric possibly involved in maintaining β-cell function (43), is impaired in metabolic syndrome subjects after correction for HDL-C (24). XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, HDL remodeling is at least in part consequence of changes in cholesteryl ester transfer protein (CETP) activity which in turn is affected by triglyceride-rich lipoproteins, and phospholipid transfer protein (PLTP) (40, 41, 46, 50, 51). Of note, recent studies suggest that administration of CETP inhibitors may decrease diabetes risk, but higher PLTP activity is associated with increased diabetes risk (52, 53). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These findings raise the possibility that alterations in the HDL particle profile consequent to changes in CETP and PLTP could affect T2D development. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Secondary analyses suggested that large HDL particles and H6P were inversely associated with incident T2D in non-obese subjects but not in obese subjects. This could be interpreted as a result of altered HDL function in individuals with obesity and metabolic syndrome. Obesity and metabolic syndrome are not only assocated with lower HDL-C and fewer large HDL particles but also with impaired HDL function exemplified as CEC (23, 54), consistent with dysfunctional HDL (55). In support of this, 2 randomized controlled studies found a beneficial effect of weight loss surgery on improving HDL function in patients with obesity (56, 57). XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Also, serum paraoxonase-1 (PON1), an antioxidative enzyme which predominantly associates with large HDL particles (58) and relates to PLTP activity (59), is impaired in metabolic syndrome subjects (60). However, paraoxonase-1 activity did not predict T2D development, making the role of this antioxidative enzyme in T2D development uncertain (61). XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The association between HDL-C and HDL particles with development of T2D have been reported to vary with sex. Higher levels of HDL-C represented a protective marker of incident T2D in women but not in men (62, 63). Additionally, higher large HDL particles, as well as greater HDL size but reduced small HDL particles, were protective against T2D in 2 previous studies in women (17, 64), consistent with our findings showing an inverse association between large HDL particles and H6P with incident T2D in women but not in men. Furthermore, higher HDL-C and higher concentration of large HDL particles in women compared with men (25, 26) could be explained by different sex hormone effects on HDL metabolism. While exogenous estrogen increases predominately large HDL, testosterone may decrease large HDL (65, 66). Hence, we confirm that decreased large HDL particles and subspecies (H6P) may be risk markers for T2D development especially in women. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">4</td>
<td class="data">High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease</td>
<td class="data">Our results add to the growing evidence that ApoB is the primary causal determinant for CAD risk among lipoprotein measurements. (8, 17, 18) XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Cholesterol underlies the development of atherosclerosis. (19) It enters the arterial wall within those ApoB-containing lipoprotein particles that are small enough to enter the tunica intima from the circulation; these particles include small VLDL, IDL and LDL particles as well as lipoprotein(a). XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The recent genetic evidence, together with the results in this work, strongly point towards the direction that the lipid content of the particles is secondary to ApoB. (8, 18, 20) These results do not invalidate LDL-cholesterol as a causal risk factor for CAD risk. Indeed, LDL particles contain an apolipoprotein B molecule, as do IDL and VLDL particles. ApoB (in particular ApoB-100) represents the total number of hepatic-derived lipoprotein particles. (21) However, this investigation suggests that the clinical benefit of lowering triglyceride and LDL-C levels is proportional to the absolute change in ApoB. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX ApoB measurements are independent of particle density, and are not affected by heterogeneity of particle cholesterol content. (22) This is particularly important for accurately capturing the number of small dense LDL particles, which are believed to be associated with atherosclerosis. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX ApoB has been shown to be a superior measure to LDL-cholesterol in the prediction of CAD risk (23) and in prediction of coronary artery calcification. (24) From a clinical perspective, statins target LDL-cholesterol levels rather than ApoB, suggesting that greater benefit might be obtained from lipid-lowering drugs that target lipoprotein particle number. (25) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX When analysing data from UK Biobank only, there was also some evidence for triglyceride content measures as an additional risk factor. This was not evident in the main analysis or the sensitivity analysis including data from the earlier CARDIoGRAMplusC4D release. This finding should therefore be interpreted with some caution. There are some caveats to the interpretation of the results of this study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although we were able to distinguish between measures of cholesterol content and triglyceride content for some categories of lipoprotein particles, we were not able to distinguish between other lipoprotein measures, such as cholesterol ester and phospholipid content, which correlated almost perfectly with cholesterol content. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
CONCLUSION =&gt; In conclusion, our agnostic investigation to identify risk factors for CAD strongly prioritized ApoB, suggesting that ApoB, representing the number of hepatic-derived lipoprotein particles, is the key determinant of CAD risk among
lipid-related measurements. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This analysis demonstrates the potential of publicly available genetic association data from high-throughput experiments combined with modern data-adaptive statistical learning techniques, for obtaining biological insights into disease aetiology. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">5</td>
<td class="data">Ceramides in Adipose Tissue</td>
<td class="data">The data described in this review and others in this series, identify ceramides as critical lipid metabolite that modulate adipose tissue function, homeostasis, and contribute to metabolic
disease. Moreover, interventions that reduce ceramide synthesis in adipose tissue, delay, or prevent various comorbidities of obesity, such as insulin resistance and liver steatosis. These discoveries, while exciting, raise several essential questions to be answered to validate ceramide as a potential therapeutic target. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First, can additional mechanisms be identified to explain ceramide action? Although initial studies identified a couple of key mechanisms (i.e., regulation of Akt) for ceramide actions, the numerous effects (e.g., regulation of thermogenic program, mitochondrial function) elicited by ceramide seems unlikely to be fully explained solely by PP2A-Akt axis or PKCz-Akt axis. Therefore, identifying additional molecular mechanisms will be crucial for understanding the roles of ceramides such that the therapeutic strategy could be developed accordingly. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, what is the role of immune-cell ceramide content in maintaining adipose tissue homeostasis? How do ceramides regulate these cell populations and how do they interact with adipocytes to gauge nutrient content? XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, how do b-adrenergic’s inhibit ceramide synthesis in adipose tissue? Delineation of the molecular targets downstream of the b-adrenergic receptor may offer additional interventional strategies to target ceramide synthesis. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Fourth, are there additional regulators (nutrients / enzymes) that modulate intracellular ceramide content? The recent development of the ceramide flux assays coupled with secondary biochemical assays might favor the identification of more regulators and lead to additional strategies to safely target ceramide synthesis for its therapeutic use. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Fifth, how various enzymes in sphingolipids synthesis and degradation pathways coordinate to maintain lipid homeostasis, particularly in response to various local and systemic stimuli. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">6</td>
<td class="data">Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study</td>
<td class="data">This biomarker study showed inverse associations of baseline plasma n-3 fatty acids and DHA with the risk of macrovascular events and for n-3 fatty acids with the risk of death among individuals with type 2 diabetes. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These inverse associations appeared approximately linear, and among the macrovascular events, n-3 fatty acids and DHA demonstrated stronger associations with cardiovascular death and non-fatal stroke. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, no significant associations were observed for the predominant fatty acids such as n-6 fatty acids, LA, MUFA and SFA with the risk of macrovascular events and death, after adjustment for multiple traditional risk factors. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The prospective associations of circulating n-3 fatty acids and DHA with the risk of CVD are consistent with the prior studies. According to previous pooled analyses, DHA in whole plasma was associated with a lower risk of fatal and non-fatal CHD (RR [95% CI]: 0.78 [0.69, 0.90] and 0.91 [0.84, 0.98], respectively) in people without a history of CVD [9]. In addition, another study reported that plasma n-3 fatty acids were associated with a lower risk of non-fatal myocardial infarction [21]. Similar inverse associations with CHD and stroke were observed in other studies which measured n-3 fatty acids in plasma phospholipid [10, 22–24], whole blood [25] and serum [26], among people without prior CVD. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These studies did not assess the C statistic and NRI; however, the present study did not detect significant improvement in predicting macrovascular events by adding n-3 fatty acids or DHA into the model including traditional cardiovascular risk factors. This indicates that the predictive power of plasma n-3 fatty acids and DHA may be limited in the presence of a complement of traditional cardiovascular risk factors. On the other hand, cardiovascular benefits of high-dose supplementation with n-3 fatty acids were recently observed in REDUCE-IT, where there were potentially greater benefits of n-3 fatty acid supplementation in those with lower plasma levels of n-3 fatty acids. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast to generally consistent results from observational studies of circulating n-3 fatty acids and DHA, the effects of n-3 fatty acid supplementation on cardiovascular outcomes in RCTs have been mixed [4, 6, 27–30]. The recent study, A Study of Cardiovascular Events in Diabetes (ASCEND) trial, of 15,480 individuals with diabetes free of prior CVD, which tested n-3 fatty acid supplementation (1 g/day) for 7.4 years, did not lower the risk of composite major vascular outcomes, while only vascular deaths were less frequent in the supplementation group than in the placebo group (RR 0.82 [95% CI 0.68, 0.98]) [31]. On the other hand, the recent AHA science advisory has suggested that the use of n-3 fatty acid supplementation was probably justified in individuals at high cardiovascular risk [8, 28]. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In REDUCE-IT, which used high-dose (4 g/day) n-3 fatty acid supplementation in 8179 individuals with established CVD or with diabetes and other risk factors, the risk of composite cardiovascular outcomes was substantially reduced (HR 0.75 [95% CI 0.68, 0.83]) [7]. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, some secondary analyses from large trials have reported the benefit of n-3 fatty acid supplementation on CVD in diabetic populations with hypercholesterolaemia [32], chronic heart failure [33] and history of myocardial infarction [34]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further investigation of the benefits of n-3 fatty acid supplementation will, therefore, be required among people with type 2 diabetes and high CVD risks. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Several mechanisms may explain the favourable associations between n-3 fatty acids and the risk of CVD. Previous clinical trials looking at intermediate cardiovascular outcomes among people with diabetes have reported that n-3 fatty acid supplementation could lower triacylglycerol concentrations [35, 36], improve arterial blood flow and attenuate inflammatory signals [37, 38]. These effects were supported by clinical trials in the general population and in experimental studies [39–41]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The present study observed the inverse associations between baseline plasma n-6 fatty acids and LA with the risk of death, but these associations attenuated after adjustment for multiple risk factors. Similar findings have been reported between serum LA and mortality in a cohort of older adults (≥65 years of age) [42]. We did not, however, detect significant associations between n-6 fatty acids and LA with the risk of macrovascular events. These results were consistent with those of previous observational studies [23, 24, 43] and directionally concordant with the recent pooled analyses of 30 cohort studies which reported that higher circulating and tissue levels of LA were associated with a lower risk of major cardiovascular events (HR 0.93 [95% CI 0.88, 0.99]) [44]. In addition, our study did not detect significant associations with the risk of CVD for circulating MUFA and SFA, which is consistent with previous studies [24, 43, 45], while some studies have reported that MUFA in blood were associated with a higher risk of CVD [46]. There were no significant associations between any fatty acids and the risk of microvascular events. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A further analysis specifically for renal outcome also demonstrated no significant associations. Although limited studies have assessed the association between circulating fatty acids and renal outcomes, in an Italian cohort of 931 adults, plasma n-3 fatty acids were inversely associated with the risk of developing renal insufficiency (creatinine clearance rate &lt;60 ml/min) [47]. However, in a cohort of 2792 individuals, levels of n-3 and n-6 fatty acids and SFA in plasma phospholipid were not associated with kidney function [48]. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  CONCLUSIONS =&gt; In conclusion, we report distinct associations of different plasma fatty acids with the risk of major clinical outcomes in individuals with type 2 diabetes. In particular, plasma n-3 fatty acids were associated with a lower risk of macrovascular disease and death, and DHA was associated with a lower risk of macrovascular disease. These results support the cardioprotective effects of n-3 fatty acids and DHA and further merit testing the role of high-dose n-3 fatty acid supplementation in individuals with type 2 diabetes.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">7</td>
<td class="data">Plasma Metabolomics Identifies Markers of Impaired Renal Function: A Meta-analysis of 3089 Persons with Type 2 Diabetes</td>
<td class="data">In this study, we investigated associations between plasma metabolites and kidney function (cross-sectionally and longitudinally) in individuals with T2D. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The key findings include several novel associations between eGFR and circulating amino acids, TGs, lipids in VLDL sub-classes, free fatty acids, and lipids in HDL subclasses cross-sectionally. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX eGFR slopes associated with tyrosine and subclasses of HDL lipoproteins (before correction for multiple testing). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX None of the metabolites measured were significantly associated with urinary albumin excretion. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These findings are in line with results from a recent study in type 1 diabetes where metabolites were mainly associated with eGFR and not albuminuria (29). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The AAA phenylalanine was strongest inversely associated with eGFR levels, followed by the BCAA isoleucine and the polar amino acid glutamine. This result replicates findings from a recent study by Barrios et al, where a strong inverse cross-sectional association between phenylalanine and eGFR was demonstrated both in 926 individuals with T2D and 4838 individuals without diabetes, after adjusting for age, sex, BMI, statin use, and hormone replacement therapy (18). Barrios et al did not find an association between phenylalanine and longitudinal changes in eGFR, similar to the findings in this study. Higher phenylalanine and lower tyrosine levels due to impaired renal conversion of phenylalanine have previously been reported in renal disease (30,31). In our study, a positive association between tyrosine and eGFR was also observed cross-sectionally and longitudinally. Recently, the results of ADVANCE trial in 3587 individuals with T2D demonstrated a positive association of phenylalanine with macrovascular diseases and all-cause mortality; however, this was attenuated after adjustment for cardiovascular risk factors. Moreover, this study showed an inverse association between tyrosine and microvascular complications (17). XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This trial demonstrated that higher levels of aromatic (histidine) and branched-chain (leucine) amino acids were associated with a lower risk of all-cause mortality. This is in line with our findings in which histidine and leucine were inversely associated with eGFR. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In a study by Niewczas et al comparing T2D progressors (n = 40) to ESRD and non-progressors (n = 40), higher levels of phenylalanine, tyrosine, and leucine were associated with a lower risk of  progression to ESRD during 12 years follow-up, albeit the results were not statistically significant after adjustment for HbA1c, albumin excretion, eGFR, and multiple testing (32). XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, we previously reported that higher glutamine was most significantly associated with having an HbA1c &lt; 53 mmol/L (33). XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this study, eGFR was inversely associated with TGs, lipid measures in VLDL subclasses, sphingomyelin, and fatty acids like omega-6 and linoleic acid but positively associated with lipid measures, except TGs, in HDL sub-classes. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This inverse relationship is in line with results in both individuals with and without diabetes from the previously mentioned study by Barrios et al (18). The associations between these lipid measures and longitudinal endpoints of ESRD and macro- or microvascular complications have to our knowledge not been tested in any study in people with T2D. We identified the lipids in HDL to be associated positively with longitudinal eGFR slopes among T2D, which became non-significant after FDR correction. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These could be correct signals reflecting cross-sectional results on eGFR in our study. The longitudinal results in our study may have missed the multiple testing threshold due to lower statistical power (n = 1100) compared to cross-sectional meta data where we had 3089 individuals.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX On the other hand, we cannot undermine the possibility of inter-metabolite relatedness as suggested by the sensitivity analysis (correlation heatmap) that may reduce the number of tests. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, in a longitudinal study by the FinnDiane Study Group including 3544 individuals with type 1 diabetes, the TG–cholesterol imbalance was associated with progression in albuminuria and all-cause mortality, as was a large HDL cholesterol (14). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Previous studies in large cohorts of dyslipidemia and DKD have demonstrated associations between routinely measured higher TG and lower HDL cholesterol levels to the progression of DKD in individuals with T2D (39,40). Higher TG and lower HDL cholesterol are clinical components of the metabolic syndrome and may also be consequences of the underlying insulin resistance (41). XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Targeting HDL cholesterol or phospholipids may be a future therapeutic approach, although previous clinical studies with HDL cholesterol increasing agents—for example, torcetrapib (42) in high-risk individuals of cardiovascular disease—have demonstrated increased risk of mortality and morbidity of unknown mechanism. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In a small study by Drew et al (n = 13), intravenous reconstituted HDL infusion in patients with T2D increased plasma insulin. It activated adenosine 5′-monophosphates–activated protein kinase in skeletal muscle when compared to placebo (43). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSION =&gt; In conclusion, the current largest-to-date study identifies metabolites associated with an impaired eGFR among individuals with T2D while none of the metabolites measured were significantly associated with urinary albumin excretion.  XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These results suggest that cholesterol and phosphoglycerides in HDL subclasses may be associated with a better kidney function while high levels of several amino acids and fatty acids, lipids in VLDL sub-classes, and TGs in all lipoproteins are associated with an impaired kidney function. The findings suggest alterations in the metabolome associated with renal impairment in T2D of primary importance in non-albuminuric DKD or the early stages of disease before development of albuminuria. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">8</td>
<td class="data">Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease</td>
<td class="data">We found lower prevalence of fibrosis (Figure 1 and Table 1) and increased concentration of phospholipids in the livers of subjects carrying the HSD17B13 rs72613567:TA variant compared with non-carriers (Figure 2). XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Analysis of the liver transcriptome using RNA-seq and qPCR revealed marked downregulation of multiple inflammation-related gene sets (Figure 3). X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Plasma concentrations of the key proinflammatory cytokine, IL-6, were lower in carriers of the HSD17B13 variant as compared with non-carriers (Figure 3). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Metabolic pathways contributing to (intrahepatic triglyceride) IHTG synthesis, including (De-novo lipogenesis) DNL and the rate of in vivo lipolysis and hepatic insulin sensitivity, were unaltered in carriers of the HSD17B13 variant compared with non-carriers (Figure 4). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The prevalence of fibrosis, the most important predictor of mortality in NAFLD (17), was significantly lower in carriers compared with non-carriers of the HSD17B13 variant (Figure 1 and Table 1), consistent with the study of Abul-Husn et al. (1) and that of Pirola et al. in 356 patients with biopsy-proven NAFLD (3). In the latter 2 studies, as in the present study, the HSD17B13 variant was not associated with a change in steatosis (Figure 1) (1, 3). In a larger study comprising 756 adults with biopsy-proven NAFLD, Ma et al. found increased steatosis in carriers compared with non-carriers of the HSD17B13 variant (rs72613567:TA) (2). Unlike previous studies, features of non-alcoholic steatohepatitis (NASH) were similar in our data (Figure 1 and Table 1). This could reflect a smaller sample size compared with previous studies. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Concentrations of hepatic phospholipids, including PCs and PEs, but not other lipids including triglycerides, DAGs, or ceramides, were increased in variant allele carriers compared with non-carriers (Figure 2). This lipid pattern is geometrically opposite to that seen in deficiency of choline, an essential nutrient, in which concentrations of PCs and PEs are decreased (18, 19). Dietary restriction of choline predisposes to fatty liver in humans, and its daily requirements to prevent liver dysfunction are highly variable (18, 20, 21). In mice, dietary restriction of choline and/or genetic inhibition of hepatic PC synthesis lead to liver inflammation, NASH (22), and liver failure (23). In contrast, increasing PC synthesis by choline treatment has been shown to prevent both sugar- and alcohol-induced cirrhosis in rats in carefully performed studies published in 1949 (24). Moreover, dietary supplementation of PC has been shown to protect against alcohol-induced liver fibrosis and cirrhosis in non-human primates, possibly by promoting collagen breakdown (25). Decreased expression of a phospholipid degrading enzyme PLD4 (Figure 3C) suggests that the phospholipid surplus could be secondary to the reduced degradation of phospholipids in HSD17B13 variant carriers as compared with non-carriers. Phospholipids constitute the surface layer of lipid droplets, and their excess could be hypothesized to enhance storage capacity of lipid droplets, in keeping with increased hepatic expression of a key lipid droplet protein, LPIN3, in HSD17B13 variant carriers (Figure 3C). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The present data thus raise the possibility that the HSD17B13 variant might protect against progressive liver disease, perhaps especially in choline-depleted individuals, by increasing synthesis and/or decreasing breakdown of hepatic phospholipids. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The molecular mechanisms linking phospholipids and progression of fibrosis are poorly understood, but at least in choline- and methionine-depleted models include altered redox status and inflammation (26). XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Analysis of the liver transcriptome in 86 subjects using RNA-seq revealed downregulation of 254 gene sets while only 2 gene sets were upregulated in carriers compared with non-carriers (Figure 3). The down-regulated genes were predominantly key inflammatory genes, such as ALOX5 and TGFB2. In keeping with the gene expression data, plasma concentrations of IL-6, a proinflammatory cytokine that has increased concentrations in NASH (27), were decreased in carriers of the HSD17B13 variant as compared with non-carriers (Figure 3D). These data are consistent with previous data on effects of the HSD17B13 variant on the liver transcriptome in the study of Pirola et al. who compared 8 carriers to 5 non-carriers (3). XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Free fatty acids originating from lipolysis and DNL are two major pathways contributing to IHTG synthesis (16). Although steatosis was not different in the present study or studies by Abul-Husn et al. (1) or Pirola et al (3), pathways of IHTG could still be different, as has been described for the PNPLA3 I148M gene variant (28). However, the HSD17B13 variant does not seem to alter either DNL or adipose tissue lipolysis when measured using state-of-the-art isotope techniques, including deuterated water and glycerol. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Unlike NAFLD associated with the PNPLA3 I148M and the TM6SF2 E167K gene variants, common NAFLD is characterized by insulin resistance (29). This is the first study to our knowledge to quantify insulin sensitivity using the euglycemic clamp technique combined with infusion of tritiated glucose between HSD17B13 variant allele carriers and non-carriers. No data on glucose and insulin concentrations were reported in studies by Abul-Husn et al. (1) or Ma et al. (2). Unlike the latter studies, in the study of Pirola et al. (3), homozygous variant allele carriers were significantly less obese than the heterozygous subjects or noncarriers (3). We found that the HSD17B13 variant allele did not affect any measure of insulin sensitivity. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX If viewed from the perspective of the effect of choline deficiency on insulin sensitivity, previous studies in mice fed a choline-deficient diet, which induces steatosis and mild inflammation, showed that mice do not exhibit insulin resistance (30). Thus, the higher concentrations of PCs and PEs in carriers than non-carriers of the HSD17B13 variant would not be expected to change insulin sensitivity.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; We conclude that carriers of the HSD17B13 variant are protected against liver fibrosis and that they have phospholipid surplus in the liver and marked downregulation of genes and plasma cytokines related to inflammation. Steatosis and pathways leading to steatosis, including DNL and lipolysis, are unchanged. All of these features are geometrically opposite to those observed in choline-deficient models in mice and humans and suggest that HSD17B13 might be an attractive pharmaceutical target in liver disease. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">9</td>
<td class="data">A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes</td>
<td class="data">In this study, we investigated the effect of 12 weeks of treatment of dapagliflozin, an SGLT2i, on plasma levels of more than 800 identified metabolites.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In general, our results show that treatment of dapagliflozin in the fasting situation is associated with increased amino acid metabolites and reduced levels of lipid species from several subclasses. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We used a bioinformatic approach to delineate molecular pathways that may contribute to the renal protective effects of the SGLT2i dapagliflozin. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Overlap at the gene expression level between metabolites targeted by dapagliflozin and intra-renal transcripts associated with DKD pointed to upregulation of the metabolites belonged to the sub-pathway of BCAA, while the corresponding BCAAs were not changed (9). XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Also, urea and urea cycle metabolites, including N2, N5 diacetyl-ornithine, N-delta-acetylornithine and argininate, were similarly increased in the two studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast to the findings of Kappel et al, (9) we observed decreased levels of TCA metabolites. The reason for the different response is unclear but may be attributable to many factors such as different populations or treatment durations. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Whereas Kappel et al found increased levels of acetyl-, propionyl- and β-hydroxybutyrylcarnitine, we have observed increased levels of butyrylcarnitine (10) and, in this study, reduced plasma levels of myristoylcarnitine. When fatty acid oxidation is incomplete, surplus acyl-groups are exported from mitochondria as acylcarnitines (16).  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Reduced levels of acylcarnitines could therefore reflect a larger degree of complete fatty acid oxidation. In contrast to the long-chain acylcarnitines, fasting increases the release of short-chain carnitines, including acetylcarnitine and propionylcarnitine from the hepatosplanchnic bed (17). Several 3-hydroxy fatty acids decreased by dapagliflozin and high levels of these fatty acids are markers of fatty acid oxidation disorders (18). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Together, these results could indicate improved fatty acid oxidation and an enhanced fasting response with a surplus of 2- and 4-chain carbons. Plasma metabolomics have also been investigated in animal models treated with SGLT2is. Treatment of obese non-diabetic mice with canagliflozin showed activation of catabolic pathways including fatty acid oxidation and signs of inhibition of mTOR, while there was activation of AMPK (19). XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In another study, the effects of ipragliflozin on metabolites were investigated in a model of diabetic nephropathy on Black and Tan BRachyury (BTBR) ob/ob mice (20). In line with our results, they observed that SGLT2is reduced the high levels of TCA cycle intermediates in the kidney of BTBR ob/ob mice. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Collectively, findings from these cross-species studies underscore the metabolic effects of SGLT2is, which may potentially contribute to long-term clinical benefits. SGLT2i treatment increases haemoglobin and haematocrit. To what extent this is secondary to plasma contraction or increased red cell mass is unknown (21). Heme, an intermediate in haemoglobin metabolism, is one of the metabolites significantly increased after dapagliflozin treatment. Increased heme levels could reflect an increased heme synthesis, but also reduced degradation of heme by heme oxygenase. Reduced plasma levels of bilirubin could indicate reduced heme degradation because carbon oxide and biliverdin, which is further reduced to bilirubin, are the end-products of heme oxygenase activity (22). Regardless of the exact underlying mechanism, the increase in heme supports a potential effect of SGLT2is on haematopoiesis (23). XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The molecular pathways selected through our bioinformatic approach have been associated with progressive renal function loss in patients with type 2 diabetes (24-26). The bioinformatics analysis showed that dapagliflozin treatment increased the TCA cycle activity. Expression of several TCA cycle enzymes was associated with increased eGFR, indicating a positive effect on renal mitochondrial function. Increased levels of metabolites and intermediates of the TCA cycle have been associated with DKD and endoplasmatic reticulum stress (24,27). The cause of the reduced levels of TCA-cycle intermediates is not clear, but may be explained by improved mitochondrial efficacy, as reflected by indications of a larger degree of complete fatty acid oxidation as well as increased gluconeogenesis, which may take place both in the liver and the kidney to compensate for urinary glucose loss. Additional support of the salutary effects on mitochondrial function is our finding that kynurenine was reduced while picolinic acid, a product of kynurenine metabolism, increased. This finding may indicate increased activity of the kynurenine pathway and increased production of quinolinic acid and NAD+ that may further support improved mitochondrial function after dapagliflozin treatment. Also, the increased plasma levels of NAA indicate improved mitochondrial function, specifically in the brain (15). XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In line with these observations, a recent study showed that a metabolite panel previously associated with reduced mitochondrial function improved after dapagliflozin in patients with type 2 diabetes and chronic kidney disease (28). Moreover, studies in experimental animals have shown improved mitochondrial function both in the heart and renal tubules following treatment with SGLT2is (29,30). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These data together support the notion that long-term renal protective effects of SGLT2is may be mediated through amelioration of mitochondrial function. We also found the superpathway of citrulline metabolism to be associated with DKD progression and targeted/increased by dapagliflozin, as evidenced by the increase in urea and reduction in glutamine. The citrulline pathway involves nitric oxide synthase as one of the key enzymes which generates citrulline from arginine in a single reaction step. Nitric oxide synthase-derived nitric oxide exerts a wide array of effects and acts in the blood vessels as a potent vasodilator, exerting anti-thrombotic effects, and also has anti-inflammatory effects (31). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Several studies have shown that SGLT2 inhibition in patients with type 2 diabetes improves endothelial function as measured by reactive hyperemia peripheral arterial tonometry and flow-mediated dilation and endothelial dysfunction has been associated with accelerated renal function decline (32-34). The exact mechanism of how SGLT2 inhibition improves endothelial function is not fully understood but may involve improved glycaemic and metabolic control, osmotic diuresis, and changes in sodium homeostasis as a result of increased natriuresis. The current study supports a potential role for improvements in endothelial function, through the citrulline pathway, as one of the potential mediators of the protective effects of
SGLT2 inhibition on kidney function. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The results of the bioinformatics approach indicated a change in the glycine degradation pathway after dapagliflozin treatment. Denovo creatine synthesis starts by the conversion of glycine and arginine to ornithine and guanidinoacetate by glycine amidinotransferase (GATM), and guanidinoacetate is then converted to creatine by guanidinoacetate N-methyl-transferase (GAMT), a reaction which is dependent on S-adenosylmethionine as methyl donor (35). In this study, plasma creatine levels increased, while the creatine precursor, guanidinoacetate, was reduced, indicating increased GAMT activity. Alternatively, reduced GATM activity explains reduced levels of guanidinoacetate and therefore increased creatine levels must be explained by causes other than changed synthesis, such as increased dietary intake of creatine. Overall, the bioinformatics analysis suggested reduced activity of the pathway, although we cannot rule out the possibility that increased creatine levels are the result of increased GAMT activity. Therefore, the suggestion of reduced glycine degradation should be carefully interpreted. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast to previous studies, this study combined metabolomics and transcriptomics to identify metabolites and pathways associated with dapagliflozin response. This approach is potentially applicable in other chronic disease settings and can be used to identify novel biomarkers for disease progression and drug efficacy and safety monitoring.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; In conclusion, the molecular pathways targeted by dapagliflozin and associated with DKD suggest that molecular processes related to energy metabolism, mitochondrial function and endothelial function may be involved in the renal protective effects of dapagliflozin. These data confirm existing and offer novel hypotheses about the molecular effects of dapagliflozin in slowing the progression of DKD. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">10</td>
<td class="data">Selecting likely causal risk factors from high-throughput experiments using multivariable Mendelian randomization</td>
<td class="data">We here introduce MR-BMA, an approach for multivariable MR which allows for the analysis of high-throughput experiments. This model averaging procedure prioritises and selects causal risk factors in a Bayesian framework from a high-dimensional set of related candidate risk factors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX As is common for statistical techniques for variable selection, MR-BMA does not provide unbiased estimates. However, as shown in the simulation study, causal estimates from MR-BMA have reduced variance and thus MR-BMA improves over unbiased approaches, like the IVW method, in terms of mean squared error and detection of true risk factors.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The primary aim of this work is to detect causal risk factors rather than to unbiasedly estimate the magnitude of their causal effects. MR-BMA is a multivariable MR approach that can analyse a high-dimensional set of risk factors. XXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX When analysing many risk factors jointly one important implicit assumption of MR-BMA is sparsity, i.e., the proportion of true causal risk factors compared with all risk factors considered is small. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Since MR-BMA evaluates all possible combinations of risk factors exhaustively or all relevant combinations of risk factors in a shotgun stochastic search there is an upper bound for the maximum model size in order to keep the computation tractable. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Sparsity is a common assumption for high-throughput data and we have seen in the applied example that the best models only contained one to three metabolites as risk factors despite allowing for a model size of up to twelve risk factors. Yet this is an important aspect of the algorithm and the maximum model size should be adjusted if models including many risk factors are expected or evidenced in the data. We demonstrated the approach with application to a dataset of NMR metabolites, which included predominantly lipid measurements, using variants associated with lipids as instrumental variables. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Previous MR analysis (23, 24) including three lipid measurements from the Global Lipids Genetics Consortium (19) have identified HDL cholesterol as potential risk factor for (age related macular degeneration) AMD. Our approach to multivariable MR refined this analysis and confirmed HDL cholesterol as a potential causal risk factor for AMD, further pinpointing that large or extra-large HDL particles are likely to be driving disease risk. Other areas of application where this method could be used include imaging measurements of the heart and coronary artery disease, body composition measures and type 2 diabetes, or blood cell traits and atherosclerosis. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX As multivariable MR accounts for measured pleiotropy, this approach facilitates the selection of suitable genetic variants for causal analyses. In each case, it is likely that genetic predictors of the set of risk factors can be found, even though finding specific predictors of, for example, particular heart measurements from cardiac imaging, may be difficult given widespread pleiotropy (25). XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX MR-BMA allows a more agnostic and hypothesis-free approach to causal inference, allowing the data to identify the causal risk factors. Multivariable MR estimates the direct effect of a risk factor on the outcome and not the total effect as estimated in standard univariable MR. This is in analogy with multivariable regression where the regression coefficients represent the association of each variable with the outcome when all others are held constant. Having said this, the main goal of our approach is risk factor selection, and not the precise estimation of causal effects, since the variable selection procedure shrinks estimates towards the null. This results in causal effect estimates being biased towards the Null when there is a causal effect and unbiased estimates when there is no causal effect. If there are mediating effects between the risk factors, then this approach will identify the risk factor most proximal to and has the most direct effect on an outcome. For example, if the risk factors included would form a signalling cascade (Supplementary Fig. 1b) then our approach would identify the downstream risk factor in the cascade with the direct effect on the outcome and not the upstream risk factors in the beginning of the cascade. Hence, a risk factor may be a cause of the outcome, but if its causal effect is mediated via another risk factor included in the analysis, then it will not be selected in the multivariable MR approach. Our approach is formulated in a Bayesian framework. Particular care needs to be taken when choosing the hyper-parameter for the prior probability which relates to the a priori expected number of causal risk factors. In the applied example the results were robust to a wide range of prior specifications for the parameter as seen in Supplementary Table 10. In addition, the prior variance of the causal parameters needs to be specified and tested for robustness as we show in the Supplementary Table 11. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX When genetic variants are weak predictors for the risk factors, this can introduce weak instrument bias. In univariable two sample MR, any bias due to weak instruments is towards the null and does not lead to inflated type 1 error rates (26). However, in multivariable MR, weak instrument bias can be in any direction (see Methods), although bias will tend to zero as the sample size increases and consequently the instrument strength increases. Selection of risk factors is only possible if there are genetic variants that are predictors of these risk factors. One of the biggest challenges of multivariable MR is the design of a meaningful study, in particular the choice of both, the genetic variants and the risk factors. The design of the study is important for the interpretation of the risk factors prioritised: The ranking of risk factors is conditional on the genetic variants used. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For instance, in our applied example we find evidence for extra-large and large HDL cholesterol concentration given that we used lipid-related genetic variants as instrumental variables. We recommend to include only risk factors which have at least one, and ideally multiple genetic variants that act as strong instruments. Caution is needed for the interpretation of null findings, particularly in our example for non-lipid risk factors, as these might be deprioritised in terms of statistical power by our choice of genetic variants. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The instrument selection and general study design are essential for the MR-BMA approach and we strongly recommend the user to be critical in the choice of genetic variants and risk factors. Moreover, similar to standard MR we urge to perform model checks and be transparent in the presentation of the removal of outlier / influential genetic variants. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A further requirement for multivariable MR is that the genetic variants can distinguish between risk factors (12). We recommend to check the correlation structure between genetic associations for the selected genetic variants and to include no pair of risk factors which is extremely strongly correlated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the applied example, we included only risk factors with an absolute correlation &lt;0.99. As we were not able to include more than three measurements for each lipoprotein category (cholesterol content, triglyceride content, diameter), care should be taken not to overinterpret findings in terms of the specific measurements included in the analysis rather than those correlated measures that were excluded from the analysis (such as phospholipid and cholesterol ester content). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Another assumption of multivariable MR is that there is no unmeasured horizontal pleiotropy. This means that the variants do not influence the outcome except via the measured risk factors. The assumption of no horizontal pleiotropy is a common and untestable assumption in MR. It is an active area of research to robustify MR against violations of this assumption. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Some of these robust methods for MR make a specific assumption about the behaviour of pleiotropic variants, such as MR-Egger (27), which assumes pleiotropic effects are uncorrelated from the genetic associations with the risk factor—the InSIDE assumption. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Other methods exclude outlying variants as they are potentially pleiotropic such as MR-PRESSO (28). XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In multivariable MR, pleiotropic variants can be detected as outliers to the model fit. Here we quantify outliers using the q-statistic. Outlier detection in standard univariable MR can be performed by model averaging where different subsets of instruments are considered (29, 30), assuming that a majority of instruments is valid, but without prior knowledge which are the valid instruments. In multivariable MR, ideally one would like to perform model selection and outlier detection simultaneously. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, we search for genetic variants that are influential points. While these may not necessary be pleiotropic, we suggest removing such variants as a sensitivity analysis to judge whether the overall findings from the approach are dominated by a single variant. Findings are likely to be more reliable when they are evidenced by multiple genetic variants.  XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
CONCLUSION =&gt; In conclusion, we introduce here MR-BMA, the first approach to perform risk factor selection in multivariable MR, which can identify causal risk factors from a high-throughput experiment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX MR-BMA can be used to determine which out of a set of related risk factors with common genetic predictors are the causal drivers of disease risk. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">11</td>
<td class="data">Association of genetic variants related to plasma fatty acids with type 2 diabetes mellitus and glycaemic traits: a Mendelian randomisation study</td>
<td class="data">The present MR study found evidence that genetic predisposition to higher plasma levels of ALA (alpha-linolenic acid), LA (linoleic acid), (palmitoleic acid) POA and  (Oleic acid) OA were associated with lower odds of type 2 diabetes, lower fasting glucose and higher HOMA-B score, whereas genetic predisposition to higher plasma levels of (eicosapentaenoic acid) EPA, (docosapentaenoic acid) DPA, (arachidonic acid) AA and (stearic acid) SA were associated with higher odds of type 2 diabetes, higher fasting glucose and lower HOMA-B score. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The associations except that for POA were driven by variants in FADS1/2, which explained the major proportion of variance in plasma fatty acid levels. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A major limitation of this MR study is that SNPs in the FADS1/2 gene cluster were associated with most fatty acids and only three or fewer SNPs were available as instrumental variables for individual fatty acids, except for POA. This limited the possibility for disentangling the association of individual fatty acids with type 2 diabetes, and performing sensitivity analyses to explore pleiotropy. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The strong associations of FADS1/2 with fatty acid levels are not surprising because FADS1 and FADS2 encode Δ-5 desaturase and Δ-6 desaturase, respectively, which are key rate-limiting enzymes in the metabolism of fatty acids (Fig. 1). XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Strong correlations between circulating biomarkers is not only an issue in the present MR study but can also be an issue in for example MR studies on metabolomics where several metabolites can be highly correlated. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our results are broadly in agreement with those of previous smaller studies of the associations of FADS1 and FADS2 genetic variants or Δ-5 and Δ-6 desaturase activities with type 2 diabetes. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A Chinese case–control study, including 331 individuals with type 2 diabetes and 421 healthy control individuals, found that the minor allele (T) of rs174616 in the FADS1-FADS2 gene cluster was associated with decreased AA/LA ratio and lower odds of type 2 diabetes [24]. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Results from a nested case-cohort study of 2653 German adults showed no overall association of rs174546, which is in complete linkage disequilibrium with rs174547, with type 2 diabetes [25]. However, that study revealed that a higher proportion of LA in erythrocytes and lower proportions of γ-linolenic acid and dihomo-γ-linolenic acid were associated with lower risk of type 2 diabetes. Furthermore, fatty acid ratios that reflect Δ5 desaturase and Δ-6 desaturase activity were respectively inversely and positively associated with type 2 diabetes [25]. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Similarly, results from a Finnish cohort study (407 overweight adults) [26] and an Iranian case–control study (95 individuals with type 2 diabetes and 95 without) [27] showed that Δ-5 desaturase activity was inversely associated with type 2 diabetes. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, a cross-sectional study of 576 Korean men showed that variants in the FADS gene cluster were associated with the proportions of LA, dihomo-γ-linolenic acid, and AA in serum phospholipids as well as with fasting insulin levels and HOMA-IR [28]. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Available data on the associations of circulating POA levels with the risk of type 2 diabetes and glycaemic traits are inconsistent [29–33]. Several population-based observational studies found that increased plasma or erythrocyte membrane POA level was associated with higher blood glucose levels [29], insulin resistance [30] and incidence of diabetes [31]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, in a prospective longitudinal study including 3630 Americans, circulating level of POA was not associated with the risk of diabetes and the positive association between POA level and insulin resistance was merely observed among men [30]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, several studies concluded that increasing plasma POA level lowered fasting insulin, insulin resistance and the risk of type 2 diabetes [32]; this has been verified by cell experimental studies [33]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the present study, genetic evidence, excluding the influences from FADS and GCKR, supports a protective effect of increasing POA levels on fasting glucose level and type 2 diabetes. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Discrepancy between these findings may be attributable to residual confounding commonly affecting observational studies, such as type 2 diabetes-related nutrients, lifestyle determinants or endogenous sources introduced by dietary POA intake or de novo lipogenesis (e.g. key enzymes in fatty acid metabolism inflammatory factors and metabolic traits encoded by POA synthesis-related genes). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX As for potential biological mechanisms, the associations of plasma fatty acid levels and genetic variations in FADS1/2 with type 2 diabetes may be mediated by impaired glucose tolerance and beta cell dysfunction, as suggested by the present MR study. It has been postulated that POA may prevent beta cell apoptosis induced by glucose or SFAs [34]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Fatty acids are crucial structural components of cell membranes. The flexibility of a membrane, determined by the ratio of unsaturated to saturated fatty acyl chains of its phospholipids, influences the effectiveness of glucose transport via insulin-dependent glucose transporters [35]. A shift from unsaturated towards saturated fatty acyl chains of membrane phospholipids results in a decrease in glucose effectiveness and insulin sensitivity [36]. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Fatty acids are further precursors of eicosanoids, which may affect type 2 diabetes risk through inflammation [36, 37]. An experimental study in mice showed that loss of Δ-5 desaturase activity promoted hepatic inflammation and implied that endogenously synthesised AA and EPA are key determinants of inflammatory disease progression [38]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Associations of fatty acids with type 2 diabetes might also be explained by the effects of fatty acids on the gastrointestinal tract [37], intestinal microbiome [39] and nervous system [37]. XXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A further mechanism whereby fatty acids might affect the risk of type 2 diabetes is through blood cholesterol levels, which are inversely associated with risk of type 2 diabetes [40]. A meta-analysis of 60 trials revealed that SFAs increase total cholesterol and LDL-cholesterol levels, whereas MUFAs and PUFAs have the opposite effect, and that all types of fatty acid increase HDL-cholesterol levels [41]. The minor allele (C) of both rs174547 and rs102275 is associated with decreased levels of LDL-cholesterol, HDL-cholesterol and total cholesterol [42]. Thus, we would have expected a higher rather than lower odds of type 2 diabetes for the minor allele of rs174547 and rs102275 if the associations were mediated by cholesterol levels. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; This MR study showed that genetic predisposition to higher plasma ALA, LA, POA and OA levels and lower EPA, DPA, AA and SA levels was associated with lower odds of type 2 diabetes, lower fasting glucose levels and higher HOMA-B score. However, the causality for any individual fatty acid, except POA, cannot be inferred from this study due to the high correlation between the fatty acids. Notably, the observed associations, except that for POA, appeared to be driven by genetic variants in or close to FADS1/2.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">12</td>
<td class="data">Plasma Lipidomic Profiling and Risk of Type 2 Diabetes in the PREDIMED Trial</td>
<td class="data">We have identified several individual molecular species and some lipid classes prospectively associated with T2D risk. Baseline LP (LPC and LPE), PC-PL, SM, and CE scores were inversely associated with the risk of T2D, whereas baseline TAG, DAG, and PE scores were directly associated with T2D incidence. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For 1-year changes in these scores, associations beyond baseline levels were mainly nonsignificant, although the point estimates remained in the same direction. However, these 1-year change analyses had suboptimal power. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We found that both LPCs and LPEs, grouped as LPs, were associated with reduced risk of T2D. Previous studies found that LPC levels were lower in individuals with obesity, insulin resistance, and T2D (17–19). In fact, increased levels of LPCs have been defined as indicators of metabolic health in obesity, as LPCs appear to have glucose-lowering and anti-inflammatory effects (20). Similarly, LPC and LPE levels were reported to be lower in patients with T2D, and in patients with diabetes, lower levels of
these lipids were associated with higher risk of CVD (21). Similarly to LP, we also found that PCPLs were inversely related to T2D risk. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Plasmalogens have been widely investigated because of their role as endogenous antioxidants, limiting the oxidation of other lipids (7,22). They may also decrease the risk of T2D through other beneficial mechanisms, such as antiapoptotic and anti-inflammatory functions (7). XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A few studies (23,24), including the EPIC-Potsdam study (25), have reported an inverse association of SMs with T2D, consistent with our results. A study of a large cohort of patients with prediabetes and diabetes also reported inverse associations between plasma odd-chain SMs and T2D (6). The knockout model of SM synthase results in mitochondrial dysfunction and impaired glucose stimulated insulin secretion, which provides mechanistic support for our findings (26). XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Unexpectedly, we found an inverse association of CEs with T2D. Contrary to our findings, previous cross-sectional studies have reported strong direct associations with T2D (6,27). However, we found similar inverse associations between CEs and CVD in the PREDIMED trial (28). It is possible that we could have detected the defined “atherogenic lipoprotein phenotype” in subjects at high T2D risk (high plasma levels of TAGs, low levels of HDL, and atypically dense LDL particles). In this situation, LDL particles are loaded with TAGs instead of CEs, and after the hydrolysis of TAGs in the liver, lipid-depleted LDL particles (small and dense) are released (29). By losing their lipid core, these particles also lose antioxidant vitamins and become dense and oxidatively damaged, which may trigger foam-cell formation and therefore atherosclerosis. This lipoprotein phenotype has also been suggested for insulin resistance and eventually T2D (30). We found that DAG, TAG, and PE scores were strongly associated with a higher risk of T2D. Higher circulating levels of DAG and short TAGs have been previously associated with T2D (6,31). Thus, our findings confirm this positive association, highlighting the adverse role of short and saturated / low unsaturated species (31). Interestingly, after adjusting each individual TAG for the total TAG score, we observed that odd-chain TAGs were inversely associated with T2D. Odd-chain fatty acids, especially C15:0 and C17:0, have been described as biomarkers of dairy product intake (32) and have been reported to be inversely associated with T2D (6,33) and CVD (34). Thus, it seems important to consider the specific fatty acid content of TAGs to establish plasma risk profiles for T2D. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our results confirm previous studies that have found that PEs are associated with high fasting glucose and T2D (6). PEs are a minor species in plasma, but they are important structural lipids in membranes. An increase in PEs and an imbalance between PC and PE have been related to obesity and non-alcoholic fatty liver disease (35–37), which are both related to T2D (6). Supplementary Table 6 displays the description of the studies used to compare and discuss the lipidome profiles associated with T2D in our population. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; Our results have important implications in helping to clarify the biological mechanisms underlying the link between dyslipidemia and T2D. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX They also suggest that in subjects at high T2D risk, a plasma lipid profile characterized by high levels of DAGs, short TAGs, and PEs and low levels of LPs, PC-PLs, SMs, and CEs could be identified before T2D onset, which could enable early intervention. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">13</td>
<td class="data">Identification and characterization of prescription drugs that change levels of 7-dehydrocholesterol and desmosterol</td>
<td class="data">HIGH-THROUGHPUT SCREENING FOR COMPOUNDS THAT TARGET CHOL BIOSYNTHESIS =&gt; Multiple analytical methods were used to screen compounds in a chemical library of FDA-approved drugs in two variants of the N2a cell line: the background cell type or “WT” (WT-N2a) and a Dhcr7-deficient cell line (D7-N2a). XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our primary analytical protocol makes use of a derivatization procedure (PTAD) to provide sensitive, selective, and rapid assays of the penultimate sterols in the Chol biosynthetic pathway, Des and 7-DHC. This method was adapted to the use of high-throughput screening instruments to semi-automate the experimental procedures from cell culture to analysis. The protocol provides absolute levels of Des, 7-DHC, and Chol normalized to cell count in UPLC / MS runs of 1 min, making possible the ability to screen commercial chemical libraries for drugs that impact Chol biosynthesis. For the data presented here, less than 3 days of mass spectrometer instrument time were used to provide the lead-hit prioritization of compounds that affect some step in Chol biosynthesis, from HMGCR to DHCR7 or DHCR24. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A first-pass screen using the PTAD protocol identifies an initial lead-hit list, which can then be verified by the use of established analytical methods to provide a more complete sterol profile. These established methods (35, 36) consume more instrument time making them less amenable for use with high throughput screening. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It should be noted that the experimental conditions of the screening procedures do involve the use of a medium with a known quantity of Chol, a known component of serum. Thus follow-up multiday experiments involving the conditioning of cells to serum-free, and thus Chol-free, medium were conducted to minimize confounding sources of Chol detected in the analysis. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX N2a cells are exceptionally useful for screening purposes because they are relatively rich in Chol (16 nmol per million cells) and Des (2.5 nmol per million cells), but 7-DHC is found at much lower levels (0.1 nmol per million cells). XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The PTAD method uses a multiple reaction mass spectrometric method that is particularly selective for 7-DHC, making it possible to readily identify library compounds that affect DHCR7 by detecting increases in the levels of 7-DHC. Analysis of 7-DHC in D7-N2a cells provides complimentary information to the screens of compounds in WT-N2a cells. D7-N2a cells have much higher levels of 7-DHC (4 nmol per million cells) than N2a and lower levels of Des (1 nmol per million cells) than the WT cell line (supplemental Fig. S1). XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A compound that affects any of the transformations that precede the formation of 7-DHC in Chol biosynthesis is detected by a reduction in the levels of 7-DHC present in the D7-N2a cells. Thus, compounds that inhibit HMGCR are readily detected by a decrease in levels of 7-DHC in D7-N2a cells without a compensatory increase in Chol. In a similar way, DHCR24 inhibitors decrease levels of 7-DHC in these cells, as do compounds that affect other transformations between HMGCR and DHCR24. In this study, one in five of the FDA-approved drugs screened was identified to have an impact on Chol biosynthesis in some manner. A number of the lead-hit compounds are well-known, such as the statins, which inhibit HMGCR (37), or azole fungicides (38) that target Cyp51. Additionally, twenty-one of the lead hits identified in this screen, including the antipsychotic, aripiprazole (30), were similarly identified in a screen of a National Institutes of Health clinical collection chemical library (25, 26) with similar Z scores (R2 &gt; 0.95). It is nevertheless of interest that 82 of the drugs that were identified in this study had an effect on levels of Des or 7-DHC that was previously unreported. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It is also of interest to put the percentage of hit compounds found in this screen in perspective with drugs that are being routinely prescribed. Utilizing the 2015 Medical Expenditure Panel Survey (39), we conclude that 27 of the top 200 most prescribed drugs affect Chol biosynthesis and, of this set of drugs, 13 target either DHCR7 or DHCR24 (Fig. 4). It should also be noted that a number of the top 200 drugs have yet to be tested for their effect on sterol biosynthesis, including compounds with high abuse potential that are not readily available for screening purposes (39). XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX THE POTENTIAL RISKS OF ELEVATED LEVELS OF 7-DHC =&gt; Perturbing DHCR7 activity has been a known human health risk since the 1960s when the DHCR7 inhibitor, AY-9944, was demonstrated to be teratogenic in rodent models (17). Since that time, a number of other chemicals have been identified as DHCR7 inhibitors and, similarly, their use is cautioned and / or altogether discontinued during pregnancy (30). In addition to increased risk of birth defects and perturbed fetal development, there is also the potential for DHCR7 inhibitors to pose increased health risks for adult patients as well. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The 7-DHC is one of the most highly oxidizable organic molecules and it accumulates upon administration of a DHCR7 inhibitor (40, 41). The increased level of 7-DHC may not in itself pose immediate toxicity, but it seems likely that 7-DHC could prime a system for a severe insult when an oxidative stress is initiated. The 7-DHC molecules are readily oxidized to form highly reactive oxysterols that have diverse biological activities and that can readily form adducts to proteins (42). In addition to the previously identified DHCR7 inhibitors, such as aripiprazole and haloperidol, this screen identified a number of antidepressants, anesthetics, antiseptics, and B-blockers, as well as many other antipsychotic medications not previously known to affect DHCR7. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Of those drugs identified as DHCR7 inhibitors here, the B-blockers, metoprolol and nebivolol, are two of the most heavily prescribed and utilized drugs in the US to treat hypertension (39). Nebivolol is the next generation B-blocker with improved physiological outcomes compared with metoprolol while still maintaining clinical efficacy, with one attributable benefit of Nebivolol being a lower efficacious steady state concentration in the blood of ~20 nM (43).  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX ASPECTS TO CONSIDER IN THE REGULATION OF DES LEVELS =&gt; Of the 49 compounds identified to potentially impact Des levels, focus was directed toward the TKIs, as many of them elevated Des levels in both the WT- and D7-N2a cell line screens. Of particular interest were the drugs masitinib and ponatinib, as they were shown to be potent modulators of multiple biomolecules associated with DHCR24 beyond Des, including 7-DHD and 24-DHL. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The effect of these two TKIs are likely translatable to human populations, as the concentrations utilized in this project for masitinib and ponatinib are similar to their known Cmax values of 51 nM and 145 nM, respectively (44, 45). In contrast, the other TKI utilized in this study, imatinib, may be even more efficacious, as it can be tolerated in humans at blood concentrations in the micromolar range (34). The only other set of compounds that affected Des levels in both cell lines were the progestin steroids (progesterone and pregnenolone), which have previously been reported to affect DHCR24 activity (31), a conclusion that our findings support. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, DHCR24 activity and protein stability have been shown to be post-translationally regulated by two distinct tyrosine residues (46), and it is possible that these specific residues may be the targets of the TKIs examined in our study.  XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This study provides evidence that masitinib is a potent elevator of Des by lowering DHCR24 protein expression levels. These findings suggest that masitinib may, in addition to the already determined pharmacological effects in AD patients, also normalize sterol homeostasis and provide additional physiological benefits in these patients. If this is indeed the case, then it may prove beneficial to identify means to normalize Des levels in all AD patients as adjuvant therapy. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX SUMMARY AND CONCLUSIONS =&gt; Chol is an essential biological molecule, and when pathologies lead to elevations or reductions of it or one of its precursors, there can be severe health consequences. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Thus, it is essential to determine regulatory mechanisms of maintaining sterol homeostasis. This is a prerequisite for evaluating the risk of altering sterols or using pharmacotherapy to normalize levels of sterols. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This work has sought to accomplish this goal by identifying a more complete pharmacopeia of Chol biosynthesis disruptors that should prove useful for researchers, translational scientists, and clinicians alike. Additionally, the results of the study provide a chemical tool set to begin exploring the mechanistic involvement of the entire Chol biosynthetic pathway in a number of disorders, including AD. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">14</td>
<td class="data">Serum metabolite profile associated with incident type 2 diabetes in Koreans: findings from the Korean Genome and Epidemiology Study</td>
<td class="data">In the present study, various biological pathways, including amino acid and choline-containing phospholipid metabolisms, were altered in the incident T2D group of our community-based cohort sample. Recent Korean reports have implicated seven metabolites (hexose, valine, and five PC aas) in obesity and T2D. These metabolites are related to the fat mass and obesity-associated (FTO) genotype (13). XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Altered metabolites associated with genetic loci were also identified in Korean T2D subjects (14). Extending these previous analyses, which investigated only the cross-sectional association between metabolites and T2D, this study sought the metabolic profiles associated with incident T2D over an 8-year follow-up period. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX AMINO ACIDS =&gt; Previous studies have identified the branched-chain amino acids (BCAAs) as among the most consistent and important metabolites in dysregulation of the peripheral glucose metabolism. BCAAs and aromatic amino acids have been implicated in insulin resistance (27), obesity (28), diabetes risk (8, 29, 30) and coronary artery disease (31). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Similarly, increased isoleucine, valine, and tyrosine were predictive markers of future T2D risk in our present study, and were also correlated with metabolic markers of insulin resistance (HOMA-IR, HbA1C, and TG). The association between BCAAs and new-onset T2D might be explained by following mechanisms. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First, the increased BCAAs may evoke catabolic materials (propionyl CoA and succinyl CoA), leading to accumulation of incompletely beta-oxidized fatty acids and glucose, impaired insulin effect, and (ultimately) disturbance of glucose control (32). XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, the composition and derangement of the intestinal microbiota might induce diabetes development (33). According to recent research, higher BCAA levels are associated with gastro-intestinal microbiome patterns such as Prevotella copri and Bacteroides vulgatus species (34), suggesting a role for the human microbiome in the association between BCAAs and T2D development. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our results imply that a healthier dietary pattern significantly reduces the likelihood of future T2D development. Thus, whether certain dietary factors interact with the potential BCAA-biosynthetic component of the gut microbiome pattern, thereby affecting BCAA levels, deserves further investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, the mammalian target of rapamycin complex 1 (mTORC1) is important for insulin signaling and secretion and the proliferation of pancreatic beta cells. The primary regulator of mTORC1 signaling is leucine (35). Long–term elevation of these BCAAs may contribute to the hyperactivation of mTORC1 and Jun N-terminal kinase signaling, presumably causing impaired insulin signaling, and subsequent early dysfunction and destruction of beta cells (36–38). Despite the accumulating evidence that BCAAs are related to T2D pathogenesis, whether increased BCAA levels are a cause or consequence of T2D has not been elucidated. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Very recently, the causal association between BCAA metabolism and T2D was clarified in a Mendelian randomization study, using genetic proxies as instrumental variables. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Informally, in attempting to estimate the causal effect of some variable X (&quot;covariate&quot; or &quot;explanatory variable&quot;) on another Y (&quot;dependent variable&quot;), an instrument is a third variable Z which affects Y only through its effect on X. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For example, suppose a researcher wishes to estimate the causal effect of smoking (X) on general health (Y).[5] Correlation between smoking and health does not imply that smoking causes poor health because other variables, such as depression, may affect both health and smoking, or because health may affect smoking. It is not possible to conduct controlled experiments on smoking status in the general population. The researcher may attempt to estimate the causal effect of smoking on health from observational data by using the tax rate for tobacco products (Z) as an instrument for smoking. The tax rate for tobacco products is a reasonable choice for an instrument because the researcher assumes that it can only be correlated with health through its effect on smoking. If the researcher then finds tobacco taxes and state of health to be correlated, this may be viewed as evidence that smoking causes changes in health.) (30). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The authors identified the BCAA-raising polymorphisms by a genome-wide approach, and associated them with elevated T2D risk. This result supports a causal pathway of BCAA metabolism in T2D pathogenesis. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the present study, we found that higher levels of alanine and arginine increase the likelihood of incident diabetes. Alanine levels might increase when the metabolism is altered by glutamate turnover (39), when alanine is released from sites other than skeletal muscle, and when alanine production is disturbed by BCAA catabolism, which is associated with increased T2D risk. Arginine plays multiple beneficial roles against metabolic abnormalities, but might also induce oxidative stress (40). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Collectively, we speculate that altered amino acid metabolisms predict the future risk of T2D through mechanisms involving impaired BCAA metabolism, increased oxidative stress, and increased muscle protein degradation, which precedes the development of T2D.  XXXXXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX BIOGENIC AMINES =&gt; The biogenic amines spermine and spermidine are involved in several cellular processes, including DNA replication, RNA transcription, and protein biosynthesis (41). They also trigger glucose-stimulated insulin release (41); moreover, spermine is a possible glycation inhibitor (42, 43). Consistent with these studies, we found a negative association between blood spermine levels and new-onset T2D, emphasizing the importance of evaluating various metabolites, such as biogenic amines, in new-onset T2D prediction. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX HEXOSES =&gt; As expected, hexose level was positively associated with new-onset T2D in our present study, even after adjusting for confounding influencers of insulin resistance. Hexose comprises not only glucose, but all six-carbon monosaccharides. Increased hexose level may indicate pancreatic beta-cell dysfunction and insulin resistance. In previous studies, the six-carbon monosaccharide fructose was increased in T2D regardless of glucose level (44), and higher intake of fructose (including sweetened beverages) was associated with insulin resistance and the risk of new-onset T2D (45). Our result was consistent with the earlier results (44, 45), confirming that hexose metabolites are valuable for evaluating associations or predicting new-onset T2D in population-based samples. XXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX GLYCEROPHOSPHOLIPIDS AND SPHINGOMYELIN =&gt; Consistent with earlier studies (6, 7), we found a possible involvement of phospholipid metabolism in incident T2D among our Korean population. Specifically, two LysoPC metabolites (17:0 and 18:2), 8 PC aa metabolites (32:1, 34:1, 36:1, 38:0, 40:1, 40:5, 42:1, and 42:5), 2 PC ae (34:3 and 36:3), SM(OH) 22:2, and SM 16:1 were significant predictors of T2D risk in this prospective study. Phospholipids such as PC and SM are the dominant components of cellular membranes and play an important role in cellular signal transduction (46). They also constitute most of the human lipoproteins (47). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The LysoPC 17:0 and 18:2 were negatively associated with incident T2D in our cohort. LysoPC a 17:0, found exclusively in dairy foods, is particularly effective in reducing T2D risk (48), indicating the beneficial effect of regularly consuming dairy products. LysoPC is a signaling molecule involved in atherogenic and inflammatory processes (49), of which the major function needs to be clearly elucidated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX PC aa is essential for the hepatic release of TG-rich very-low-density lipoprotein (46). On the other hand, PC ae is an antioxidant that inhibits lipoprotein oxidation (50). Previous studies have shown that PC ae levels are reduced in obese or insulin-resistant subjects (50, 51). Furthermore, reduced SM synthesis is associated with increased levels of reactive oxygen species and reduced insulin secretion (52). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The significant contributions of LysoPC, PC, and SM to T2D development in the present study, and the correlations of these metabolites with blood phenotype (observed as expected), support the hypothesis that altered choline-containing phospholipid metabolism potentiates the development of T2D. Several recent studies have also identified the metabolites associated with food intake, and related them to the metabolic diseases at the population level (53–58). XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Untargeted metabolomics analysis in the subset of African Americans from the Atherosclerosis Risk in Communities (ARIC) Study cohort identified 48 pairs of significant association between diet and metabolites (53). Specifically, ‘sugar-rich foods and beverages’ were associated with metabolites related to oxidative stress and lipid profiles (53). Another approach to reveal the association between dietary pattern and plasma/urinary metabolites reported that O-acetylcarnitine and phenylacetylglutamine are positively associated with different food groups, red-meat and vegetable intakes, respectively (54). Given that diet can be a primary and secondary (by induction of metabolic responses) source of metabolites (57, 58), we further tested the interrelationships among dietary quality, metabolites, and T2D incidence. In this study, only 22 metabolites were significant predictors of incident T2D. After controlling for covariates, multiple regression analysis revealed that a healthier diet was significantly associated with reduced PC aa 32:1 level and increased the SM(OH) 22:2 level. To test whether each of these two metabolites may act as a mediator in the observed negative association between dietary quality and T2D risk, both dietary score and metabolite were considered in the Cox proportional regression model. The result showed that each metabolite and dietary score remained significant in combination, although the HRs were somewhat attenuated. This indicates that a better diet quality, characterized by well-balanced nutrient intakes reduces the future T2D risk both dependently and independently of intermediate metabolites. Given that food intake and relevant nutrients possibly interact with the environment and the gut microbiome, and that these interactions would be reflected in the blood metabolites, the links among dietary intake, gut microbiota and metabolic biomarkers and their associations with T2D must be further investigated. Indeed, the consumption of PC-containing foods such as meat and eggs reportedly increases the T2D risk (59), possibly through bacterial transformation of PC and consequent production of trimethylamine N-oxide (60, 61). In addition to the complexity and differences of etiology of T2D and environmental factors including diet, ethnic difference also should be considered to interpret metabolic profile in a specific population. Because the response to the specific stimulus (e.g. chemicals, nutrients, etc.) can be distinct depending on gender and ethnic group (62), separate analysis in a certain population is required to apply the identified metabolites for planning the preventive strategy as well as for pharmacological targeting to treat T2D. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSION =&gt; In conclusion, our study showed that metabolites relevant to amino acids, biogenic amines, spermine, hexoses, and choline-containing phospholipid metabolism are associated with incident T2D in a prospective community-based cohort study. Through targeted metabolite profiling, we elucidated the underlying biochemical pathway of T2D pathogenesis. However, many of the covered metabolites were choline-containing phospholipids with structural similarities and metabolic inter-relationships, which hindered the comprehensive assessment of the metabolic alterations preceding T2D. Our results confirm that metabolites beyond the conventional T2D risk factors are important for preventing or controlling the development of new-onset T2D. With this knowledge, we can develop strategies for early intervention against average-risk T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">15</td>
<td class="data">Could Ceramides Become the New Cholesterol?</td>
<td class="data">While it is premature to equate the nascent studies relating ceramides to diabetes and heart disease with the exhaustive body of literature surrounding cholesterol, a foundation for such a comparison is beginning to emerge. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX One wonders whether ceramides are currently in the same position that cholesterol was in the 1980s. Will serum ceramides show the same prognostic utility as LDL cholesterol in large epidemiological studies? XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Will mutations in genes encoding ceramide modifying enzymes prove relevant to diabetes and heart disease?  XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Will ceramide synthesis inhibitors prove to be as efficacious in humans as they are in rodents? XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Regardless of what one thinks of this comparison or the likely answers to these questions, human beings are starting to monitor ceramide levels and are seeking answers about the ramifications of an altered ceramide profile.  XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">16</td>
<td class="data">Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease</td>
<td class="data">There are several novel findings in this targeted plasma metabolomics study. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First, profiling of plasma acyl-carnitines revealed evidence for incomplete FAO and intriguingly, accelerated catabolism of amino acids in individuals with T2DM and kidney disease. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, a reduction in plasma phosphatidylcholine levels and elevation of long-chain sphingomyelin and ceramide levels suggested remodeling of sphingolipids in T2DM with DKD. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, we found that impaired renal filtration function and albuminuria levels were associated with different metabolite signatures. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Targeted metabolomics provides an excellent survey of energy-yield pathways and fuel substrate selection (5). In addition to incomplete FAO as indicated by an elevation in b-oxidation-derived even-number acyl-carnitines (Table 5 and Figure 1), our data point to an accelerated catabolism of amino acids, especially aromatic amino acids, in patients with DKD (23, 25). XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This is suggested by elevated levels of amino acid-derived acylcarnitines (C3, C5, C3-DC, C4-DC, C5-DC, and C6-DC) and lower plasma levels of tyrosine and tryptophan in participants with DKD (P = 0.002 and P = 0.014 in an unadjusted model, borderline significance after adjustment for age, sex, and ethnicity) (Table S1). XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The depletion of aromatic amino acids has been reported by other studies in both diabetic and non-diabetic populations with chronic kidney diseases (6,11,29). It is worth noting that the flux of amino acids and its oxidation in mitochondria occur only under special circumstances such as aerobic physical exercise (30,31). XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore, the accelerated amino acid catabolism in DKD is intriguing, and the sensory signals that trigger amino acid flux and oxidation in these patients remain largely unknown. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX On the other hand, a large body of evidence has shown that excess intracellular and circulating acylcarnitines may exacerbate metabolic disturbance and lead to cytotoxicity (24,32,33). Hence, it is conceivable that accumulation of FAO and amino acid-derived metabolic intermediates in plasma may play a role in the progression of DKD (Figure 1). Another metabolic feature of DKD observed in the current study is the elevation of a cluster of dicarboxyl and hydroxyl acylcarnitines in plasma (Table 5 and Figure 1). XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Increased formation of dicarboxyl and hydroxyl dicarboxylic acids via u- FAO and u-1 FAO and their conversion to the corresponding acylcarnitines may be attributed to acyl-CoA accumulation in DKD (34) u-Oxidation is a rescue pathway when mitochondrial fatty acid oxidation is impaired (27,34). A recent study by Kraus et al. indicated that endoplasmic reticulum stress might elevate short-chain diacid levels (22). Thus, accumulation of short- and long-chain dicarboxylacylcarnitines may indicate mitochondrial stress and /or endoplasmic reticulum stress that may lead to activation of alternative FAO pathways in DKD. Accumulation of acetyl-CoA-derived C2 (acetylcarnitine), as observed in our study, points to a mismatch between energy substrate flux and its utilization in DKD. However, due to the observational nature of our study, we are unable to elucidate whether the imbalance is due to accelerated flux or a reduced downstream utilization, or both. A strong body of evidence supports that mitochondrial function is markedly impaired in patients with DKD. A decrease in electronic transport chain activities accompanied by an overall reduction in mitochondrial content and PGC-1a expression has been found in diabetic kidney (9,35). Similar defects have been observed in diabetic islet, heart, and skeletal muscle (36). XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore, impaired mitochondrial function may at least partially explain the substrate flux/oxidation imbalance in DKD. On the other hand, insulin resistance and other related metabolic disturbance in DKD may impair mitochondria and restrict its ability to select glucose as preferred substrate for oxidation (metabolic inflexibility) (35,37). Therefore, the increased flux of fatty acids and amino acids into mitochondria may be a compensation for impaired glucose utilization (38).  XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Notably, fuel supply and oxidation may not necessarily be reduced in the presence of mitochondrial dysfunction. For instance, frank mitochondrial dysfunction in humans (e.g., myopathies with impaired electron transport chain activity) is accompanied by increased fuel flux and oxidation to compensate for the impaired ATP synthesis (39). Taken together, we postulate that both impaired mitochondria function and energy substrate oversupply in individuals with T2DM may be involved in intramitochondrial metabolic intermediates accumulation and their extracellular overflow to circulation. A future in vivo tracing study by isotope-labeled substrates may provide insights into substrate flux, selection, and oxidization in DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We found that long-chain sphingomyelin and ceramides are elevated in participants with DKD, suggesting that the sphingomyelin-ceramide pathway may play a part in renal complications. The underlying pathological mechanisms may involve impairment of mitochondria function, enhanced generation of reactive oxygen species, activation of apoptotic pathway, elevation of inflammation tone, and endoplasmic reticulum stress (40). XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The latter may contribute to the aforementioned overproduction of short-chain diacids and long-chain dicarboxylacylcarnitines in DKD (22). XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The observed pattern of reduction in phosphatidyl-choline and increment in sphingomyelin levels may suggest sphingolipid remodeling in DKD, as sphingomyelin can be synthesized from phosphatidylcholine by choline-phosphotransferase action (41). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Another novel finding in our current study is the association of renal filtration function and albuminuria levels with distinct metabolite signatures. Early studies have found that both eGFR and ACR are independent predictors of CKD progression (42). In addition, genetic studies have found little overlap between loci of eGFR and ACR (43). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Association of sphingomyelin with albuminuria has been reported in diabetic patients, and inhibiting conversion of sphingomyelin to ceramide might protect kidney function and reduce albumin excretion in animal models (14,44,45). Interestingly, we found that metabolite signature for sphingomyelin-ceramide metabolism was independently associated only with albuminuria but not with renal filtration function in T2DM. These data echo findings from an early study showing that polymorphism of ceramide synthase 2 (CerS2) was associated only with changes in albuminuria but not eGFR in patients with diabetes (46). Our data reinforce the notion that albuminuria and decline of filtration function may represent complementary, if overlapping, manifestations of kidney damage (47). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX An inverse association of acylcarnitine levels with eGFR has been reported in non-diabetic populations (13). Our current study extended the early findings by showing that among many acylcarnitine sub-species that differed significantly between DKD versus non-DKD controls, only short-chain diacids and amino acid-derived acylcarnitines were strongly and independently associated with eGFR (Tables 2 and 3). This finding is principally agreeable with findings from an early, small study that reported that amino acid-derived acylcarnitines predicted progression to ESRD in T2DM (11).  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXCONCLUSIONS =&gt; In conclusion, our targeted plasma metabolomics study implicates altered energy substrate selection, imbalance of substrate flux and utilization, as well as remodeling of sphingolipids in T2DM with DKD. The association of distinct plasma metabolite signatures with eGFR and albuminuria suggest different pathophysiological processes underlying these 2 related manifestations of DKD in individuals with T2DM. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">17</td>
<td class="data">Deciphering lipid structures based on platform-independent decision rules</td>
<td class="data">Experiments carried out for rule development and verification =&gt; The experimental execution is described in detailed protocols presented in Supplementary Note 1 and Supplementary Table 1. Data obtained are discussed in the main text and shown in Supplementary Tables 2 to 10, and Supplementary Figure 13. No statistical testing was applied. Further information is provided in the Life Sciences Reporting Summary published alongside this paper. Detailed data and further details on results are available online (see “Data availability” at the end of this section). XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Application note 1 =&gt; Collision energies in mass spectrometry are considered optimal for a subclass / adduct when both the head group and chain fragments are equally well represented. Since these energies vary depending on the subclass / adduct, as a tradeoff we selected energies which delivered the best overall result with the platform we used for the given lipidome in control experiment 1. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Application note 2 =&gt; The basic fragment rules are based on published results (8,21). They were adapted and extended by visual inspection of spectra from control experiment 1 and biological data. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We determined detectable fragments, identified mandatory fragments, derived intensity rules, and extracted decisive differences for many isobaric / isomeric subclasses / adducts. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further, we determined intensity relationships characteristic for sn-position assignment. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, we found novel fragment ion relationships, such as the relative intensity of the sodiated form of a carboxylated chain fragment that allowed for differentiation between 1,2- and 1,3-diacylglycerols at optimal collision energies, and demonstrated the software’s capability to distinguish regio-isomers under certain chromatographic conditions (Supplementary Fig. 4 and Supplementary Table 14). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We defined more than 1,000 decision rule sets for lipid subclasses/adducts for various MS platforms and experimental conditions. These decision rule sets cover the major lipid subclasses and mass spectrometers commonly used today and will serve as a point of entry for investigators unfamiliar with lipid data analysis. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The direct visual feedback particularly provides an easy introduction to fragmentation patterns of lipids. Importantly, decision rule sets developed are provided along with software for the algorithm, which can be downloaded from http://genome.tugraz.at/lda2. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, raw data, results of detailed analysis, comments about information content that can be derived from the various adduct ions, and suggestions about optimal collision energies for subclasses / adducts are available. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Application note 3 =&gt; In general, isobars or isomers from different lipid subclasses / adducts are chromatographically separated only slightly, and such separation cannot be judged from MS1  spectra. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Thus, we expanded our algorithm to separate MS1 peaks consisting of pairs of isobaric or isomeric subclasses / adducts. The algorithm extracts ion chromatograms from the absolute intensities of distinct fragments belonging solely to one or the other species, and computes the retention time (RT) maxima of either lipid species. A weighted mean (based on abundances of the fragments) is used to estimate the RT of such maxima. If there is at least one MS/MS scan between the maxima, or the maxima are in the vicinity of two different adjacent MS/MS spectra (in the range of 20% of the distance between the spectra), the mean of the two RTs is defined as the position of the split of the MS1 peak. If the RT cannot be determined using absolute intensities, the same procedure is applied to relative intensities. If this also fails, the MS1  peak intensity is distributed according to the intensities of the distinct fragments. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, for isobars /isomers of different subclasses / adducts (e.g. protonated PC and PE), this approach is highly inaccurate and should be avoided, because intensities of the fragments typically do not reflect the MS1 intensities. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX To verify this, we pooled lipid standards of PC, PE, LPC, and LPE subclasses, where isomeric species can be observed as protonated and sodiated adduct ions, and deliberately worsened chromatography parameters to generate overlapping MS1 peaks (Supplementary Fig. 14). This experiment revealed that a successful peak split primarily depends on the availability of MS/MS scans. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Whereas successful splits were frequent for PC/PE species and for platforms with high MS/MS scan rates, less well-separated LPC/LPE species were often left unsplit (Supplementary Table 4). Nonetheless, the presence of either isomer was detected in almost all cases (97%). XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Application note 4 =&gt; LDA detects and assigns structural isomers of the same lipid subclass/adduct from a shared MS1 peak, whereupon the abundance of the MS1 peak is split according to intensities detected in the MS/MS spectra (Supplementary Fig. 12). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX To this end we determined detection rate, accuracy, and variability of results obtained from experiments with structural isomers mixed in concentration ratios up to 1:20. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX As expected, results varied depending on MS ion mode and ionization mode (Supplementary Tables 6 and 7, and Supplementary Fig. 13). Whereas negative ion mode generally produced results with low coefficients of variation, positive ion mode led to results with high coefficients of variation due to low abundance chain fragments. In fact, at higher concentration ratios, chain fragments of low abundance species are not detectable at all. An interesting showcase for a potential pitfall due to a low MS/MS sampling rate was found for PE acquired on QTOF in positive ion mode. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Whereas chromatographically separated isomeric PE 36:4 species produced excellent lipid molecular species ratios, mixed PE 36:2 species produced much higher abundances for PE 18:0/18:2 in comparison to PE 18:1/18:1. The reason is that, in this particular case, the QTOF instrument reported MS/MS spectra only at the end of the MS1  peak; therefore, the slightly earlier eluting PE 18:1/18:1 yielded lower 18:1 chain intensities. Interestingly, chain fragments of some species reflect the true ratios quite well (e.g. PC 34:0 in negative ion mode), while others usually underestimate the true ratio (e.g. PE 36:4). Generally, to derive absolute intensities of pairs of structural isomers from the same MS1  peak, calibration curves are strongly recommended. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Application note 5 =&gt; In a benchmark test of (Lipid Data Analyser) LDA versus LipidBlast7, we used data from both the first control experiment and the biological experiment, both acquired on Orbitrap Velos Pro in CID +50% and -50%, and on 4000 QTRAP +45 eV and -45 eV, respectively. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For LipidBlast evaluation, we used the recommended MSPepSearchGUI (http://peptide.nist.gov/software/ ms_pep_search_gui/MSPepSearch.html). The same m/z tolerances were applied in both LDA and LipidBlast. The specificity and sensitivity of LipidBlast depend on a so called matching factor (22), a value ranging from 0-999. Using the default setting of 450 for the matching factor, many lipid standards in control experiment 1 were not detected. Consequently, the matching factor was lowered to 10, in which case LipidBlast detected almost all of the lipid standards in negative ion mode. Further reduction did not improve the sensitivity of LipidBlast. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In positive ion mode, irrespective of the matching factor setting, LipidBlast was not able to identify as many lipid molecular species as was LDA. Details about the LipidBlast parameters are given in Supplementary Note 2. In this benchmark, we used only lipid subclasses / adducts that both LDA and LipidBlast are able to detect. Correct assignment of lipid species and lipid molecular species identified in liver lipidomes was verified by manual inspection of the spectra, and by aligning them with the respective retention time data.  (23). XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Code availability and technical details =&gt; The algorithm presented is embedded in the Java software package LDA (version 2.5.2) which performs MS1  peak deconvolution (13), and supports several operating systems such as Windows, MacOS, Linux and other Unix-based systems. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Calculations were performed on a 64-bit Windows 7 desktop PC equipped with an Intel Core i7-2600 CPU at 3.4GHz and 16GB RAM under Windows 7. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Decision rule sets were tested on the following MS/MS platforms: 4000 QTRAP and QTRAP 6500 from AB Sciex; G6550A QTOF from Agilent Technologies; Orbitrap Elite, Orbitrap Velos Pro in CID and HCD mode, and Q Exactive from Thermo Fisher Scientific; SYNAPT G1 HDMS QTOF from Waters. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The primary raw data format is mzXML24; however, the software allows for direct processing of vendor formats from AB Sciex, Agilent Technologies, Bruker Daltonics and Thermo Fisher Scientific by an integrated version of msConvert25, as we obtained permission for redistribution of vendor-provided libraries from respective mass spectrometer manufacturers. For Waters “.raw” directories, installation of Mass++ (http://masspp.jp) is required. LDA including the decision rule sets is freely available from (http://genome.tugraz.at/lda2). The source code is released under a GNU GPL v3 license and is available from https:// github.com/ThallingerLab/LDA2/releases/tag/2.5.2. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Data availability =&gt; Data and analysis of results from control experiments 1-3, the biological experiment, LipidBlast benchmarking, HCD characterization, and detection of regio-isomers are available from the MetaboLights26 repository with accession numbers MTBLS394 (Control experiment 1), MTBLS391 (Control experiment 2), MTBLS398 (Control experiment 3), MTBLS396 (Biological experiment), MTBLS397 (Benchmarking), and MTBLS462 (HCD characterization and regio-isomers), respectively. Raw data and results are available from authors’ website too (http://genome.tugraz.at/lda2). Detailed data documentation can be found in Supplementary Note 5. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">18</td>
<td class="data">A combination of plasma phospholipid fatty acids and its association with incidence of type 2 diabetes: The EPIC-InterAct case-cohort study</td>
<td class="data">We evaluated fatty acid profiles among adults in 8 European countries and derived a FA-pattern score that represents a combination of both essential and non-essential fatty acids and that is characterised by high relative concentrations of linoleic acid (18:2n-6), stearic acid (18:0), odd-chain SFAs, and VLSFAs (&gt;=20 carbons), and by low relative concentrations of γ-linolenic acid (18:3n-6), monounsaturated fatty acids (MUFAs), and long-chain SFAs (14:0 and 16:0). The unique combination was associated with dietary, metabolic, and genetic factors, and prospectively associated with a lower incidence of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Comparing the top fifth to the bottom fifth of the FA-pattern score, T2D incidence was lower by approximately 60%. This robust association with incident T2D was independent of established risk factors and also any single fatty acids or fatty acid subclasses. These findings support the hypothesis that a combination of multiple fatty acids is an important marker for the development of T2D above and beyond the roles of single types of fatty acids. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The combination of essential and non-essential fatty acids is of strong interest for further clinical or population-based investigations to predict
T2D risk, identify interventional agents for T2D prevention, and better understand the aetiology of T2D. The combination of fatty acids contributing to the identified FA-pattern score fits with known mechanisms involving the de novo lipogenesis (DNL) pathway. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In DNL, fatty acids including 14:0, 16:0, 16:1n-7, and 18:1n-9 are synthesised endogenously, where stearoyl-CoA desaturase (SCD) converts 16:0 to 16:1n-7 as a rate-limiting step of fatty acid synthesis. The inverse correlation of 18:2n-6 with these fatty acids may reflect its role as a ligand of peroxisome proliferator-activated receptor α (PPARα) [2,5]. PPARα down-regulates SCD and ELOVL (elongation of very-long-chain fatty acid) enzymes, explaining the observed inverse correlation of 18:2n-6 with MUFAs, 16:0, 18:3n-6, and other n-6 PUFAs [2]. An exception of PPARα&apos;s action is activation of ELOVL3, which leads to synthesis of VLSFAs in the adipose tissue [35] and supports the observed associations between 18:2n-6, 18:0, and VLSFAs. While our findings are in line with the benefit of dietary PUFAs (predominantly 18:2n-6), other major PUFAs (e.g., omega-3 PUFA) contributed little to the primary fatty acid combination. This could reflect their diverse roles in eicosanoid pathways and pro- and anti-inflammatory pathways, and their associations with dietary intakes (e.g., fish) independent of DNL-driving dietary factors [5]. These suggested mechanisms are linked to the development of T2D. Activation of PPARα suppresses hepatic DNL and pro-inflammatory pathways that lead to insulin resistance, dyslipidaemia, and fatty liver [2,5,36]. In an experimental setting, for example, PPARα knock-out mice developed fatty liver exhibiting overt hepatic lipogenesis [37]. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Main products of DNL include 16:0 and diacylglycerols that cause a pro-inflammatory response, endoplasmic reticulum stress, and insulin resistance [1,38]. Thus, our analysis yielded a combination of multiple fatty acids that may represent biological pathways related to insulin resistance, inflammatory responses, and T2D risk. This was confirmed with the observed associations of FA-pattern score with metabolic risk factors in an expected direction and the association of FA-pattern score with genetic predisposition to insulin resistance. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Associations of gene variants with fatty acids and with incident T2D cannot be confounded by long-term lifestyle characteristics. Therefore, the specific gene variants, the identified combination of fatty acids, and the risk of T2D are likely to be on the same causal pathway, warranting future research to elucidate how insulin resistance specifically alters fatty acid profiles or vice versa. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our analysis and prior studies derived a similar combination of fatty acids [12-15], but no previous studies to our knowledge evaluated T2D incidence as an outcome. Past studies used different methods and examined varied numbers of fatty acids (10 to 42) of phospholipids [15], cholesteryl esters [12,15], plasma [13], or adipose tissue [14]. Despite the differences, all of the studies reported a combination of fatty acids partly driven by higher levels of 18:2n6 with lower 16:0, which could reflect activity of DNL [39]. These combinations were found to be associated with lower blood pressure, greater endothelial function, less weight gain over time, or lower risk of metabolic syndrome [12-14]. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, an association with ischaemic heart disease or stroke was not significant [15]. The inconsistency depending on outcome is predictable as DNL could promote insulin resistance, but suppress atherosclerosis [36]. Statins and other lipid-lowering drugs also alter fatty acid profiles [10] and have divergent effects on heart disease and T2D [40]. Thus, a fatty acid pattern can be a future focus of investigations of cardiometabolic diseases and related interventions. The association of the FA-pattern score with incident T2D was not fully explained by any single fatty acid, but was partly attenuated by adjustment for odd-chain SFAs and VLSFAs. These SFAs are associated with lower risk of cardiometabolic diseases [16,41,42], while their biological roles remains understudied. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX High phospholipid VLSFAs may reflect high activity of PPARα, which leads to VLSFA synthesis and less insulin resistance, apoptotic cell death, and
pancreatic dysfunction [41,43]. Blood odd-chain SFAs may partly reflect dairy consumption [3,44], gut microbiota [45], or endogenous synthesis through α-oxidation [46], and thus any correlates to those factors could explain our findings. Evidence for these mechanisms and relationships with other fatty acids remains scarce and deserves further investigation. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Dietary correlates with the combination of fatty acids deserve discussion, as they were replicated in EPIC-InterAct and NHANES: alcohol and soft drinks as negative correlates, and coffee, fibre, and PUFAs as positive correlates. The finding for alcohol consumption is likely to reflect its lipogenic effect, a risk factor for liver cirrhosis and T2D [47]. Regarding coffee consumption, polyphenols may deactivate DNL [48] and lower triglyceride levels and T2D risk [49-51]. Increased PUFA intake (predominantly n-6 PUFAs) could increase insulin sensitivity as well as lower DNL [2,5,52]. Our findings for soft drinks and fibre may also reflect their glycaemic and anti-glycaemic effects, respectively, as a high glycaemic effect leads to insulin secretion and DNL [2,53].   XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; In conclusion, we identified a combination of plasma phospholipid fatty acids characterised by high relative concentrations of 18:2n-6, VLSFAs, and odd-chain SFAs and low relative concentrations of long-chain SFAs and MUFAs, some of which are synthesised endogenously. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This particular profile was associated with a 3-fold lower relative risk of incident T2D in European populations after adjustment for confounding. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX While both genes and diet were linked to the FA-pattern score, association of the FA-pattern score with T2D was independent of established
risk factors for T2D and not driven by individual fatty acids. These findings highlight that multiple fatty acids are jointly related to the development of T2D.   XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">19</td>
<td class="data">Biomarkers for predicting type 2 diabetes development-Can metabolomics improve on existing biomarkers?</td>
<td class="data">4 metabolites =&gt; galacticol, mannose, galactose + 2-hydroxybutyric acid new predictors of T2D. Established measures of T2D risk remain the best predictor of T2D risk in this population. Additional markers detected using metabolomics are likely related to these measures as they did not enhance the overall prediction in a combined model. XXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">20</td>
<td class="data">Improvement of myocardial infarction risk prediction via inflammation-associated metabolite biomarkers</td>
<td class="data">Using a targeted metabolomics approach across three cohorts, we identified arginine, LPC 17:0 and LPC 18:2 as metabolite biomarkers for incident MI. Adding arginine, LPC 17:0 and LPC 18:2 to the FRS significantly increased the predictive value in fasting cohorts and in a meta-analysis of the three cohorts. These metabolite biomarkers were independent of conventional risk factors for MI, but strongly attenuated the hsCRP–MI associations indicating a potential role in systemic inflammation. Although this is the first time that these three metabolites in combination have been suggested as biomarkers for incident MI, each has been linked to CVD. (31–35). XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX ARGININE =&gt; An SD increase in serum arginine concentrations was associated with a 26% higher risk of incident MI risk in the meta-analysis. Ornithine, a product of splitting urea from arginine, is associated with CHD. (36) A possible mechanism linking arginine and inflammation is production of oxygen radicals (O2−) and peroxynitrite. Arginine is metabolised to NO via the NO synthases NOS3 and NOS2 in vascular cells. (37) In the presence of high concentrations of O2−, NO reacts with O2− to generate peroxynitrite, reducing the bioavailability of NO and contributing to inflammatory processes. (38, 39) Additionally, peroxynitrite and O2− trigger the uncoupling of NO synthases, shifting the production of NO to O2−, (40) creating a feedback loop (figure 3). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX LYSOPHOSPHATIDYLCHOLINES =&gt; LPCs are associated with lipid metabolism, inflammation and MI. (31–34, 41, 42) In our study, participants with higher serum LPC 17:0 and LPC 18:2 concentrations had a lower risk of MI. LPCs also have a negative association with a combined CVD outcome of MI, ischaemic stroke and sudden cardiac death, (14) further supporting our findings, and LPC 18:2 is associated with CHD. (16) LPCs are associated with inflammatory processes via a variety of mechanisms (figure 3). LPCs can increase expression of NOS3, which is involved in NO synthesis. (31) LPCs can also drive production of antioxidant enzymes, for example, SOD3, which reduce superoxide anion concentrations (figure 3). (32) As a consequence, lower LPC concentrations may increase oxidative stress and promote inflammation as indicated by the negative association with hsCRP. Finally, LPCs increase the synthesis of prostaglandin I2 resulting in improved vasodilation. (34, 41) Thus, lower LPC concentrations may contribute to endothelial dysfunction, increasing the risk for MI. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX HIGH-SENSITIVITY C REACTIVE PROTEIN =&gt; hsCRP is a measure of systemic inflammation. Our three metabolite biomarkers explained 10% of the variation in hsCRP concentrations and attenuated the hsCRP–MI association coefficient by 34%–74%, making it no longer significant (see online supplementary table S6). Therefore, inflammation likely represents a pathway through which our novel biomarkers are associated with MI. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX       MI RISK PREDICTION AND PREVIOUS CVD STUDIES =&gt; Metabolomics can potentially reveal causal biomarkers with strong predictive value for CVD, (9) and baseline metabolomics profiles are associated with risk of death or incident MI. (11) Recently, there have been several metabolomic studies using general population-based cohorts. (14–16, 36) Stegemann et al used a shotgun lipidomics approach to identify lipid species associated with incident CVD. (14) Würtz et al used a Nuclear magnetic resonance (NMR)-based approach to identify CVD-associated metabolites and calculate a risk score for CVD. (15) Vaarhorst et al also used an NMR-based approach and identified metabolites associated with incident CHD; however, their score did not significantly increase CHD risk prediction. (36) Ganna et al used an LC-MS / MS-based lipidomics approach and associated LPC 18:2 with CHD. (16) Covering 140 metabolites, our MS approach is more comprehensive than that taken by Stegemann et al (135 metabolites), Vaarhorst et al (100 metabolites) or Würtz et al (68 metabolites), and with 266 incident MI events, our study is the largest by the number of MI events. Additionally, while previous studies assessed a combined cardiovascular endpoint, (11, 14, 36) we exclusively analysed incident MI. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  CONCLUSION =&gt; We identified three metabolite biomarkers associated with incident MI which improved MI prediction when added to the FRS. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We replicated this MI prediction improvement in independent fasting samples. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These three metabolites were associated with hsCRP and attenuated the hsCRP–MI association while being independent of other traditional CVD risk factors, indicating a potential link to systemic inflammation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">21</td>
<td class="data">Effect of Insulin Resistance on Monounsaturated Fatty Acid Levels: A Multi-cohort Non-targeted Metabolomics and Mendelian Randomization Study</td>
<td class="data">bile acid, glycerophospholipid + caffeine metabolism associated with IR + FA biosynthesis =&gt; related to impaired insulin secretion XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Discovered + replicated causal effects of (insulin resistance) IR on lower levels of the mono-unsaturated (fatty acids) FAs (palmitoleic) POA + (Oleic Acid) OA + suggestive evidence for higher levels of aromatic amino acid tyrosine. Sensitivity analysis =&gt; no pleiotropic effects of the genetic instruments. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Causal effects =&gt; largely unaffected =&gt; exclusion of prevalent diabetes cases. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  All IR-increasing conditions =&gt; associated with down-regulation of SCD-1 (rate-limiting enzyme for mono-unsaturated FA biosysnthesis) =&gt; reduced endogenous prodn of OA + POA. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Palmitic + Stearic acid (saturated FAs) =&gt; SCD-1 Introduces double bonds =&gt; POA (16:1n-7) + OA (18:1n-9), respectively =&gt; major precursors cholesteryl esters + triglycerides (TGs) =&gt; packaged =&gt; very low density lipoprotein (VLDL) particles =&gt; secreted by the liver. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Reduced SCD-1 activity =&gt; adverse vascular outcomes: Inhibition of SCD-1 in hyperlipidaemic mice =&gt; increase aortic atherosclerosis despite protective effects on obesity + IR (37). Reduced SCD-1 activity =&gt; enrichment of saturated FA in VLDL + LDL =&gt; atherogensis =&gt; macrophage-induced vascular inflammation. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX   Competing effects on vascular + metabolic health. IR =&gt; reduces SCD-1 activity =&gt; counteracts the metabolic consequences of IR by improving insulin signalling BUT concomitantly =&gt; increases risk of CVD =&gt; saturated FA-induced proinflammatory changes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX IR +vely associated with OA (FDR-adjusted, p = 0.035, after adjustment for BMI pbmi &gt; 0.05) + POA levels (p = 0.091, pbmi &gt; 0.1) in contrast to -ve genetic associations in MR studies  XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Molecular mechns (1) =&gt; reduced tyrosine catabolism =&gt; IR-induced oxidative stress =&gt; elevations of methionine, cysteine + glutathione (antioxidant) =&gt; tyrosine hydroxylase inhibition (44). Molecular mechns (2) =&gt; inactivation of tyrosine aminotransferase XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Summary =&gt; multiple independent cohorts of community residents =&gt; causal effect of IR on circulating OA, POA + tyrosine levels =&gt; new insights into the metabolic signature of IR + impaired insulin secretion. 1st attempt =&gt; explore at large scale =&gt; causal effects of genetic IR =&gt; non-selected set of plasma metabolites. Potential implications =&gt; presumed IR-induced inhibition of monounsaturated FA biosynthesis =&gt; health outcomes =&gt; (require validation in experimental models) =&gt; form part of explanation for elevated CVD risk in IR that is independent of T2D development. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">22</td>
<td class="data">Branched Fatty Acid Esters of Hydroxy Fatty Acids are Preferred Substrates of the MODY8 Protein Carboxyl Ester Lipase</td>
<td class="data">The biochemical function of CEL extends beyond established substrates of TAG / DAG + CE to include regulation of bioactive FAHFAs XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX explain the endogenous phenotypes seen in CEL -/- mice, e.g. how CEL influences lipoprotein assembly + secretion + how loss of CEL promotes atherosclerosis (34). XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">23</td>
<td class="data">Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study</td>
<td class="data">By applying a mass spectrometry–based acylcarnitine profiling platform, a panel of acylcarnitines, especially long-chain
acylcarnitines, was found to be significantly associated with future risk of type 2 diabetes and also substantially improved predictive ability for incident diabetes beyond conventional risks, including BMI and fasting glucose. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Previously, studies in obese and diabetic animal models demonstrated the links of acylcarnitines with mild FAO dysregulation and “mitochondrial stress,” which led to or worsened insulin resistance and glucose deterioration (4). Moreover, treating myotube with acylcarnitines resulted in decreased Akt phosphorylation and glucose uptake in response to insulin stimulation (19). Indeed, suppression of mitochondrial fatty acid import or acylcarnitine synthesis could alleviate lipid-induced insulin resistance (4,19), supporting the postulation that lipid-induced “mitochondrial stress” predates the emergence of glucose deterioration and diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX To date, only a few small case-control studies and a weight loss trial showed that acylcarnitine profiles were associated with insulin sensitivity (20,21). Moreover, significantly different acylcarnitine profiles were observed among subjects with normal glucose tolerance, prediabetic states, or type 2 diabetes in a German study (22). Recently, several prospective studies indicated that medium- and/or long-chain acylcarnitines predicted  cardiovascular events or mortality in people  aged &gt;85 years or selected patients undergoing cardiac catheterization or dialysis (23–25). XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, previous European studies using the targeted BIOCRATES metabolomics platform failed to demonstrate a significant association between acylcarnitines and incident diabetes (26,27). Notably, the differences in study design, methodology (LC-MS/MS vs. flow injection analysis without chromatographic separation), and statistical analyses, as well as ethnic differences in genetic background and lifestyle might also explain, to a certain extent, the discrepancy between our study and others. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the current study, introducing selected acylcarnitines to the predictive models substantially improved the predictive ability for type 2 diabetes beyond conventional risk factors such as BMI and fasting glucose (AUCs: 0.89 vs. 0.73) (Fig. 2). Therefore, as a relatively simple alternative approach to assess mitochondria FAO dysregulation in vivo, specific acylcarnitine patterns may be considered promising early biomarkers for diabetes prediction. It was noticed that most of the long chain acylcarnitines were consistently associated with increased risk of incident diabetes. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Long-chain fatty acids are oxidized predominately inside mitochondrion (28). They are transported across the mitochondrion inner membrane as long-chain acylcarnitines after being esterified from activated long chain acyl-CoA by carnitine palmitoyl transferase I (CPT1), and consequently de-esterified by CPT2 to acyl-CoA for b-oxidation (5). As initial metabolites of b-oxidation, the accumulation of long-chain acylcarnitines might reflect relatively severe conditions of FAO dysregulation and mitochondrial overload with an impaired tricarboxylic acid cycle (4). Previously, obese individuals and individuals with diabetes were shown to have higher non-esterified fatty acids and long-chain acylcarnitines than those of non-case subjects (7). Although the underlining mechanism is unclear, studies in vitro showed that treatment with long-chain acylcarnitines induced insulin resistance and oxidative stress in human myotubes (19), as well as regulated calcium efflux in cardiac tissue and human ether-`a-go-go-related gene (hERG) channels in renal cells (29,30) Likewise, the potential functional roles of these long-chain fatty acid derivatives might go beyond biomarkers of mitochondrial dysfunction. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Unlike those of long-chain acylcarnitines, the associations of medium-chain acylcarnitines with diabetes remain uncertain. One plausible explanation might be that different precursors or metabolic compartments are involved in the generation of medium-chain acylcarnitines, which could be later b-oxidation metabolites of long-chain fatty acids, or directly esterified derivatives from medium-chain fatty acids (31). In fact, controversial results of medium-chain fatty acids were reported as proinflammatory agents in some studies in vitro (32) but as antimicrobial, anti-inflammatory agents in other studies in vivo and in vitro (33,34). Certainly, the role of medium-chain acylcarnitines in metabolic disorders remains to be elucidated. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX On the other hand, elevated circulating 3-dehydroxycarnitine and 3-dehydrocarnitine, the precursors of L-carnitine productions (35), were shown to be associated with lower risk of incident
diabetes. Previously, carnitine was suggested to improve insulin-stimulated glucose utilization and type 2 diabetes–related metabolic disorders in humans and rodents (36–38). Although the mechanistic interpretation remains unclear, the administration of 3-dehydroxycarnitine in a mouse model lacking L-carnitine transporter improved fatty acid metabolism (39), implicating the potential benefits of these carnitine precursors on maintaining energy hemostasis. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Other interesting findings were that dicarboxylic acid acylcarnitines with odd chains or even chains exerted different impacts on the development of type 2 diabetes. Malonylcarnitine (C3DC) was suggested to be an indicator to reflect malonyl-CoA levels (40). Malonyl-CoA is one of the key regulators in mammalian energy homeostasis by inhibiting mitochondrial CPT1 and FAO (41). Notably, insulin-resistant patients with obesity and type 2 diabetes had high muscle malonyl-CoA concentrations (42). However, it remains unclear whether malonyl-CoA accumulation, indicated by accumulated C3DC, serves as a feedback signal to suppress excessive b-oxidation and mitochondria stress by blocking CPT1 activity, thereby to switch fuel utilization from fatty acids to glucose in order to counteract lipid-induced insulin resistance (4). Nevertheless, the positive C3DC-diabetes association in our study highlighted the role of malonyl-CoA in diabetes pathogenesis. Unlike odd-chain dicarboxylic acids, even-chain dicarboxylic acids are derived from v-oxidation of fatty acids and thereafter undergo b-oxidation (43). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Intervention studies indicated that sebacic acid (C10DC fatty acid) and dodecanedioic acid (C12DC fatty acid) had favorable impacts on glycemic control and energy utilization in patients with type 2 diabetes (43). In accordance with these findings, the observed inverse associations of C10DC and C12DC acylcarnitines with incident diabetes in our cohort supported potential benefits of sebacic acid and dodecanedioic acid in type 2 diabetes. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The elastic netmodel, performed successfully in both predictive accuracy and sparsity for the high-dimensional data sets (16), was used in the variable selection and model construction. Furthermore, our results were cross-region validated between Beijing and Shanghai, two megalopolises in Northern and Southern China with different lifestyles and environmental exposures. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; In summary, the current study suggested that acylcarnitines significantly improved the predicting power for type 2 diabetes when compared with conventional risk factors, suggesting the potential utility of acylcarnitines as novel early predictors in diabetes risk assessment. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">24</td>
<td class="data">Sphingolipids Contribute to Human Atherosclerotic Plaque Inflammation</td>
<td class="data">Recent data highlighted sphingolipids as potential therapeutic targets in the atherosclerotic process. Sphingolipids are increased in human plaque tissue, and in vitro studies have shown possible effects of these lipids on the atherosclerotic process. However, no studies have studied their association to atherosclerotic plaque phenotype and their potential role as pro-inflammatory mediators in human atherosclerosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX SPHINGOLIPIDS AND PLAQUES ASSOCIATED WITH SYMPTOMS =&gt; All 6 analyzed sphingolipids were increased in plaque tissue associated with symptoms, suggesting a possible relationship between these sphingolipids and plaque vulnerability. Glucosylceramide and lactosylceramide have in previous studies been shown to be increased in human atherosclerotic plaques, (3, 4) but differences between symptomatic and asymptomatic plaques have not previously been studied. However, the increased levels of sphingolipids observed in the symptomatic plaques do not tell us whether sphingolipids contribute to plaque instability or whether they result from increased inflammatory activity after the event of a plaque rupture. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX SPHINGOLIPIDS AND ATHEROSCLEROTIC PLAQUE INFLAMMATION =&gt; To assess plaque inflammation, the content of macrophages in plaques was determined histologically, and plaque content of cytokines was measured in plaque homogenates. Glucosylceramide, lactosylceramide, and dihydroceramide correlated with plaque content of macrophages. The positive association between glucosylceramide and macrophages may be explained by the fact that glucosylceramide levels are high in human plaque monocytes as shown by Chatterjee et al. (4) Accordingly, it has been shown that ox-LDL increases macrophage lactosylceramide synthesis, (15) but the association with lactosyl-ceramide and macrophages may also be the effect of enhanced macrophage migration because of lactosylceramide dependent induction of adhesion molecule expression on monocytes and endothelial cells. (13) Because histological measurement of macrophages on cryosections from the 1-mm thick fragments of the most stenotic region of a plaque is a blunt, limited way to study inflammation, we also evaluated cytokine levels in the majority of the plaque tissue. This provided a more complete characterization of the inflammatory activity within the plaque and showed that all analyzed sphingolipids, with the exception of S1P, correlated with several proinflammatory cytokines and in general most strongly to MCP-1, MIP-1β, and IL-6. Yet, S1P correlated positively with the proinflammatory cytokines RANTES and TNF-α. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX SPHINGOLIPIDS, NEUTRAL LIPIDS AND OX-LDL =&gt; To further evaluate the association of sphingolipids and plaque instability, the content of neutral lipids (oil red O) and ox-LDL were measured histologically. The vulnerable plaque is known to be rich in ox-LDL. (16) Ox-LDL increases matrix metalloproteinase-2 activity, an enzyme that is highly present in plaques and activates neutral sphingomyelinase in human aortic smooth muscle cells, which in turn activates the sphingomyelin / ceramide pathway resulting in enhanced sphingomyelin hydrolysis into ceramide and eventually S1P. (17) However, in this study, ceramide correlated with plaque content of ox-LDL, LDL, and sphingomyelin (r=0.836; P&lt;0.001). Additional analyses to evaluate plaque A-SMase were performed, but beyond the location of the enzyme, we were not able to distinguish differences in enzyme activity. Studies by Chatterjee et al (18, 19) have also shown that the biosynthesis of lactosyl-ceramide from glucosylceramide is regulated by LDL and ox-LDL levels. Higher levels of LDL suppress lactosylceramide synthase, an enzyme promoting synthesis of more complex glycosphingolipids from glucosylceramide (Figure 1), which thereby inhibits synthesis of lactosylceramide from glucosylceramide. Both lactosylceramide and glucosylceramide correlated with plaque content of lipids in the present study. Despite not reaching significance (P=0.06), a tendency was found between plaque content of ox-LDL and lactosylceramide, fitting with the idea of ox-LDL promoting lactosylceramide formation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX SPHINGOLIPIDS AS POSSIBLE INDUCERS OF INFLAMMATION IN VITRO =&gt; To investigate whether the measured sphingolipids induced an inflammatory response in vitro, (human coronary artery smooth muscle cells) HCASMCs were incubated with the different sphingolipids in increasing concentrations. All 6 sphingolipids induced a significant release of IL-6 from HCASMCs in high concentration (10 μmol/L), consistent with the correlations found in plaque homogenates. Glucosylceramide, lactosylceramide, dihydroceramide, sphingomyelin, and S1P were also shown to induce IL-6 release already at concentrations of 1 μmol/L. Additional experiment also confirmed that glucosylceramide induced a significant release of MIP-1β, TNF-α, MCP-1, and RANTES from HCASMCs. Interestingly, glucosyl-ceramide induced the release of these cytokines even at relatively low concentrations when compared with the median plaque concentrations of glucosylceramide. Few studies have investigated the associations between ceramide, glycosphingolipids, and atherosclerotic plaque inflammation. However, some evidence supports the associations found in this study. Accordingly, the levels of MCP-1, a strong inducer of monocyte migration, has been shown to be increased in mouse models accumulating ceramide. (9) Furthermore, Bietrix et al (14) showed that inhibition of glucosylceramide synthase decreased TNF-α and MCP-1 mRNA expression. The hypothesis of glucosylceramide as an inducer of TNF-α and MCP-1 expression / release is supported by our findings. Glucosylceramide correlated with both TNF-α and MCP-1 in plaque homogenates and induced a release of these cytokines in vitro. Although sphingolipids were only shown to induce an inflammatory response in HCASMCs and not in human macrophages, this does not rule out their potential contribution to atherosclerotic plaque inflammation. According to the present ex vivo and in vitro findings, sphingolipids do seem to play an important role in atherosclerotic inflammation. As the (vascular smooth muscle cells) VSMCs are located in the media or in the cap near the endothelium and the arterial lumen, the release of cytokines from these cells would induce an inflammatory activated state in the endothelium and stimulate inflammatory cell migration. This suggests that sphingolipids may contribute to an early inflammatory response and attract inflammatory cells to the site of atherosclerotic plaque development rather than activating monocytes and macrophages within the atherosclerotic tissue. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX APOPTOSIS OF VSMCs IS INDUCED BY SPHINGOLIPIDS =&gt; VSMCs are important for maintaining plaque stability. (20) The loss of stabilizing VSMC is one of the important features of the vulnerable plaque leading to a thin protective cap and risk for developing a subsequent plaque rupture. (21–24) Whether ceramide and lactosylceramide can be considered as inducers of apoptosis is controversial. As mentioned, lactosylceramide has been shown to induce proliferation in human aortic smooth muscle cells; conversely, there is also evidence for lactosyl-ceramide and ceramide as mediators of SMase-induced apoptosis in human osteosarcoma cell lines and endothelial cells. (5–7) According to our results, ceramide and lactosylceramide were negatively associated with plaque content of VSMCs. These findings were further supported by the positive correlation found between ceramide, lactosyl-ceramide, and plaque levels of caspase-3. Although a tendency toward increased plaque levels of glucosylceramide and caspase-3 levels was found, the association did not reach statistical significance. To evaluate the effect on apoptosis, HCASMCs were incubated with the different sphingolipids in increasing concentrations. At concentrations of 1 and 10 μmol/L, glucosylceramide, lactosylceramide, and ceramide were shown to induce apoptosis, whereas only concentrations of 10 μmol/L induce cellular necrosis. The levels of sphingolipids needed for inducing apoptosis in vitro are generally higher than the median levels of sphingolipids in the plaque tissue. However, it is difficult to compare concentrations in plaque tissue and in cell culture medium. Considering the median levels of glucosylceramide, lactosylceramide, and ceramide (0.25, 0.12, and 0.11 μmol/g wet weight plaque, respectively) and the concentrations needed to induce cellular apoptosis and IL-6 release (1–10μmol/L), it cannot be excluded that the used concentrations are of biological relevance. Furthermore, knowing that the atherosclerotic plaque is a heterogeneous tissue, it is likely that the levels of sphingolipids will differ in different locations within the tissue, and local concentrations of sphingolipids may be several times higher than the median homogenate levels at some locations. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX S1P DOES NOT ASSOCIATE WITH PLAQUE INFLAMMATION OR VULNERABILITY =&gt; In contrast to the other investigated sphingolipids, S1P has been suggested to have anti-atherogenic as opposed proatherogenic properties. (25) In plaque tissues, S1P did not correlate with either histological markers of plaque vulnerability or inflammation. When analyzing plaque cytokine levels, S1P was significantly correlated with TNF-α and RANTES. However, S1P failed to induce an inflammatory cytokine release from HCASMCs in vitro. Only at a high concentration (1 and 10 μmol/L), in comparison to median plaque levels (3.1×10−4 μmol/g), was an increase in IL-6 release detected, suggesting that the effect on IL-6 release is not biologically relevant in vivo. Interestingly, S1P was the only sphingolipid that was positively associated with the growth factor PDGF in the plaque tissue. PDGF stimulated VSMC growth and collagen production and is generally considered to contribute to a stable plaque phenotype. PDGF may also stimulate S1P production by activating sphingosine kinase leading to increased S1P levels. (26) S1P was unexpectedly found to correlate with caspase-3 levels. On the contrary, S1P did not induce HCASMC apoptosis in the in vitro experiments, not even at high concentrations. It has been suggested that an imbalance in ceramide / S1P levels could differentiate between cellular apoptosis and survival. (27) Considering the median ceramide / S1P ratio (109 / 0.31 nmol/g), this could be a possible explanation. However, it could be argued that this theory should show an inverse association rather than a positive association between S1P and caspase-3. Furthermore, ceramide and S1P levels correlated positively (r=0.321; P&lt;0.001), which may not support this theory although it does not exclude it. Taken together, the present findings suggest that S1P levels may be associated with cellular apoptosis but does not contribute to it. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX mRNA EXPRESSION OF SPHINGOLIPID PATHWAY ENZYMES =&gt; As the synthesis and degradation of sphingolipids are tightly regulated by a broad spectrum of enzymes, RNA sequencing was performed to investigate whether an increase in plaque levels of sphingolipids and glycosphingolipids could be explained by differential expression of genes coding for enzymes involved in relevant pathways. In the current analysis, no significant differences in the expression of these enzymes were observed. This does not rule out the role of these enzymes in plaque progression, as enzyme activity or localization could also be involved and remain to be evaluated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  CONCLUSIONS =&gt; In conclusion, this is the first study to demonstrate that glucosylceramide, lactosylceramide, ceramide, dihydroceramide, sphingomyelin, and S1P are increased in human atherosclerotic plaques associated with symptoms. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The current analysis also provides evidence that ceramide, lactosylceramide, and particularly glucosylceramide are not only associated with plaque inflammation and vascular smooth muscle apoptosis but also contribute to it. Our findings suggest an important role for sphingolipids in vulnerable plaque formation and that inhibiting specific targets in sphingolipid formation may, therefore, be a potential therapeutic target. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">25</td>
<td class="data">Adiponectin levels predict prediabetes risk: the Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study</td>
<td class="data">In our biracial cohort study of healthy offspring of patients with diabetes, we found an inverse association between adiponectinemia and the risk of incident prediabetes / diabetes during longitudinal follow-up. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Among initially normoglycemic persons, an approximately 5 μg/dL higher baseline plasma adiponectin level corresponded to approximately 40% lower rate of progression to prediabetes / diabetes during a mean follow-up period of 2.6 years. Among the 110 participants who reached an end point, only 10 participants progressed directly to T2DM, whereas the vast majority (100 participants) progressed to prediabetes. Thus, our findings are particularly germane to the pathobiology of prediabetes. Despite the well-known ethnic and gender differences in plasma adiponectin levels, (20–22) which were evident in the present study, the association of adiponectin status with incident prediabetes was quite consistent across gender and ethnicity in our cohort of African-Americans and European Americans with parental history of T2DM. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The point estimates of decreased risk for prediabetes were of the same order of magnitude in black and white offspring (0.44 and 0.48, respectively), although the 95% CI was wider among the latter. Notably, adjustment for BMI increased the adiponectin-associated OR for prediabetes from 0.48 to 0.61, with a wider 95% CI. However, the observation of a nominal reduction (approximately 40%) in the risk of incident prediabetes, despite adjustment for BMI, suggests that the decreased prediabetes risk associated with higher baseline adiponectin levels is partly but not entirely mediated by adiposity-related mechanisms. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Several previous cross-sectional and longitudinal studies have established that low adiponectin levels are associated with increased risk of T2DM. (5–11) In the prospective Diabetes Prevention Programme (DPP), which enrolled participants with prediabetes, an approximately 3 μg/mL higher baseline adiponectin level predicted a 20–40% lower risk of progression to T2DM during approximately 3 years of follow-up. (11) In the present report, we found that an approximately 5 μg/mL (1 SD) higher baseline adiponectin levels predicted a 40% lower risk of progression from normoglycemia to prediabetes. The latter finding indicates that the association of adiponectin with diabetes risk is evident at a much earlier stage in the pathogenesis of dysglycemia. Thus, the ability to maintain high adiponectin  production might be protective of dysglycemia in persons at high risk for T2DM, whereas hypoadiponectinemia could be a risk factor for the initiation of early glucose abnormalities leading to prediabetes and diabetes. These notions are consistent with the favorable cardiometabolic profile of adiponectin that has emerged since its discovery. (1–11 32 33) XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The mechanisms whereby adiponectin exerts its favorable cardiometabolic effects are not fully understood, but could involve improvement in insulin action, decreased inflammatory tone, interaction with fibroblast growth factor (FGF)-21 and amelioration of lipotoxicity, among others. (34–39) In rodent models, overexpression of adiponectin is associated with several beneficial effects, including improved metabolic flexibility, decreased inflammatory markers, decreased steatosis, improved insulin sensitivity, decreased apoptosis and preservation of β cell function. (35 36) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX An interaction between adiponectin and FGF21, a potent regulator of metabolism and energy utilization, has also been reported. (38 39) The administration of FGF-21 decreases blood glucose levels and increases insulin sensitivity in mouse models of obesity and insulin resistance, through upregulation of adiponectin expression. (39) Furthermore, FGF-21 is involved in the clearance of toxic ceramides in obese animals, and adiponectin-knockout mice appear to be refractory to the ceramide-lowering effects of FGF-21. (39) These data indicate that adiponectin may be a critical mediator of the favorable metabolic and insulin sensitizing effects FGF-21. (39 40) XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX At the clinical level, the improvement in insulin sensitivity following treatment with PPAR-γ agonists has been shown to be mediated, at least in part, by upregulation of adiponectin expression. (41 42) From the foregoing, interventions that increase adiponectin levels would be attractive candidates for clinical trials, with the goal of diabetes prevention and improvement in cardiometabolic health. Interventions that have been reported to increase adiponectin levels include exercise, (43) weight loss, (44) smoking cessation (45) and treatment with PPAR-γ agonists, (41 42 46 47) PPAR-α agonists, (48) ACE inhibitors (49) and angiotensin II receptor blockers. (50) In clinical trials, many of the aforementioned interventions have been associated with favorable glucoregulatory outcomes. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Indeed, prediabetic participants randomized to the lifestyle intervention arm in the DPP experienced an increase in circulating adiponectin levels, and showed a 58% relative risk reduction in incident diabetes, compared to the placebo group. (11) Cross-sectional and longitudinal studies have previously reported a consistent association between low adiponectin levels and prevalent T2DM, impaired glucose homeostasis and an unfavorable cardiometabolic profile. (2–11)  XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXCONCLUSIONS =&gt; In conclusion, among healthy African Americans and European Americans with parental history of T2DM enrolled in the POP-ABC study, baseline adiponectin levels were inversely related to the risk of incident prediabetes. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This predictive relationship was evident, despite gender and ethnic differences in baseline adiponectin levels. Based on our finding, it can be predicted that interventions that boost adiponectin levels may offer protection against the risk of dysglycemia, regardless of gender or ethnicity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">26</td>
<td class="data">Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase</td>
<td class="data">Metabolomic profiling of statin use in longitudinal cohorts uncovered an intricate association pattern of circulating lipoprotein, fatty acid, and metabolite changes, which adds to our understanding of the LDL-C–independent effects of statins. Statin use was associated with pronounced lowering of numerous lipids and fatty acids consistent with the cardioprotective effects. By contrast, statin use did not markedly affect the circulating levels of recently identified biomarkers for cardiometabolic risk such as amino acids, glycolysis- and glycogenesis-related metabolites, or ketone bodies (5,6,21,31). The genetic proxy for HMGCR inhibition gave rise to a strikingly similar association pattern, providing unconfounded evidence that the observed metabolic changes arise as a consequence of the mechanism-based effect of statins (Central Illustration). XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These insights into an extensively studied therapeutic agent illustrate how metabolomics, combined with genetic proxies mimicking pharmacological action, can elucidate the molecular effects of known targets, clarify treatment indication, and potentially be used to inform drug development (19,20,34). XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Inhibition of HMGCR by statins leads to upregulated expression of LDL receptors in the liver, which in turn increases the uptake of circulating LDL particles. Using lipoprotein subclass profiling, statin therapy also was shown to be associated with considerable lowering of IDL and very small VLDL particle concentrations, beyond the anticipated decrease in LDL particles. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These remnant lipoprotein particles carry 20% to 30% of circulating cholesterol; they are small enough to enter the arterial intima and, therefore, possess the potential to cause atherosclerosis (14). Because total triglyceride concentration is highly correlated with the amount of IDL and small VLDL particles and their cholesterol levels, the triglyceride measure may partly reflect the cardiovascular risk mediated by the atherogenic remnant particles (14,15). XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Indeed, accumulating genetic evidence suggests that triglyceride levels reflect causal processes related to coronary heart disease (13–15); however, the likely underpinning mechanism is the remnant cholesterol carried in the IDL and VLDL particles (14,15,35). Detailed lipoprotein profiling demonstrated that statins are effective in lowering remnant cholesterol, whereas triglycerides are only modestly decreased by statin therapy. These results suggest that statins are substantially more efficacious for lowering remnant cholesterol than would be projected based on their ability to lower triglycerides. If the cardiovascular risk reflected by triglycerides is due to remnant cholesterol rather than triglycerides per se (14,35), then our results indicate cardioprotective benefits of statins beyond LDL-C lowering and suggest broader indications for statins in treating remnant hyperlipidemia. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The fatty acid composition of lipoprotein lipids vary greatly depending on the abundance of cholesteryl esters, triglycerides, and phospholipids (36). In accordance with linoleic acid being the primary constituent of cholesteryl esters—the dominant lipid in LDL particles—statin therapy led to the greatest lowering of this omega-6 fatty acid. Absolute levels of omega-3 fatty acids were only modestly decreased, in agreement with prior studies (12,37). These results are consistent with omega-3 fatty acids being primarily bound to the phospholipids, which only account for some 30% of the lipids in LDL particles (36). Monounsaturated and saturated fatty acids were decreased to a broadly similar extent as total triglycerides and phospholipids, respectively, which is coherent with the main fatty acid compositions for these lipid classes (36). The changes in the relative fatty acid balance due to statin therapy were modest. Although lower levels of the ratio of omega-6 fatty acids to total fatty acids have been associated with higher cardiovascular risk (5,38), evidence for a causal relation is lacking. The overall consistency between the genetic and longitudinal association patterns indicate that the various fatty acid modulations are on-target effects of HMGCR inhibition rather than due to cholesterol independent properties of statins (37). XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We also assessed whether statin therapy would be associated with biomarkers in various non-lipid
pathways. (Glycoprotein acetyl) GlycA, a measure of systemic inflammation and a biomarker for CVD and all-cause mortality (5,6,32,33,39), was modestly lowered, in accordance with the proposed anti-inflammatory properties of statins (7,8). XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, both longitudinal and genetic analyses provided no evidence for substantial effects of statins on amino acids, glycolysis and gluconeogenesis metabolites, and ketone bodies. Several metabolites in these pathways have recently been shown to be risk markers for CVD and type 2 diabetes (5,6,17,21,31). Although the potential causal roles of these biomarkers remain unclear, our results suggested that statin therapy would not be efficacious for lowering the cardiometabolic risk associated with these markers. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; High-throughput metabolomic profiling in large cohorts with multiple time points and genetic information elucidated the pharmacological effects of statins on lipoprotein subclasses including their lipid constituents and fatty acid composition. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These results suggest a more efficacious role of statins for lowering remnant cholesterol levels than would be expected based on the ability of statins to lower circulating triglycerides. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The absence of robust associations of statin use with circulating amino acids, glycolysis and gluconeogenesis metabolites, and ketone bodies suggest minimal pleiotropic effects on these non-lipid biomarkers. As a corollary, statin therapy appears to have little or no efficacy on these novel markers of cardiometabolic risk. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The exquisite match between the metabolic association patterns from observational and genetic analyses serves as a proof of concept, illustrating how the combination of metabolomics and genetic proxies for drug mechanisms can facilitate the assessment of pharmacological action and on-target effects for known therapies and novel drug targets. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although Mendelian randomization of drug targets has been used previously (19,20,34), our study was
the first to our knowledge to combine the concept with observational results across a wide range of cardiometabolic biomarkers. As extensive metabolomics and genetic data are increasingly becoming available in large biobanks, such comprehensive molecular profiling can augment drug development in both preclinical and clinical trial stages to elucidate molecular mechanisms, clarify pleiotropic effects, and inform treatment indication. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">27</td>
<td class="data">Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review</td>
<td class="data">THE WAY FORWARD =&gt; The global challenges of diet-related obesity, diabetes, and CVD present enormous health and economic burdens (404) and emphasize the imperative of prioritizing nutrition in clinical care, advocacy, research, and policy. Scientific advances provide a wealth of new evidence on the key dietary priorities for cardiometabolic health. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These include food-based priorities for more fruits, non-starchy vegetables, nuts, legumes, fish, vegetable oils, yogurt, and whole grains; and fewer red meats, processed (sodium-preserved) meats, and foods higher in refined carbohydrates and salt (Figure 3). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Red meats should be minimized to prevent diabetes; butter used occasionally but not emphasized; and other foods (e.g., unprocessed poultry, eggs) consumed in moderation according to personal preference. Coffee and tea can be enjoyed, with possible (but not yet confirmed) benefits; and alcohol, if consumed, should be moderate (up to 1 drink/day for women and 2 drinks/day for men). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Harmful additives, in particular sodium, trans fat, and added sugar, will generally be lower in such diets and must be further minimized through strong policy actions. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX There is growing evidence and consensus for such food-based dietary patterns as the best means to reduce CVD, obesity and weight gain, and diabetes, (21) replacing outdated emphases on total fat, other isolated nutrients, or calorie counting. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">28</td>
<td class="data">Does Diacylglycerol Accumulation in Fatty Liver Disease Cause Hepatic Insulin Resistance</td>
<td class="data">Link between DAG content =&gt; PKCs =&gt; insulin resistance. Some studies FAIL to find a relationship.</td>
</tr>
<tr>
<td class="r data">29</td>
<td class="data">Biomarkers of rapid chronic kidney disease progression in type 2 diabetes</td>
<td class="data">In this study of individuals with type 2 diabetes and CKD3 we found that within a large set of candidate and global discovery biomarkers, at least 62 showed some evidence for association with subsequent rapid renal function decline. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Many of these biomarkers showed high correlations with each other and with clinical covariates so that a much sparser set of 14 biomarkers contained most of the predictive information beyond clinical covariates. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We found that the increment in prediction with these biomarkers was of sufficient magnitude that it would be useful for risk stratification into clinical trials. Some of the biomarkers identified in the most predictive panels are already known to be associated with eGFR (that is, β2-microglobulin and cystatin-C), whereas others have little or no prior data (for example, SDMA/ADMA ratio, FGF-21, and uracil). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The best biomarker panel for prediction consisted of the restricted clinical covariates along with 35 biomarkers; however, this was only modestly better than the best sparsemodel that only required measurement of 14 biomarkers. The expense and logistics associated with validation and subsequent utilization of any new panel means that the 14 biomarker panel represents a more pragmatic approach. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This panel of biomarkers now warrants further evaluation in other cohorts. We used clinical creatinine measurements to calculate eGFR in this study, and as there is considerable variability in this measure, it is unsurprising that the in-sample measure of creatinine was also selected in our biomarker panels. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Space does not permit a detailed discussion of each of the 14 biomarkers selected and some of the associations have been described elsewhere. (5,6) Here we focus on some of the more novel associations. One of the strongest predictive biomarkers in our study released during proteolytic breakdown of nuclear proteins and both have been studied as biomarkers for cardiovascular disease (CVD) (7–9). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX SDMA is primarily excreted via the kidney and is strongly associated with renal function, (7) but there is also some evidence that the protein methyl-transferase PRMT5 that synthesizes SDMA regulates interleukin-2-gene expression, (10) suggesting that higher levels of SDMA might also reflect inflammation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We did not find any association of SDMA with inflammatory biomarkers such as C-reactive protein, but there was a positive correlation (rho = 0.39) with interleukin-2 receptor α levels. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, rather than a bioactive effect of SDMA itself, the observed prediction in our study may simply indicate that SDMA accumulates when filtration falls and thus it is predictive because it is a good biomarker of filtration. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast to SDMA we found that ADMA was only weakly inversely correlated with eGFR but more strongly correlated with arginine. The ratio may be a biomarker of these complex interactions and we note that was the ratio of SDMA/ADMA. SDMA and ADMA are models including the ratio yielded higher AUROCs than models including ADMA and SDMA separately. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX KIM-1 is a protein expressed on the apical membrane of proximal tubule cells. Its ectodomain is shed into the lumen and serves as a urinary biomarker of kidney injury, although there have been mixed results for it as a prognostic biomarker in diabetic kidney disease, (11,12). Studies have shown that KIM-1 expression is increased in the glomerulus in diabetic animal models (13) and is elevated in their plasma (14). XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Recently, it was reported that shed KIM-1 also serves as a blood biomarker of kidney injury in humans, as plasma KIM-1 levels were higher in patients with acute kidney injury than in healthy controls or postcardiac surgery patients without acute kidney injury (2). In that study serum KIM-1 level at baseline in type 1 diabetes patients strongly predicted rate of eGFR loss and risk of ESRD during 5–15 years of follow-up. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We identified associations with rapid progression of two fibroblast growth factor members FGF-21 and FGF-23. FGF-21 is a 181 amino acid polypeptide secreted predominantly by the liver and adipose tissue and has been shown to play an important role in lipid and energy metabolism (15,16). Previous studies have reported cross-sectional associations with eGFR (17). Median serum FGF-21 levels were  &gt; 7–15-fold higher in dialysis patients than controls (18,19) but fell after short-term angiotensin blockade (19). In cross-sectional studies FGF-21 levels were also elevated with albuminuria even when eGFR was  &gt; 60 ml/min (20). FGF-21 was independently associated with urinary albumin in type 2 diabetes (20). XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The kidney has relatively low levels of FGF-21, (21) and FGF-21 activity depends on the tissue-specific expression of its cofactor Klotho β that is predominantly in the liver and adipose tissue rather than the kidney. Thus, association between FGF-21 and renal disease progression may reflect simple accumulation in renal disease. However, it might also reflect an antifibrotic response; it was shown that FGF-21 prevented the expression of profibrotic cytokines, including transforming growth factor-β1 in the kidney (22). XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX FGF-23 is a 32-kD bone-derived hormone with several known endocrine functions in the kidney, including the promotion of urinary phosphate excretion and the inhibition of the hydroxylation of 25-hydroxyvitamin D (23). Elevated FGF-23 was an independent risk factor for ESRD in patients with relatively preserved kidney function and for mortality across the spectrum of CKD (24). XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Recently, it was shown in 13,448 subjects of the Atherosclerosis Risk in Communities study (ARIC) that higher serum level of FGF-23 were associated with increased risk of incident ESRD, independent of the baseline level of kidney function and a number of other risk factors (25). XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX C16-acylcarnitine was one of the strongest predictors of rapid progression in our study. Previously in the KORA cohort, acylcarnitines and especially the ratio of serine to glutarylcarnitine were associated with eGFR, (26) and in FinnDiane study urinary acylcarnitines were associated with</td>
</tr>
<tr>
<td class="r data">30</td>
<td class="data">Comparative study of glucose homeostasis, lipids and lipoproteins, HDL functionality, and cardiometabolic parameters in modestly severely obese African Americans and White Americans with prediabetes: implications for the metabolic paradoxes</td>
<td class="data">African Americans experience type 2 diabetes and the associated cardiovascular morbidity and mortality disproportionately more than white Americans (16,17). XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, the exact contributions of obesity to type 2 diabetes and coronary heart disease in African Americans remain debatable. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Thus, whether severe obesity differentially modifies the metabolic mediators and precursors of pre-diabetes, type 2 diabetes, and CVD in African Americans and white Americans remains to be investigated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Given the increasing epidemic of obesity and its potential impact on glucose regulation, prediabetes, and type 2 diabetes among US ethnic and racial populations, we felt it was imperative to perform a comprehensive assessment of clinical and metabolic characteristics of modestly severely obese African Americans and white Americans with prediabetes. Thus, in the current study, we recruited individuals with a BMI &gt; 30 kg/m2 who had prediabetes. These patients had greater than class III obesity with a mean BMI of &gt; 35 kg/m2 and lean body fat &gt; 40% in both groups. We found that BMI and the percent body fat were greater in African Americans than in white Americans with prediabetes. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Pathogenic mechanisms underlying prediabetes, impaired glucose tolerance, and type 2 diabetes are characterized by abnormalities in b-cell secretion, hepatic glucose production, and glucose disposal (i.e., insulin-mediated [Si] and non–insulin-mediated [Sg and GEZI] glucose disposal) in patients with prediabetes and type 2 diabetes. These abnormalities are more prevalent in African Americans than white Americans. We (2,3,6,11) and others (4,9,10) have previously shown greater IR (lower Si or higher HOMA-IR) and hyperinsulinemia as well as hepatic glucose overproduction or hepatic IR in healthy non-obese and mildly obese African Americans than white Americans (9). These abnormalities antedated the development of prediabetes and type 2 diabetes in African Americans by decades (2). XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the current study, we observed that modestly severely obese African Americans tended to have somewhat lower fasting and post–glucose challenge serum glucose levels when compared with white Americans with prediabetes. However, paradoxically, African Americans had greater A1C levels than white Americans. This finding is similar to those in recent reports (30,31). In the current study, we found that the mean fasting and post–glucose challenge levels, as well as the corresponding serum insulin and C-peptide levels, tended to be lower in modestly severely obese African Americans than white Americans with prediabetes. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this context, in a previous study (2,3,5) in mildly obese or overweight African Americans, we demonstrated that prediabetic subjects had antecedent poor b-cell function (as assessed by serum insulin and C-peptide levels). This was not the case in the current study of modestly severely obese African Americans. In the current study, the serum insulin and C-peptide response during the OGTT, when corrected for prevailing glucose (insulinogenic index, insulin / glucose, or C-peptide/glucose ratios; data not shown) levels were similar in African Americans and white Americans with prediabetes. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX To examine in detail b-cell function and insulin sensitivity in modestly severely obese African Americans and white Americans with prediabetes, we performed FSIVGTT in both groups. We found that AIRg and DI were higher in African Americans than white Americans with prediabetes. Thus, our modestly severely obese African Americans with prediabetes had astonishingly fairly well preserved b-cell function and the ability to compensate for the prevailing skeletal muscle IR when compared with white American counterparts. Obesity is a major cause of IR in the general population and patients with type 2 diabetes (1–4). Unlike previous reports, we found no significant differences in Si values in modestly severely obese African Americans and white Americans with prediabetes. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It should be noted that previous studies (2,3,5,6,11) have shown that in vivo total body glucose disposal consists of both insulin mediated (Si) and non–insulin-mediated or glucose-mediated (Sg or GEZI) glucose disposal. In this regard, we have previously demonstrated that, while Si is lower, Sg is higher in healthy African Americans with and without a family history of type 2 diabetes (11). Contrary to the Si, we were therefore intrigued that obese African Americans with prediabetes had significantly higher Sg and GEZI values when compared with white American counterparts. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data suggest that the greater Sg and GEZI values could serve as important compensatory mechanisms to maintain normal or nearly normal glucose tolerance in modestly severely obese African Americans with prediabetes. The mechanism of the putative greater Sg and GEZI values, however, remains to be elucidated in obese and nonobese African Americans with and without prediabetes. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The typical lipid and lipoprotein profiles
associated with obesity, type 2 diabetes, IR, and metabolic syndrome are characterized by higher serum TG and lower HDL-C levels. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, we (27) and others (1,23–26) have reported that insulin-resistant African Americans rather have normal or higher HDL-C and apoA1 levels, and lower serum TG levels than white American counterparts. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the current study, our modestly severely obese, insulin-resistant African Americans with prediabetes had significantly lower serum TG levels, a normal or higher HDL-C level and HDL/TG ratio, and apoA1 level when compared with their white American counterparts with similar IR (Si).  XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our findings suggest that the favorable lipid and lipoprotein profiles in the obese and non-obese African Americans appear to be independent of the degree of obesity (22,23,27). We should note that the lower serum TG levels and the normal or higher HDL-C and apoA1 levels in African Americans are also found in other blacks of African ancestry residing in diverse geographic locations (5,8).  XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  High-density lipoprotein has been regarded as an important antiatherogenic lipoprotein with several critical roles in lipid transport and atherogenesis (12–15). Recently, one of the potential mechanisms for these HDLs - antiatherogenic functions - has been attributed to PON1 activity, which is cosegregated with HDL in the circulation (20,21). PON1 inhibits the oxidation of LDL, suppresses inflammation, improves endothelial function and injury repair (antiapoptotic effect), and enhances reverse cholesterol transport activity (12–14,20,21). Thus, our recent findings that PON1 activity is 50% lower in nondiabetic, postmenopausal African American women than their white American counterparts were unexpected. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our previous study (22) also showed that oxidized LDL and CRP levels were higher in non-diabetic, postmenopausal African American women than in white Americans. These observations suggested that HDL was dysfunctional in African Americans and could play a critical role in atherogenesis in African Americans (22). XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, our study and those by other investigators did not examine the potential effects of the severity of obesity on these cardiometabolic markers in African Americans and white Americans with prediabetes. We found in our present study of modestly severely obese subjects with prediabetes that PON1 and oxidized LDL levels were not different in white Americans and African Americans. This was surprising and unexpected. Therefore, we examined some of the additional qualitative functions of HDL such as subclinical inflammation (CRP) and adipocytokines (IL-6). In this regard, previous studies (32–34) have demonstrated higher serum CRP levels in obese African Americans than white Americans. We found in the current study that CRP and IL-6 levels were not statistically significant in modestly severely obese African Americans with prediabetes compared with their white American counterparts. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, serum adiponectin, a very potent adipose derived insulin sensitizer, is associated with lower rates of type 2 diabetes, metabolic syndrome, and CAD. Serum adiponectin levels are lower in African Americans and patients with obesity and IR (35,36). In the current study, adiponectin levels tended to be lower but not significantly different in modestly severely obese African Americans and white Americans with prediabetes. Although the mechanism is unknown, we speculated that adaptive metabolic processes associated with a severe degree of obesity may be partly responsible. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  SUMMARY =&gt; In summary, the current study demonstrated several metabolic paradoxes in modestly severely obese African Americans with prediabetes when compared with their white American counterparts. We found that modestly severely obese African Americans and white Americans with prediabetes had somewhat similar glucose responses and Si values, but required diverse regulatory mechanisms. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX While white Americans with prediabetes maintained glucose homeostasis via increased b-cell secretion, their African American counterparts had higher non–insulin-mediated glucose disposal. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, modestly severely obese African Americans with prediabetes showed persistently lower Si and PON1 values as well as paradoxical relationships between Si and HDL-C and TG levels, and HDL-C/TG ratios. In contrast, the insulin-resistant modestly severely obese white Americans maintained the well-established relations between Si and HDL-C and TG levels, and HDL-C/TG ratios. XXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXCONCLUSION =&gt; We conclude that the regulation of glucose homeostasis and lipid/lipoprotein metabolism appears to differ in modestly severely obese African Americans and white Americans with prediabetes. Furthermore, in the current study modestly severely obese African Americans had attenuation in some of the cardiometabolic parameters when compared with white Americans with prediabetes. Nevertheless, the modestly severely obese African Americans with prediabetes retained the paradoxical relations of Si and HDL-C/TG ratios. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We speculate that the pathogenetic mechanisms for glucose intolerance and perhaps atherogenesis appear to be different in modestly severely obese African Americans and white Americans with prediabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">31</td>
<td class="data">Characteristics of glucose metabolism in Nordic and South Asian subjects with type 2 diabetes</td>
<td class="data">In this study we examined ethnic differences in glucose and fat metabolism and energy expenditure in basal and clamp hyper-insulinemic conditions in subjects with T2D, of SA or NOR ethnicity, living in Oslo, Norway. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We found evidence of ethnic differences in fasting endogenous glucose production, and indications of possible differences in the choice of substrates for energy expenditure both in basal and clamp conditions. The concept of ethnicity and ethnic groups is complex, consisting of both socio-cultural and biological components that are not clearly defined [12]. The term South Asian ethnicity is often used, although the South Asian region is diverse, with several countries (Pakistan, India, Bangladesh and Sri Lanka), and differences in culture, religion and diet. In diabetes research, using the term South Asian can nonetheless be justified, in view of the fact that the high prevalence of diabetes and increased insulin resistance is present in the whole region [13], particularly in urban areas, and also after migration to Western countries [1]. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
This study shows a significantly higher fasting (endogenous glucose production) EGP in SA compared to NOR patients, which was not explained by any of the examined possible confounding factors. During clamp hyperinsulinemia the EGP was lowered, and the ethnic difference was
attenuated. Even so, EGP clamp was still not negligible, and constituted almost 40% of TGD in SA and 25% in NOR patients.  XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Hyperinsulinemia during clamp is often said to suppress EGP almost entirely [14,15], and euglycemic clamp studies are still frequently performed without the measurement of endogenous glucose production [16,17]. However, several authors have demonstrated that EGP clamp persists [18–20]. We here present further evidence that EGP clamp can be substantial in type 2 diabetic patients, even with serum insulin concentrations during clamp as high as 1000–1500 pM. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This finding underscores the importance of controlling for hepatic glucose production during clamp studies. Measuring EGP via the isotope tracer dilution method is both time consuming and costly. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In an attempt to find predictors for the estimation of EGP clamp from variables that are easier to measure, we looked at a group of variables which correlated with EGP clamp. Only FPG remained significantly related to EGP clamp in regression analyses, and it explained only 15% of EGP clamp variation in the whole patient group. When looking at the correlations in the separate ethnic subgroups, most variables only correlated significantly in the NOR group. The exogenous glucose infusion rate did not correlate to EGP clamp at all. In the SA group, the only significant correlation was between EGP clamp and TGD, merely reflecting the high percentage of EGPclamp in TGD in this group. We therefore suggest that measuring EGP clamp, in addition to the exogenous glucose infusion rate, is essential for correct estimation of total glucose disposal rate. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Some ethnic groups residing in tropical climates, including SA, have previously been shown to have lower (resting energy expenditure) REE than Westerners [21], however, several authors have advocated the need for adjusting REE for fat free mass (FFM) and fat mass (FM), as well as age and sex [4,22]. The lower REE in SA is in this way shown to be due to differences in body composition and not due to ethnicity per se. We find it to be the case also in our study. Our two ethnic groups display clear differences in body composition, and adjusting for these differences, mainly FFM, attenuates the ethnic difference seen in REE. This, however brings us back to the complex concept and definition of ethnicity, whence it can also be argued that lower FFM is an ethnic characteristic of South Asians. This has been described in other studies [23,24]. In basal, resting conditions, energy production is for the most part derived from lipids, and less from carbohydrates [25]. This is also reflected in our study, by the highly significant correlation between REE and fat oxidation in both ethnicities. In the SA subgroup, however, there is also a near-significant correlation between REE and EGP-basal. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This could signify increased use of carbohydrates as energy substrate in the fasting state in SA, to such an extent that it becomes important for the total REE. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, we did not find any ethnic differences in basal (respiratory quotient) RQ or in (change in respiratory quotient) DRQ from fasting to clamp hyperinsulinemic conditions, that would have clearly indicated an ethnic difference in metabolic flexibility. The values of basal RQ and DRQ in our subjects were comparable to the group with diabetes in the recently published study by van de Weijer [26]. In that study, they also demonstrated that insulin stimulated RQ is mainly dependent on glucose disposal rates, which in our study are similar in the two groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our NOR participants are significantly more obese than the SA, which could in part explain why there is no obvious ethnic difference in (total glucose disposal) TGD. After adjustment for difference in waist circumference, as well as the endogenous glucose production, the ethnic difference in TGD came closer to significance. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In our study we found a non-significant trend towards higher both oxidative and non-oxidative glucose metabolism in SA compared to NOR subjects in the basal, post-absorptive state. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
The total EGP basal was significantly higher. This points towards a higher degree of hepatic insulin resistance in SA. One could speculate that a possible higher basal oxidative glucose metabolism in muscle, triggered by increased substrate availability
from fasting hyperglycemia, leads to less use of lipids as energy substrate, again leading to lipid accumulation and further aggravation of the hepatic insulin resistance, as described in the metabolic inflexibility hypothesis [3]. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In postabsorptive conditions skeletal muscle contribution to total metabolism is modest [3]. A possible ethnic difference in muscle metabolism could thus have been masked. The hepatic insulin resistance could also initially have been caused by increased lipid storage in the liver due to adipose tissue overflow [2]. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Percentage truncal fat was similar in our two ethnic groups, although the NOR group was significantly more obese. In a previous study we found that even though a group of Pakistani and Norwegian subjects with T2D had similar abdominal adipose tissue distribution, the visceral adipose tissue was more metabolically active in the Pakistani subjects (Wium C, Eggesbo HB, Ueland T et al, 2013, unpublished data). An increased supply of NEFA from visceral adipose tissue to the liver would, in addition
to the effect of increasing the insulin resistance, constitute a source of substrate for gluco-neogenesis. Gluconeogenesis is known to be increased in subjects with T2D, being in large part responsible for the increased post-absorptive EGP. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX When using [6,6-2H2] glucose as tracer, Cori cycling is included in the estimation of the total glucose disposal, and has been shown to be increased 25% in T2D in general [27]. It is possible that the increase in non-oxidative glucose metabolism in SA in large part corresponds to increased Cori cycling, due to substrate availability through hyperglycemia in tissues, with lactic acid production in muscle or other tissues by anaerobic glycolysis, then transport back to the liver and re-use as substrate in gluconeogenesis, creating a vicious circle. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The data in this study are baseline results from a vitamin D intervention trial. It was therefore of interest to look for associations between baseline 25-hydroxyvitamin D levels and measures of insulin sensitivity and insulin secretion. We found significantly lower median 25-hydroxyvitamin D levels in the SA group. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Could differences in vitamin D status explain some of the ethnic differences in glucose metabolism? Several epidemiological studies have in recent years shown a relationship between vitamin D and diabetes [28,29], the metabolic syndrome [28], insulin resistance [30,31], and some studies also with insulin secretion [32]. However, in most of the published studies that report significant associations, or an effect of vitamin D intervention, the primary end points have been surrogate markers based on fasting blood values, like the HOMA indices [28, 33, 34]. The few studies using more sophisticated methods, like OGTT, IVGTT or clamps have usually not been able to show similar significant relationships [35–39]. We did not find any association between levels of 25-hydroxyvitamin D and TGD or AIRg. The question therefore still remains whether there is a genuine and causal relationship between vitamin D and diabetes, and we have to await results from randomised, controlled trials.  XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; We have demonstrated higher basal EGP in SA patients with established T2D. Clamp EGP can be substantial in patients with established T2D, and cannot be estimated from the surrogate markers measured. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We found no ethnic difference in insulin sensitivity or in first phase insulin secretion. Findings of near
significant correlations between REE, EE clamp and EGP in the SA group only, might indicate increased post-absorptive glucose metabolism in the SA group, at the expense of lipid metabolism, but these results have to be confirmed in larger studies. Finally, we found no indication of any relation between vitamin D and insulin sensitivity and secretion. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">32</td>
<td class="data">Ethnic variation in the activity of lipid desaturases and their relationships with cardiovascular risk factors in control women and an at-risk group with previous gestational diabetes mellitus: a cross-sectional study</td>
<td class="data">Lipid desaturase enzymes have a wide tissue distribution and we evaluated desaturase activities on the basis of fatty acid compositions in a range of plasma lipid pools. Fatty acids in the FF pool would be expected to reflect adipose tissue metabolism, being largely the product of adipose tissue lipolysis and there is previous evidence for this with respect to SCD-16, SCD-18 and D5D activities [15]. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the TG pool, fatty acids would be expected to reflect fatty acid metabolism in the liver (following VLDL secretion) and be influenced by both recent meal content and by endogenous metabolism. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Fatty acids in the CE pool would also be expected to reflect hepatic metabolism, but would relate to diet over preceding weeks to months. The fatty acid composition of the PL pool is more difficult to interpret [15] and it is, therefore, of interest that there were strong correlations between desaturase activities derived from CE and PL pool fatty acid compositions. Moreover, in general, ethnic differences in desaturase activities and associations between desaturase activities and metabolic risk factors were most apparent when desaturase activities were calculated from the fatty acid compositions of the CE and PL pools. Nevertheless, with standardization for potential confounders, lower SCD-16 activity was apparent in all pools in African Caribbean and Asian Indian women relative to white Europeans. Similar, though slightly less consistent differences were seen with SCD-18 activity. Overall, these observations strongly support the conclusion that white European women have higher SCD activity than Asian Indian or African Caribbean women. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Genetic variation has been reported in Scd-1 [16] but differences in polymorphism frequencies between Asian Indians, African-Caribbeans and white Europeans do not appear to have been described. We found D6D activity to be significantly lower in Asian Indian women relative to white Europeans. D6D metabolises the first step in conversion of the essential fatty acids linoleic (18:2 n-6) and alpha linolenic (18:3 n-3) to longer chain, polyunsaturated fatty acids and our observations are consistent with the proposal that reduced D5D activity might be responsible for lower polyunsaturated fatty acid concentrations in Asian Indians [17]. Genetic variation might underlie the lower D6D activity in Asian Indians but definitive studies of ethnic variation in the Fads2 gene that codes for D6D have yet to be carried out. D5D activity was significantly higher in African Caribbean women relative to white Europeans. D5D metabolises eicosatrienoic acid to arachidonic acid and higher arachidonic acid levels have been reported previously in people of Black African origin [18]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Recent evidence has confirmed an association between high levels of C16 and C18 saturated fatty acids in the plasma PL pool and increased risk of CHD and between high levels of n-6 polyunsaturated fatty acids and decreased risk of CHD [21]. The relatively low SCD activity in Asian Indian women might be expected to be associated with higher C16 and C18 fatty acid levels and the relatively lower D6D activity with lower n-6 polyunsaturated fatty acid levels. Both characteristics we identified in Asian Indians would, therefore, accord with their elevated risk of CHD. However, no such consistencies could be inferred with regard to the relatively low risk of CHD in African Caribbean women. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Independently of ethnicity, SCD-16 activity was positively associated with BMI, waist circumference and serum triglycerides. Positive associations between SCD activity and adiposity have been reported previously [13,14], and a positive association with serum triglyceride concentrations is well-documented [11,22]. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The independent associations we observed between D6D and D5D activity and risk factors were generally similar to those described by others [13,15], with positive associations between D6D activity, adiposity and triglycerides and negative associations between these risk factors and D5D activity. Previous studies have found a positive association between insulin sensitivity and D5D activity, calculated from skeletal muscle phospholipid composition [23,24] but we found little evidence for associations between desaturase activities calculated from plasma fatty acids and either glucose levels or insulin sensitivity. The single positive association noted between insulin sensitivity and D5D activity derived from fatty acid ratios in the TG pool and may have been a chance finding. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX With regard to ethnic variation in risk of T2DM, it could be speculated that the lower SCD activities in African Caribbeans and Asian Indians might contribute to increased levels of saturated fatty acids, increased levels of which may be associated with increased risk of T2DM [25,26]. However, given the overall lack of association between diabetes risk factors and desaturase activities, it seems unlikely that ethnic variation in desaturase activity contributes to ethnic variation in risk of T2DM.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; Despite low SCD activities in African Caribbeans and Asian Indians possibly contributing to a tendency to higher C16 and C18 saturated fatty acid levels, it seems unlikely, given the absence of any association between desaturase activities and plasma glucose concentrations or insulin resistance, that ethnic variation in desaturase activities contributes to ethnic variation in risk of T2DM. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Similarly, variation in desaturase activities showed no consistency with the lower risk of CHD in African Caribbeans. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, the relatively low D5D activity we observed in Asian Indian women suggests a contribution from lower desaturase activities to the higher risk of CHD in Asian Indians. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">33</td>
<td class="data">Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement</td>
<td class="data">We summarized important areas for future research in areas of race / ethnic and sex disparities in endocrine disorders based on our literature review for this statement in Table 10. We also summarize in Table 11 areas for future research to address race / ethnic disparities in diabetes generated from the 2011 Strategic Planning Report of the Diabetes Mellitus Interagency Coordinating Committee (18, 19) that supplement those highlighted by our review. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Several important themes emerged in examining our current understanding of disparities in endocrine disorders. Compared with NHW populations, there are certain disorders for which NHB populations have a lower incidence (e.g. macrovascular complications of diabetes mellitus and osteoporotic fractures) or a similar incidence (e.g. thyroid cancer); however, once they have the disorder, NHBs have worse outcomes and higher mortality. This is likely related to inadequate access to high-quality health care among minority populations. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, NHBs with diabetic nephropathy have lower mortality on dialysis than NHWs, despite a higher incidence of ESRD. Understanding the factors contributing to better survival will be beneficial in extending dialysis survival for other race / ethnic groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although osteoporotic fractures are more common in NHW women, preventive interventions should target all race / ethnic groups to reduce the morbidity and mortality associated with fractures. In addition to exploring the etiology for these disparities in clinical, population based, and health services research studies, basic science and translational studies are also needed to explore underlying molecular mechanisms that may contribute to disparities.  XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Obesity is an important contributor, not only to diabetes risk in minority populations, but also to sex disparities in thyroid cancer, which is more common in women. This suggests that population interventions targeting weight loss may have a favorable impact, even on non-diabetes-related endocrine disorders. Our statement also highlights important implications regarding the definition of obesity in different race / ethnic groups. Fat distribution is an important determinant of risk of metabolic disorders such as type 2 diabetes and CVD, and there is evidence that current cut-points for WC may underestimate disease risk in Asian-Americans and overestimate disease risk on NHB women. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX . NHW females suffer osteoporotic fractures more frequently than their male counterparts; XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">34</td>
<td class="data">A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects</td>
<td class="data">increased fat accumulation in the liver (steatosis) =&gt; tightly correlated with insulin resistance + T2D (6). Modestly elevated bile acid levels =&gt; decrease steatosis (7). Loss of the nuclear receptor LRH-1 =&gt; decreases bile acid levels (1, 2). Suggests =&gt; LRH-1 agonist =&gt; increase bile acids =&gt; decrease steatosis =&gt; improve fatty liver. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Dilauroyl PC (C12:0/C12; DLPC) + diundecanoyl PC (C11:0/C11:0; DUPC) =&gt; strong stimulation on LRH-1. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX PLPC + DUPC BUT NOT the bile acid (BA) cheno-dexycholic acid (CDBA) or the more conventional phospholipid dipalmitoyl PC (C16:0/C16:0, DPPC) also activated the synthetic LRH-1 reporter. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX DLPC + DUPC responsiveness was not altered in mutant LRH-1 derivatives previously shown to inactivate responses to LRH-1 phosphorylation (10) or sumoylation (11), BUT was strongly decreased by mutations shown to block phospholipid binding . XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX DLPC + DUPC =&gt; failed to activate PPARa.  PPARa is specifically bound + activated by 1-palmitoyl-2-oleoyl (C16:0/c18:1) PC12, + C16:0/c18:1 PC failed to affect LRH-1 transactivation. XXXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX DLPC =&gt; no effect on rosiglitazone binding to PPAR-y. A stringent test of specific binding. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX DLPC + DUPC act in vitro as LRH-1 agonists. Functional results =&gt; may also act directly as agonists in vivo. Unclear =&gt; how they might transit the cell membrane + cytosol and enter the nucleus. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Both CA and DUPC/DLPC treated mice showed =&gt; decreased serum fatty acids (NEFA) and hepatic triglycerides (TG) =&gt; associated with decreased serum glucose =&gt; in DUPC/DLPC, BUT NOT =&gt; CA treated mice. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX DLPC treatment =&gt; substantially improved glucose homeostasis =&gt; LRH-1 f/f DIO mice =&gt; indicated by GTT/ITT + these responses were absent in LKO DIO mice. DLPC treated LRH-1 f/f DIO mice =&gt; decreased fasting serum glucose + insulin levels =&gt; 80% decrease in homeostatic model assessment of insulin resistance (HOMA-IR). XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX LRH-1 is required for antidiabetic effects of DLPC. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Sphingolipids =&gt; sphingosine + lyso-sphingomyelin =&gt; potential endogenous  antagonists =&gt; SF-1 transactivation (19) XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The beneficial effect of DLPC on steatosis =&gt; significantly decreased expression of the transcription factor SREBP-1c + downstream lipogenic targets. Two complimentary mechanisms contribute to this decrease. SREBP-1c =&gt; autoregulates its own expression XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">35</td>
<td class="data">Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41)</td>
<td class="data">The high expression level of GPR41 in sympathetic ganglia =&gt; indicates that GPR41 might play an important role in these cells. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  A series of in vitro and in vivo studies with GPR41 -/- mice showed =&gt; that an SCFA propionate potently activates SNS at sympathetic ganglia.  XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The mechn of GPR41-mediated activation of sympathetic ganlion neurons is not mediated by cAMP inhibition =&gt; but rather involves GBy and MAPK signalling.  XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Furthermore =&gt; the major ketone body B-Hydroxybutyrate =&gt; antagonizes SCFA-GPR41 signalling + thereby inhibits SNS.  XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX   As SCFAs + ketone bodies reflect the nutrient conditions =&gt; these monocarboxylic metabolites =&gt; appear to control energy balance by directly regulating GPR41-mediated sympathetic activation XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The GPR41-SNS activation pathway may work as one of the important physiological mechanisms for these metabolic fuels to regulate body energy balance. GPR41 had been reported to be expressed in adipose tissue in mice (19) + humans (14) + to stimulate leptin secretion (18, 19). XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Recent studies =&gt; however =&gt; have reported that GPR41 =&gt; is not expressed in mouse adipose tissues (29 - 32). Our quantitative RT-PCR (qRT-PCR) analysis also found that GPR41 is not detected in mouse adipose tissues. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast to GPR41 =&gt; we found that GPR43 is highly expressed in mouse adipose tissues by qRT-PCR =&gt; confirming previous reports (28). Because propionate can activate GPR43 (14) =&gt; it is possible that propionate can affect the SNS by GPR43-mediated effects on adipocytes =&gt; especially by secretion of leptin =&gt; potently  activate the SNS (33) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However =&gt; administration of propionate induced a similar extent of alterations in metabolic parameters + leptin levels in wild-type + GPR41 -/- mice =&gt; propionate-activated GPR43 responses in GPR41 -/-  mice were similar to wild-type mice. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The results further confirmed the previous reports that SCFAs =&gt; can promote leptin secretion from adipose + not via GPR41 (29, 30). Taken together =&gt; the results showed that the effects of SCFAs on SNS activity may not be mediated by their effects on adipocytes from which adipocytokines such as leptin that can change sympathetic nerve activity can be secreted. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX GPR41 is a Gi/o-coupled G protein-coupled receptor (GPCR) related to =&gt; inhibition of cAMP production (17). In general =&gt; Gi/o-coupled GPCRs =&gt; work as an inhibitory system. However =&gt; our study shows that activation of GPR41 by SCFA excites the SCG neurons by generating action potential =&gt; releases noradrenaline from sympathetic nerve terminals =&gt; showing that GPR41 mediates an excitatory signalling. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Recently =&gt; many excitatory responses in a variety of cell systems have been reported to be mediated via GBy but not via Ga(i/o) (34). Our study =&gt; selective antagonists for Ga(i/o) and GBy also showed that =&gt; GPR41-mediated excitation of SCG neurons =&gt; mediated by GBy signalling but cAMP inhibition by Ga(i/o) is not. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Furthermore =&gt; our siRNA experiments showed that =&gt; GPR41-mediated activation of sympathetic neurons involves PLCB and MAPK signalling (35, 36) + because GBy signalling activates MAPK signalling via PLCB in Gi/o-coupled GPCRs (34) =&gt; our results may indicate that GPR41-induced sympathetic activation involves GBy-PLCB-MAPK signalling. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Under fed conditions =&gt; a substantial proportion of total dietary energy intake derives from SCFAs produced via the colonic fermentation of dietary fibres by gut microbiota (5 - 10%) (37). XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Levels of SCFAs in the gastrointestinal tract vary significantly =&gt; depending on the amount of non-digestable fibre in the diet + also relate to the composition of the gut microbiota. Change in the amount + compostion of the gut microbiota =&gt; implicated in cardiovascular diseases + obesity in humans (38, 39). Ketogenic conditions =&gt; have been suggested as a reason for the increased incidence of cardiac disorders (40, 41). Furthermore =&gt; SCFAs have recently been reported to profoundly affect inflammatory responses via the chemoattractant receptor GPR43 (15). XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">36</td>
<td class="data">alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population</td>
<td class="data">Using a non-targeted biochemical screening approach in a large and well characterized cohort of non-diabetic subjects representing a wide spectrum of insulin sensitivity, we identified a–hydroxybutyrate (a–HB) as a biomarker segregating with clamp-derived IR in subjects with normal glucose tolerance. Furthermore, a–HB segregated with dysglycemia (IFG+IGT) independently of, and in
addition to, IR. Importantly, these associations were independent of sex, age, and BMI. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Thus, together with other biomarkers, a–HB may provide a diagnostic tool to identify IR and/or IGT earlier than currently used clinical tests. a–HB is an organic acid derived from a-ketobutyrate (a–KB) (Figure 7). a–KB is produced by amino acid catabolism (threonine and methionine) and glutathione anabolism (cysteine formation pathway) and is metabolized to propionyl-CoA and carbon dioxide [25]. a–HB is formed as a by-product during the formation of a–KB via a reaction catalyzed by lactate dehydrogenase (LDH) or a–hydroxybutyrate dehydrogenase (a–HBDH) (Figure 7), an LDH isoform present in the heart [26]. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Accumulation of a–HB is postulated to occur in vivo when either XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (a) the formation of a–KB exceeds the rate of its catabolism, which leads to substrate accumulation, or XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (b) there is product inhibition of the dehydrogenase that catalyzes the conversion of a–KB to propionyl-CoA [25,27]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX a–KB is also produced as a result of the conversion of cystathionine to cysteine. Under conditions of increased oxidative stress, a higher flux of cysteine into production of glutathione, the primary antioxidant in cells, occurs from a shift in homocysteine production from transmethylation of methionine to transsulfuration of homocysteine to produce cystathionine [28] (Figure 7). XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In one report, a–HB was associated with excess glutathione demand and disrupted mitochondrial energy metabolism and shown to derive from hepatic glutathione stress [28], supporting the idea that elevated a–HB may be associated with increased oxidative stress in the IR state. a–HB may become elevated by at least two mechanisms:  XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (1) elevation of hepatic glutathione stress resulting in an increased demand for glutathione production, and XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (2) elevation of the NADH / NAD + ratio due to increased lipid oxidation. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The first mechanism likely contributes to increased a–HB formation by supplying more a–KB substrate from increased cysteine anabolism (Figure 5). Consistent with this interpretation, we observe statistically significant elevation of both a-KB and cysteine with increasing insulin resistance from the global screening data (Figures 2 &amp; 5, Table 2), similar to the trend observed with a-HB. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In support of the second proposed mechanism, increased lipid oxidation is a metabolic feature of IR, and is indexed by the insulin-inhibited FFA concentration [7,14]. Our finding of a positive association between steady state FFA and plasma a–HB concentrations in the whole cohort supports the possibility that an increased NADH/NAD + ratio favors reduction of a–KB to a–HB (Figure 7). XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Changes in other important IR-associated metabolites within metabolic pathways leading to the formation of a-KB and a-HB are highlighted in Figure 7. For example, reduced levels of glycine (Figure 6E) and serine upstream of a-KB formation may be consistent with increased gluconeogenesis which is observed with IR in db- / db- mice [29]. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our interpretation that a redox imbalance may contribute to elevated a-HB in the context of IR is consistent with our finding that branched-chain alpha-keto acids, such as 3-methyl-2-oxobutyrate, are elevated with IR (Table 3). These increases may be due to the effect of the redox imbalance on the directionality of the dehydrogenases that reduce / oxidize these keto acids (Figure 7). In addition, a-HB has also been observed to be elevated in T2D subjects and animal models of T2D, as well as in severe lactic acidosis and ketoacidosis [25, 27, 30, 31, 32, 33, 34]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Interestingly, in normal subjects and T2D patients, it has been shown that restoration of the NADH / NAD + redox balance by glutathione infusion therapy resulted in improvement of insulin sensitivity and b-cell function in normal subjects and in T2D patients [35]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In a recent study comparing the urinary profiles of 98 intermediary metabolites measured by targeted MS in 74 obese and 67 lean individuals, Newgard et al. identified a metabolic signature for the accumulation of branched-chain amino acids, the glutamine / glutamate couple, several acylcarnitines, and some aromatic amino acids (phenylalanine and tyrosine) using principal component analysis [36]. These metabolites were also related to insulin resistance (as determined by the HOMA index) and interpreted as marking the metabolic consequences of excessive fat and protein intake, with impairment of insulin signaling and mitochondrial overload. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It is noteworthy that in the non-targeted metabolomics approach of the present study, lipid molecules, branched-chain amino acids, and acylcarnitines were also featured among the top 30 metabolites that RF analysis associated with the M value (Figure 2). The current data narrow down the complex interactions of amino acid and lipid metabolism [37] to highlight the importance of a single marker, a–HB, which may reflect oxidative burden in the context of IR. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX With an unmet need for a practical clinical test that accurately measures IR in individuals, identification of a–HB as a significant biomarker for separating IR from IS subjects using a fasting plasma sample could lead to development of such a diagnostic test. a–HB in combination with other biochemical and clinical parameters may also prove to be useful as a clinical indicator of subclinical abnormalities of glucose metabolism. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">37</td>
<td class="data">miR-375 enhances palmitate-induced lipoapoptosis in insulin-secreting NIT-1 cells by repressing myotrophin (V1) protein expression</td>
<td class="data">Previous studies have consistently demonstrated that there is a progressive deterioration in β-cell function and β-mass in type 2 diabetes [10], and the reduction of β-mass is attributable to the accelerated apoptosis, in which elevated circulating free fatty acids (FFAs) are one of the pivotal predisposing factors responsible for β-cell apoptosis [16;17]. Recent studies highlighted the importance for one particular islet specific miRNA, mir-375, in the regulation of β-cell function and the maintenance of normal pancreatic α- and β-mass [26;27]. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the present study, we further examined the role of mir-375 in the regulation of palmitate-induced β-cell lipoapoptosis. We found that NIT-1 cells, a NOD derived β-cell line, with ectopic mir-375 duplexes are much more susceptible to palmitate induced lipoapoptosis. In contrast, NIT-1 cells are remarkably resistant to palmitate-induced lipoapoptosis once the endogenous mir-375 was suppressed by a specific antisense oligo, 2&apos;-O-Me-375. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our study also demonstrates that the expression levels of V1 protein are inversely associated with β-cell lipoapoptosis. Since V1 could be a target for mir-375 [27], our data suggest that mir-375 probably enhances β-cell lipoapoptosis by downregulation of V1 expressions in β cells. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The cellular population for a particular organ is determined by the balance between the rates of cell division and programmed cell death named apoptosis. Once the apoptosis rate for a particular cell type becomes higher than that of cell replication, a reduction for cell population would occur, which subsequently leads to organ decompensation. Loss of β-mass late in the course of obesity is a typical example that β-cell apoptosis exceeds cell division, which then predisposes to the development of type 2 diabetes. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Lipoapoptosis, a type of apoptosis caused by dysregulated lipid metabolism, has recently been recognized to occur in obesity and aging. Excessive accumulation of long-chain fatty acids is associated with altered leptin liporegulation and, as a result, when non-adipose tissues such as pancreatic islets are exposed to an excess of long-chain fatty acids, the cell would undergo lipoapoptosis. The effect of thermal, hypoxic or cytotoxic factors on apoptosis has been well demonstrated [32], while metabolic causes of programmed cell death, particularly lipoapoptosis, have received less attention. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although recent studies in ZDF (fa/fa) rats suggested an important role for the ceramide pathway in the late destructive phase of lipid overload in the pancreatic β cells [16], the overall underlying mechanisms leading to lipoapoptosis remained poorly understood. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our studies in the current report provided strong evidence indicating a pivotal role for miRNA in the regulation of β-cell lipoapoptosis. Although we are only beginning to appreciate the immense potential of miRNAs as controllers of gene networks, there is already substantial evidence that these small non-coding RNA molecules play a central role in a variety of physiological processes, including tissue differentiation, cell proliferation, and apoptosis. miRNAs are a growing class of non-coding RNAs involved in the regulation of gene expression by translational repression. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Islet-specific mir-375 is originally characterized by Poy and colleagues from analysis of miRNAs in endocrine cell types of the pancreas [27]. Recent functional studies indicated that mir-375 plays an indispensable role in normal glucose homeostasis, β-mass turnover in newborns and adaptive β-cell expansion in response to increasing insulin demand in insulin resistance [26]. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data now provide evidence indicating that mir-375 could also act as a proapoptotic factor implicated in the pathogenesis of β-cell lipoapoptosis. Studies have shown that some evolutionarily conserved proteins characterized in neuronal cells are also present in the pancreatic β cells. V1 is such a protein that is highly expressed in both neuronal cells and pancreatic β cells. V1 (also known as myotrophin) is a 12-kD protein, which was originally identified from the hypertrophied ventricles of spontaneously hypertensive rats and rat cerebellum [33;34]. By 3-dimensional alignment, Knuefermann and colleagues demonstrated that mammalian V1 resembles a truncated IκBα without the signal response domain and PEST sequence [35]. Therefore, V1 was later validated as an anti-apoptotic factor in cardiac myocytes, neuronal cells and fibroblasts [36-38]. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the current study, we further noticed that the expression levels for V1 in NIT-1 cells are inversely associated with palmitate-induced lipoapoptosis, indicating that V1 could also act as an antiapoptotic factor in maintaining β-cell viability. Of important note, we limited our study in the current report to one of the pivotal targets for mir-375, the pancreatic islet-specific V1 protein. It is possible that mir-375 also targets additional factors implicated in the regulation of β-cell apoptosis. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For example, a recent study also suggests that mir-375 could target PDK1 mRNA, a key molecule for PI 3-kinase signaling in the pancreatic β cells [29], which has been demonstrated to be involved in the regulation of cell survival and proliferation [39;40]. Therefore, multiple signaling pathways could be regulated by mir-375, by which mir-375 enhances β-cell lipoapoptosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The modified synthetic anti-miRNA oligonucleotides (AMOs) were found to be useful tools for specific repression of targeted miRNA expressions, thereby helping to unravel the function of miRNAs and their targets. The 2′-O-methyl oligonucleotides have been shown to irreversibly inhibit small RNA function in vitro and in intact cells in a sequence-specific fashion, presumably by stoichiometric binding to RISCs containing the cognate miRNA, and thus preventing interaction with its mRNA targets [41]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Similar to antisense-based oligonucleotides (ASOs), AMOs may contribute to the prioritization of pharmaceutical targets and have the potential to eventually progress into a new class of therapeutic agents. Here we have designed a 2′-OMe modified anti-mir-375 oligonucleotide, 2′-O-me-375, and demonstrated its high potency for repression of endogenous mir-375 expressions in NIT-1 cells (Figure 2). As 2′-O-me-375 transfected NIT-1 cells were almost completely protected from palmitate-induced lipoapoptosis (Figure 3), 2′-O-me-375 could be a useful “off-target” reagent for mir-375 with significant implications in both experimental and clinical studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; Impaired β-cell function and possibly β-mass deficit appear to be reversible, particularly at the early stage of disease when the limiting threshold for reversibility of the decreased β-mass has probably not been passed. Our data in the current report indicate that mir-375, a pancreatic islet-specific miRNA, could be a pivotal regulator of lipoapoptosis in the pancreatic β cells.   XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">38</td>
<td class="data">Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity</td>
<td class="data">There is growing evidence that subtle aberrations in lipid metabolism occur in obesity and T2DM. As advanced MS/MS technology for detection of altered AcylCN levels enables the detection of mild defects in FAO, we hypothesized that it would also detect FAO defects in obese participants with or without T2DM. Although our primary focus has been on skeletal muscle FAO, plasma AcylCN could also be derived from other tissues, such as liver and cardiac muscle.  XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, in a study in which elevated AcylCNs were observed in serum and skeletal muscle from insulin-resistant rats, there was no increase observed in liver, suggesting that the serum AcylCN originated mainly from the skeletal muscle (9). XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our results show that both obese and T2DM subjects with similarly increased NEFAs and similar BMIs equally accumulated AcylCNs of both full-length fatty acids and of the first intermediates of β-oxidation. The T2DM subjects also accumulated a wide variety of later β-oxidation intermediates. When NEFA release was inhibited by short-term insulin clamp, plasma AcylCN values were reduced, with a significantly blunted response in the T2DM subjects, as would be expected if they are “metabolically inflexible” (4). Interpretations were based on AcylCN profiles of patients with known genetic disorders of mitochondrial FAO (8). XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The AcylCN profile includes substrates of both fatty acid and amino acid β-oxidation. Even-chain AcylCNs containing up Integrative Physiology to 20 carbons accumulate in response to incomplete fatty acid β-oxidation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, amino acid catabolism produces odd-chain- length species such as C3–CN and C5–CN, although C4–CN can be derived from either amino acid or fatty acid metabolism. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Acetyl (C2)–CNs derive from carbohydrate catabolism and from the ultimate product of β-oxidation, acetyl- CoA. After an overnight fast, FAO is stimulated, increasing saturated AcylCN levels while branched-chain amino acid (BCAA) metabolism is spared, reducing C5 entry from leucine and isoleucine, resulting in reduced C5–CN levels.  XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX As both obese and T2DM subjects had similarly elevated NEFAs during fasting, the next question is whether they efficiently process this flood of fatty acids. One locus of regulation is the limitation of entry into β-oxidation by CPT1, which trans-esterifies the activated longchain acyl-CoA to its AcylCN before entry into mitochondria. This regulation limits C16–, C18–, and C18:1–CN levels, resulting in increased free-CN:C16–CN. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, both obese and T2DM groups had similarly elevated C16–, C18–, and C18:1–CN and free-CN, with the free-CN:C16–CN ratio decreased in obese participants (P &lt; 0.05) with a similar trend in T2DM participants (P &lt; 0.07) (Table 3). XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This finding is inconsistent with CPT1-based limitation of β-oxidation flux. Thus, in both obesity and T2DM, similar quantities of NEFAs are readily activated into AcylCN that can either pass into the mitochondria via carnitine AcylCN translocase or can exit the cell for other disposal. Inside, the AcylCN is deesterified back to acyl-CoA and enters the β-oxidation spiral. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We also observed increased levels of C14:1–CN and C16–OH–CN, species that arise from activity in the initial rounds of β-oxidation involving very-long-chain acyl-CoA dehydrogenase and longchain 3-hydroxyacyl-CoA dehydrogenase, respectively, yielding unaltered C14:1–CN:C16–CN and the C16–OH–CN:C16–CN ratios. This overall pattern is consistent with obese and T2DM subjects having similarly increased initial fluxes through β-oxidation in response to elevated NEFAs rather than having a CPT1 generated block, as had been suggested previously (5). With AcylCNs of ≤10 carbons, the pattern of AcylCN accumulation by groups diverged. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Most straight-chain- and hydroxy-AcylCN products from these later steps of β-oxidation (medium- and short-chain processing) accumulated in a stepwise pattern from non-significant elevations in the obese subjects to significant elevations in the T2DM subjects (Figures 2 and 3), with several species significantly increased in T2DM relative to both the obese and lean subjects. In addition, the C8–CN:C16–CN ratio was significantly increased in the T2DM relative to the obese subjects, supporting this trend toward a more severe defect in the T2DM participants. The trends are consistent with a study of rat diabetic myocardium, which found that overall AcylCN levels increased with an accumulation of 3-OH–AcylCNs (14). XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Thus, T2DM subjects display a second more global defect in their mitochondrial function that is characterized by an enhanced accumulation of intermediates such as the chain shortened straight-chain products of FAO (C4– to C14–CN) characteristic of a more generalized dysfunction in either FAO or at the interface of FAO and the ETC (15). In addition, they accumulate intermediates from substrates that would be expected to decrease in quantity rather than accumulating during fasting, such as the products of BCAA oxidation (C5–, C5–OH–, and C3–CN). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX As the BMI, waist circumference, and basal free fatty acid levels of the T2DM subjects were nearly identical to levels in the obese subjects, the more “abnormal” AcylCN patterns are not due to increased body fat or basal NEFA levels but most likely result from IR. The insulin infusion studies further support the hypothesis that the T2DM participants differ in their FAO regulation. Overall, in response to insulin infusion, all AcylCN species decreased significantly. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This finding verifies that plasma AcylCN species are responsive to short-term alterations in NEFA levels. However, the T2DM subjects had a blunted decrease in the levels of many AcylCNs, leading to an AcylCN pattern that did not normalize to the extent observed in the obese group. The higher NEFA levels and lower RQ seen in the T2DM participants during insulin infusion, suggest that the insulin clamp did not block release of free fatty acids or flux into β-oxidation to the degree found in either lean or obese participants. This finding is consistent with the hypothesis that T2DM participants exhibit metabolic inflexibility (4). Only one other group has reported decreased plasma AcylCNs (C10–, C12–, and C14:1–CN) with elevated insulin and that was in response to an oral glucose tolerance test (16). XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX One marker of abnormal FAO was specifically associated with T2DM. C4DC–CN levels in
T2DM were nearly double than those observed in obese or lean participants. Furthermore, C4DC–CN correlated highly with fasting plasma glucose (r = 0.72) and with HbA1c (r = 0.74). Consequently, this AcylCN species may be a biomarker at the intersection of combined gluco and lipotoxicity (17,18). It should be noted that C4DC–CN as identified using this methodology represents the sum of both methyl-malonyl-carnitine and succinyl-carnitine, which have the same molecular mass. Therefore, additional analyses will be required to specifically identify the affected species. However, whether the elevation is due to methyl-malonyl-carnitine and / or succinyl-carnitine, this finding is consistent with our observation of increased C3–CN and suggests a potential defect in the utilization of succinyl-CoA in the tricarboxylic acid cycle in T2DM. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our findings are consistent with recent reports in rodents and in cell culture showing that insulin-resistant skeletal muscle displays increased incomplete β-oxidation, resulting in increased AcylCN intermediates in serum and muscle (9,19,20). When rats were fed a high fat diet, obesity and IR were induced and many of the same AcylCN species we observed in humans were increased in serum and skeletal muscle (9). Muscle AcylCNs were even more elevated in Zucker diabetic fatty rats, a model of severe IR where incomplete FAO has been experimentally confirmed (10). These rodent data indicate that IR in skeletal muscle is associated with excessive (at least in the fed state) yet incomplete β-oxidation (fed and fasted state) and impaired switching to carbohydrate substrate during the fasted-to-fed transition. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Two recent human studies comparing AcylCN patterns in lean and obese (21) or obese individuals with or without T2DM (22) observed some of the same patterns we observed in this study. The first study reported no increase in C2–CN and similar elevations of four of the AcylCN that we observed in obese participants (21). Higher C3– and C5–CNs and BCAAs were observed in obese individuals, and these metabolites correlated with degree of IR (21). In addition, they observed elevations of C6– and C8:1–CN. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXIn contrast, another recent study found that women with T2DM had decreased C3–CN with increased C2–CN levels compared to obese women (22). However, consistent with our findings, they also observed that T2DM subjects accumulated medium-chain intermediates. Although we cannot explain these discrepant findings, the lean participants in the first study appeared to have impaired fasting glucose (100.5 mg/dl) and a higher percentage of males (70 vs. 57%, P = 0.09440) and the second study was limited to African-American women, who have been shown to have a lower FAO compared to the matched white women (23). XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Nonetheless, there is general agreement for the association of T2DM with accumulation of medium-chain fatty acid intermediates and for IR to be associated with excessive BCAA metabolism. However, these contradictory studies along with our finding that when results were examined by sex, nearly all of the increases in BCAA-derived CN metabolites (C3–CN and C5–CN) in T2DM relative to obese subjects occurred in male subjects suggest that BCAA metabolism may be regulated differently by race and sex or even by some other unexpected variable such as BCAA composition of the diet (21). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; In summary, the circulating AcylCNs in obese and T2DM participants fall into two distinct patterns. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First, the T2DM and obese participants have a similar accumulation of long-chain AcylCNs and AcylCN species that arise from activity in the initial rounds of β-oxidation, consistent with increased flux at entry into mitochondrial β-oxidation. Diabetic participants also displayed a secondary accumulation of many shorter chain AcylCNs that are suggestive of inefficient complete FAO or interactions between β-oxidation and ETC. They also showed an inability to efficiently switch from fat metabolism during the insulin clamp, as
reflected in their inability to lower their AcylCNs as effectively as either the lean or obese  subjects. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, the elevation in C4DC–CN in the T2DM participants is intriguing; its robust correlation with two indexes of glycemic control supports its association with elevated blood glucose. As such, it is possible that C4DC–CN may be a useful biomarker of gluco-and lipotoxicity in T2DM.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">39</td>
<td class="data">Microbiota and SCFa in Lean and Overweight Healthy Subjects</td>
<td class="data">Recent reports =&gt; possible correlation between the human gut microbiota =&gt; obesity. There is a focus on the significance of the human microbiota to wellbeing (16, 22, 26, 40). XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Assumption =&gt; proportional representation of the Firmicutes + Bacteroidetes =&gt; may play a role in the development of obesity (22, 40). XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Members of both groups produce =&gt; SCFA from dietary compounds which escape digestion in the small intestine =&gt; thus supplying the host with an additional amount of energy. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXNormal colonic epithelia derive 60 - 70% of their energy from SCFA, particularly butyrate (41) XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Proprionate =&gt; largely absorbed by the liver =&gt; precursor for gluconeogenesis, lipogenesis + protein synthesis (42, 43). XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Acetate =&gt; enters the peripheral circulation to be metabolised by peripheral tissues =&gt; substrate for cholesterol synthesis (21) XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Within our study group =&gt; total SCFA content =&gt; increased significantly from 84.60 mmol/l in lean =&gt; 103.87 mmol/l =&gt; obese subjects.XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Known proprionate producers =&gt; belonged to the genera Bacteroides + Prevotella =&gt; joint cells numbers were more numerous in overweight (P = 0.001) volunteers. Note =&gt; Bacteroidetes =&gt; increased in overweight + obese subjects. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Note =&gt; Bacteroidetes =&gt; increased in overweight + obese subjects. This study consistent with previous studies =&gt; which showed that despite weight loss =&gt; no change in the relative counts of the Bacteroides spp or percentage of Firmicutes (44, 47) =&gt; thus the assumption that it is not the ratio of Firmicutes and Bacteroidetes that is important =&gt; but rather the amount of SCFA produced. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX When carbohydrate intake was lowered in their study =&gt; acetate proportion increased, butyrate decreased + proprionate remained unaffected (order unchanged) (44). XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Leaner people =&gt; had a higher ratio of acetate to butyrate + propionate. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The respective ratio =&gt; was higher, only slightly, in lean volunteers of our study. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Increase in the proportion of Bacteroides spp. which are the major representatives of the Bacteroidetes =&gt; from lean to obese subjects =&gt; but in contrast to earlier reports =&gt; linked an increased ratio of Firmicutes to Bacteriodetes + high amounts of SCFA to obesity (16, 22, 23). XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Conversely =&gt; unable to identify any correlation of obesity with higher proportions of Firmicutes or higher concns of methanogenic Archaea in obese volunteers. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX   Interestingly =&gt; redn of Bacteroidetes + bifidobacteria =&gt; has influence on obesity (49) XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">40</td>
<td class="data">Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins</td>
<td class="data">W-3-PUFAs alleviates obesity induced insulin resistance + advanced hepatic steatosis. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Beneficial effects of W-3-PUFAs  =&gt; upregulation of genes involved in insulin sensitivity =&gt; PPAR-y, glucose transport =&gt; GLUT-2 + GLUT-4, insulin receptor signalling =&gt; IRS-1 + IRS-2 in both adipose tissue + liver. Also expression + production of potent anti-inflammatory, antisteatotic + insulin-sensitizing adipokine =&gt; adiponectin + induced phosphorylation of AMPK. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Decrease in W-6-PUFA-derived eicosanoids (PGE2 + 5-HETE) + increased prodn of =&gt; protective W-3-PUFA-derived lipid mediators (protectins + resolvins) =&gt; mimicked insulin sensitizing + antisteatotic effects of W-3-PUFAs. Effects of resolvins + protectins more potent than their W-3-PUFA precursors   XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX W-3-PUFAs =&gt; reduced formation of eicosanoids from 5-lipoxygenase pathway of arachidonic acid metabolism. The 5-lipoxygenase pathway is an established potent steatogenic factor in obese mice. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Inhibition of arachidonic acid derived eicosanoids =&gt; increased synthesis of bioactive intermediaries from W-3-PUFAs =&gt; 17-HDHA, resolvin D1, + protectin D1, BUT not resolvin E1 (because resolvin E1 was below the limit of detection from our samples). These oxygenated products of W-3-PUFAs =&gt; evoke potent protective actions =&gt; in nanomolar + picomolar ranges =&gt; resolution of unremitting inflammation. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Obesity =&gt; low grade inflammation. W-3-PUFAs =&gt; lipid mediators (protectins + resolvins) =&gt; resolution of local inflammation =&gt; underlie beneficial effects of these compounds on insulin resistance + hepatic steatosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  Current study =&gt; strong support =&gt; increased intake of W-3-PUFAs =&gt; prevent metabolic liver disease + similar to the improved outcomes reported in arthritis, cystic fibrosis, IgA nephropathy, diabetes, ulcerative colitis, Crohn&apos;s disease asthma + sepsis XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Sum of findings in current study + reported literature =&gt; W-3-PUFAs =&gt; reduce incidence of necroinflammatory liver injury; strong rationale for dietary supplementation with W-3-PUFAs in patients with liver disease. W-3-PUFAs dietary supplementation could be given to marginal steatotic liver donors, currently excluded due to presence of macrovesicular steatosis XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">41</td>
<td class="data">Insulin resistance and body fat distribution in South Asian men compared to Caucasian men</td>
<td class="data">This study first compared characteristics of body fat content and
distribution between South Asian and Caucasian men having similar BMI. It then examined the functional characteristics of adipose tissue, particularly as related to insulin sensitivity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX BMI, WAIST CIRCUMFERENCES, AND % TOTAL BODY FAT =&gt; For a given BMI or waist circumference, South Asian men had approximately 6% higher total body fat than Caucasian men. Our findings indicated that the threshold for obesity in South Asians is approximately 2 kg/m2 lower than in Caucasians. A waist circumference of 10 cm lower in South Asians confers a similar estimate of % body fat. The findings correspond to reported data [12]. These discrepancies should be considered to be indicative of body fat content, and adjustments required for BMI or waist circumferences to define obesity do not entirely account for possible differences in inherent insulin resistance in the South Asian population. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX ETHNIC DIFFERENCES IN VISCERAL FAT =&gt; We did not find that South Asians preferentially deposit fat in visceral adipose tissue. Even though South Asians had a higher % body fat, they did not have a higher absolute amount or % of total fat as visceral fat (Table 1). This was particularly evident when the two groups were matched for % body fat (Figure 3). XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In fact, ratios of intraperitoneal fat / abdominal subcutaneous fat were higher in Caucasian men than in South Asians. The ratios observed in Caucasians are similar to those reported for a large population of Caucasian men in the Dallas Heart Study [13]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The lower ratios found in South Asians indicate that they are not prone to preferential deposition of body fat in the visceral compartment; this makes it unlikely that the increased insulin resistance found in South Asians can be explained by preferential accumulation of visceral fat. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX TRUNCAL SKINFOLDS AND HIP CIRCUMFERENCE =&gt; In spite of higher % body fat for a given BMI in South Asians, there were no differences in hip circumferences between the two groups, or in waist-to-hip ratios. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX On the other hand, truncal skinfolds thicknesses were higher in South Asians. This implies that South Asians show a preferential accumulation in truncal fat over gluteofemoral fat. Thus, if South Asians have preference for body fat compartmentalization, it is for truncal subcutaneous fat, and not visceral fat. This finding is consistent with our previous reports, which have also shown a strong relationship between  subcutaneous fat and insulin resistance [3,9]. Furthermore, we have for the first time shown that truncal skinfolds predict % total body fat independent of ethnicity (figure 1). XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX ADIPOCYTE SIZE =&gt; A potentially important finding in this study was that South Asians had larger abdominal subcutaneous adipocytes than Caucasians. This was true even when the two groups were compared at similar body fat contents (Figure 3). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX There is a growing body of evidence that large adipocytes are dysfunctional. Large adipocytes have been shown to predict insulin resistance and type 2 diabetes independent of obesity [14]. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance [15]. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It is conceivable that genetic factors influencing adipocyte size may play a role in insulin resistance. Even if a predisposition to insulin resistance observed in South Asians cannot be attributed to preferential accumulation of visceral fat, it can still be asked whether all of the excess insulin resistance observed in the South Asian population can be explained by a hidden high body-fat content, or perhaps an excess of truncal subcutaneous fat. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX As shown previously [3] and again in Figure 2, increasing body fat content is accompanied by progressively lower insulin-mediated glucose disposal rates. This makes it likely that a portion of the greater insulin resistance observed in South Asians can be explained by ‘‘hidden’’ obesity, i.e., excess body fat content not seen with standard BMI or waist circumference measurements. It is further possible that a predisposition for deposition of fat in the trunk accentuates insulin resistance.  XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Previous studies have shown that truncal fat is metabolically more active than lower body fat [16,17]. If so, a maldistribution of body fat in South Asians could contribute significantly to their greater insulin resistance. This study provides several lines of evidence to support the concept that preferential accumulation of truncal fat in South Asians is accompanied by a metabolic profile that predisposes to insulin resistance and type 2 diabetes. The finding of large adipocytes is consistent with previous studies showing ‘‘dysfunctional’’ characteristics of large cells. In our study, abdominal adipose size was inversely correlated with both glucose disposal rates and with adiponectin levels (Figure 2B and 2C).  XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further, when subgroups were matched for % body fat, adipocytes size was still significantly greater in South Asians. In addition, glucose disposal rates and adiponectin levels were lower, and leptin levels were higher in South Asians (Figure 3) confirming our previous reports [18]. The current study thus provides insights as to why South Asians are predisposed to insulin resistance compared to Caucasians. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First, for a given BMI, waist circumference, or waist-to-hip ratio they carry a higher % total body fat than Caucasians. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, they preferentially accumulate body fat in truncal (and abdominal) Subcutaneous adipose tissue (although not in visceral adipose tissue). This maldistribution of body fat gives rise to metabolic abnormalities beyond total body fat such has been previously reported. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX And third, South Asians have larger adipocytes, higher NEFFA and lower adiponectin which suggest a dysfunctional adipose tissue playing a role in metabolic abnormalities beyond total and truncal fat.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXCONCLUSIONS =&gt; This study shows that when South Asian men are compared to Caucasians, they have a higher % total fat for a given BMI and they preferentially accumulate this fat in truncal adipose tissue. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, they do not preferentially accumulate intraperitoneal fat. Truncal adipose tissue in South Asians is characterized by abnormally large adipocytes which likely are dysfunctional—as shown by high levels of NEFA and low levels of adiponectin. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These abnormalities in adipose tissue appear to contribute importantly to increased insulin resistance observed in South Asians. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">42</td>
<td class="data">Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men</td>
<td class="data">These studies demonstrate that the prevalence of insulin resistance in healthy, young, lean Asian-Indian men is 3- to 4-fold greater than lean men of other ethnic groups. Furthermore, when adjusted for the (insulin sensitivity index) ISI, this increased prevalence of insulin resistance in Asian-Indian men was associated with an ~2-fold increase in (hepatic tri-glyceride) HTG content and plasma IL-6 concentrations compared with Caucasian men. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, there were no differences in the prevalence of insulin resistance among Asian-Indian women compared with the other ethnic groups, suggesting a potentially important protective role of estrogen in this process (16, 17). XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX There is increasing evidence for a causal relationship between hepatic steatosis and hepatic insulin resistance both in rodent models with hepatic steatosis and in patients with non-alcoholic fatty liver disease (4, 18–25). Short-term high-fat feeding in rats has been shown to result in hepatic steatosis and hepatic insulin resistance, which were both reversed after treatment with the mitochondrial uncoupling agent 2,4-dinitrophenol (21). XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Comparable results were observed in patients with severe lipodystrophy where chronic leptin replacement therapy was shown to reverse their hepatic steatosis and hepatic insulin resistance (18). In addition, rosiglitazone treatment in patients with T2DM has been shown to lower HTG content and ameliorate hepatic insulin resistance (26, 27). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, recent studies have demonstrated that a relatively small weight loss (~8 kg) in patients with poorly controlled T2DM reversed their hepatic steatosis and normalized fasting plasma glucose concentrations, rates of hepatic glucose production, and hepatic insulin responsiveness (19). XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The molecular mechanism of fat-induced hepatic insulin resistance is unclear; however, recent studies in rodents suggest that intracellular increases in diacylglycerol activates protein kinase Ce, which activates a serine kinase cascade that in turn blocks insulin stimulation of IRS-2 tyrosine phosphorylation, an early step in insulin signaling (21, 22, 25). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Recent studies have also suggested that visceral adiposity may play an important role in causing hepatic insulin resistance through its release of fatty acids and adipocytokines to the liver via the portal vein (28–31). However, we found no differences in the circulating concentrations of adiponectin or TNF-a between the Asian-Indian men and Caucasian men, suggesting that these adipocytokines are not likely playing a major role in causing the increased prevalence of insulin resistance in the Asian-Indian men. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, we did observe an ~2-fold increase in plasma IL-6 concentrations in the Asian-Indian men that persisted even after adjustment for the ISI. Recent studies in rodents have demonstrated that acute infusions of IL-6 caused insulin resistance in both liver and skeletal muscle (32). Whether this increase in plasma IL-6 concentration is playing a causative role for the increased prevalence of insulin resistance in the Asian-Indian men or is secondary to the hepatic steatosis and insulin resistance remains to be determined. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We also assessed pancreatic B cell function in a subgroup of Asian-Indian men and Caucasian men and found that there was an ~30% increase in basal   cell responsivity (Phib) in the Asian-Indian men compared with the Caucasian men. However, this compensatory increase in pancreaticB cell function was inadequate for their degree of insulin resistance as reflected by a 60% reduction in the disposition index in the Asian-Indian men. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; In summary, the results of this study indicate that the prevalence of insulin resistance is 3- to 4-fold higher in young, lean, healthy Asian-Indian men compared with men in other ethnic groups. This increase prevalence in insulin resistance in the Asian-Indian men was associated with increased HTG content
and plasma IL-6 concentrations. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These data suggest that Asian-Indian men may be genetically predisposed to develop hepatic steatosis and hepatic insulin resistance at a lower BMI than other ethnic groups. Furthermore, increased prevalence of non-alcoholic fatty liver disease in the Asian-Indian men has important implications for future health risks in these individuals because this condition is associated with steatohepatitis, which may progress to cirrhosis and end-stage liver disease. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, these data suggest that there are significant ethnic differences in the pathogenesis of insulin resistance between Asian-Indian men and Caucasian men, which may have important therapeutic implications for prevention and treatment of T2DM in this ethnic group and possibly explain the lower efficacy of lifestyle intervention in the Indian diabetes prevention study compared with the U.S. and Finnish diabetes prevention studies (33–35). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">43</td>
<td class="data">Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study</td>
<td class="data">The present report yielded several novel findings: (1) A broad range of abnormalities in lipoprotein composition precedes the onset of diabetes; (2) the associations for small HDL particle concentration and large VLDL size were independent of the greater insulin resistance present in prediabetic subjects; and (3) the findings were consistent across glucose tolerance categories and in the 3 ethnic groups of the IRAS.  XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These results are based on 2 different statistical approaches: (1) logistic regression analyses with incident diabetes as the dependent variable and (2) ANCOVA models with the lipid variables of interest as respective dependent variables. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Both approaches yielded similar results, which strengthens the results of the present study and the conclusion we would like to draw from these results. Thus, the present study provides evidence that abnormalities in lipoprotein composition occur before the onset of type 2 diabetes and therefore might contribute to the increased cardiovascular disease risk in prediabetic subjects. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although we believe that the highly significant findings (P=0.001) are robust, given the number of hypotheses tested and our use of stepwise methods, replication in other data sets is warranted. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In one previous report (in which gradient gel electrophoresis was used), the preponderance of small LDL particles was identified as a risk factor for the development of diabetes in elderly individuals (8).  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  In this study, subjects with small dense LDL particles had a &gt; 2-fold increased risk of incident diabetes over 3.5 years, independent of age, sex, glucose intolerance, and body mass index. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Adjustment for either fasting insulin or triglycerides, however, rendered the association nonsignificant, suggesting that small dense LDL reflects underlying insulin resistance (as represented by elevated triglycerides and/or elevated fasting insulin levels) rather than a causal relation between this lipoprotein phenotype and the development of diabetes.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX No measure of insulin resistance is available from this report. In the present study, LDL size, as assessed by NMR technology, was also related to incident diabetes, but adjustment for insulin resistance (as directly measured) rendered this association non-significant. This indicates that the association of LDL size to incident diabetes is indeed explained by the (inverse) association of LDL size with insulin resistance, as shown in previous cross-sectional studies.(19, 20). XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the present study, VLDL particle size and small HDL particles, rather than LDL particle size, emerged as significant contributors to incident diabetes. The relation of these 2 lipoprotein particle measures to incident diabetes was independent of metabolic covariates, including insulin resistance. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This is potentially important because in previous reports, both VLDL size and small HDL particles (21) or HDL size (inversely) (3,21) have been related to increased insulin resistance. Additionally, these and other NMR-identified lipoprotein abnormalities, which were prevalent in patients with type 2 diabetes, have been attributed to the underlying increased insulin resistance in these patients rather than the diabetic state itself (21) NMR technology has been used to investigate compositional lipoprotein abnormalities in several previous studies involving diabetic populations, including diabetic mice, (22) patients with type 1 diabetes, (23,24) patients with type 2 diabetes, (21,25) or individuals with insulin resistance (21). XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In a cross-sectional study, a relation of small HDL to renal dysfunction was shown in patients with type 1 diabetes (23). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In a placebo-controlled intervention trial, atorvastatin reduced concentrations of medium and small VLDL, as well as large and medium LDL, and increased concentrations of large HDL (25).  XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our findings were consistent in the 3 ethnic groups of the IRAS as well as in subjects with NGT or IGT at baseline, but we found a gender interaction reaching borderline significance in the logistic regression models. Such a finding would be supportive of previous analyses from the San Antonio Heart Study, indicating that prediabetic women have a greater burden of cardiovascular risk factors than men (26) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, because of the relatively small number of cases of incident diabetes in women (n = 76) and in men (n = 53), respectively, this finding needs to be interpreted with caution. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX How might a relation of lipoprotein size and subclass composition to incident diabetes be explained? First, a causal relationship might exist, ie, alterations in lipoprotein size and subclass composition might directly affect the pathophysiology of type 2 diabetes, namely, increased insulin resistance and/or impaired insulin secretion. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Free fatty acids are released from VLDL particles, and an excess of free fatty acids, in turn, has been shown to directly affect insulin resistance, namely, by inhibiting hepatic glycogen synthesis and glucose oxidation. (27) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Furthermore, we have shown in the present study that the relation of VLDL size to incident diabetes is attenuated after adjustment for insulin resistance, as directly measured. This indicates that increased insulin resistance in prediabetic individuals contributes (to some extent) to the demonstrated associations. Accordingly, in a previous report in which clamp techniques were used to assess insulin resistance, large VLDL particle concentration was suggested as the primary abnormality underlying the complex lipoprotein subclass pattern associated with increased insulin resistance (high serum triglycerides, decreased LDL size, increased overall LDL particle concentration, decreased large and increased small HDL particles) (21).  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, common genetic factors might underlie both the demonstrated lipoprotein abnormalities and diabetes risk. A number of studies have demonstrated that small dense LDL is genetically influenced, (28) and a common polymorphism in the cholesteryl ester transfer protein gene affects HDL and LDL particle size (29). XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Potential candidate genes linking insulin resistance and dyslipidemia include the hepatic lipase gene and the fatty acid binding protein gene 2. (30) XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, lipoprotein abnormalities associated with the risk of developing diabetes might indicate a pro-atherogenic state in prediabetic individuals. It has indeed been shown in previous reports that the prediabetic state is characterized by an increased prevalence of cardiovascular risk factors (4 –7). The present report extends this knowledge; abnormalities of size and composition of both VLDL and HDL particles have been related to cardiovascular disease. (24, 31–33). XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the present study the lipoprotein parameters in prediabetic subjects resembled that in overt diabetic patients rather than that in non-converters (Table 2). The view of a pro-atherogenic risk profile in prediabetic individuals is further supported by data from the Nurses’ Health Study, showing that the risk of developing cardiovascular disease in prediabetic women was increased, even before the onset of diabetes (10) XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX   The present study provides supportive data that might explain this finding; whether these demonstrated pro-atherogenic lipoprotein abnormalities in prediabetic individuals are related to increased insulin resistance or rather impairment in insulin secretion is the topic of further ongoing analyses. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In summary, we have shown a range of lipoprotein abnormalities in prediabetic individuals. These findings extend previous work indicating a pro-atherogenic state in healthy, non-diabetic subjects who subsequently develop diabetes. This finding has important clinical and public health implications, providing a rationale for an aggressive prevention strategy in individuals at high risk of developing diabetes, such as those with IGT. Such a prevention strategy yields the potential to favorably affect diabetes incidence and also, and equally importantly, the development of cardiovascular disease.</td>
</tr>
<tr>
<td class="r data">44</td>
<td class="data">DHHC7 Palmitoylates Glucose Transporter 4 (Glut4) and Regulates Glut4 Membrane Translocation</td>
<td class="data">4 out of 23 ectopically expressed DHHC proteins (DHHC2, DHHC3, DHHC7 + DHHC15) =&gt; were able to palmitoylate GLUT4. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX DHHC3 + DHHC7 =&gt; showed strong interaction with GLUT4. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First conclusion =&gt; DHHC3 + DHHC7 =&gt; might represent =&gt; PATs for GLUT4. DHHC7 KO mouse tissues =&gt; silenced GLUT4 palmitoylation BUT NOT in DHHC3 KO mouse tissues =&gt; final conclusion =&gt; DHHC7 is a major PAT for GLUT4. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Knockdown of DHHC7 in CHO-IR cells + 3T3-L1 adipocytes + primary adipocytes =&gt; impaired insulin-dependent GLUT4 membrane translocation XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX DHHC7 KO mice =&gt; developed hyperglycaemia + showed glucose intolerance =&gt; similar to GLUT4 adipose + muscle-specific KO mice (19 - 21) =&gt; confirming that  =&gt; DHHC7 regulates GLUT4 palmitoylation + plasma membrane insertion  XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Higher levels of overexpression of DHHC proteins =&gt; did not result in more efficient substrate palmitoylation =&gt; oligomerization of DHHC proteins =&gt; known to suppress PAT activity (42) XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In Summary =&gt; 1) identified DHHC7 as the major palmitoyl acyltransferase for GLUT4; 2) DHHC7 plays an important role in the regulation of insulin-dependent GLUT4 PM translocation + body glucose homeostasis. Study =&gt; implicates =&gt; DHHC proteins =&gt; glucose metabolism. Still a lot to be understood about DHHC7 + its regulation in glucose metabolism</td>
</tr>
<tr>
<td class="r data">45</td>
<td class="data">Lipids and glucose in type 2 diabetes: what is the cause and effect?</td>
<td class="data">From an initial perception that a disorder of glucose metabolism was the primary event in the pathogenesis of type 2 diabetes, there is now a growing appreciation that chronic elevation of FFA levels is an early event that contributes to the development of this disease. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX FFAs induce insulin resistance, which increases with FFA levels, and this can be a beneficial adaptive response during starvation and pregnancy. However, insulin resistance can become counterproductive when there is an excess of energy intake associated with physical inactivity. The extra fuel is stored in visceral and subcutaneous fat depots. As fat accumulates, there is an ongoing increase in the levels of plasma FFAs, which causes insulin resistance. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, the deficit of another product of adipose tissue (e.g., adiponectin) may contribute to increased insulin resistance. To counter insulin resistance and prevent hyperglycemia, insulin levels increase. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In individuals with a genetic predisposition for diabetes, however, the pancreas cannot compensate for the increased secretory demands placed on it, resulting in type 2 diabetes. The pivotal role of FFAs in the development of insulin resistance and type 2 diabetes suggests that the optimal therapeutic intervention should decrease plasma FFA levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The PPAR family is intimately involved in lipid metabolism. Two subtypes of these receptors are the site of action of synthetic PPAR agonists: PPAR-a and PPAR-Y. The former increases fatty acid oxidation, whereas the latter results in the redistribution of fat from visceral to subcutaneous body fat and an increase in adiponectin. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The outcome of activation of PPAR-Y is a lowering of plasma FFA concentrations and improved insulin sensitivity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The effects of PPAR-a on lipid metabolism may also bring about improvements in insulin sensitivity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The currently available PPAR agonists selectively activate either PPAR-a (i.e., fibrates) or PPAR-Y (i.e., TZDs) and have been shown to improve lipid metabolism. It may be that dual agonism with PPAR-a/Y agonists will provide additional benefits above and beyond those achieved with sole activation of either PPAR-a or PPAR-Y. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">46</td>
<td class="data">Ethnicity and type 2 diabetes: focus on Asian Indians</td>
<td class="data">5. PREVENTION OF DIABETES IN ASIAN INDIANS: TARGETING INSULIN RESISTANCE =&gt; 5.1 DIET AND EXERCISE =&gt; Reduction in dietary fats and caloric intake will promote weight control and reduce insulin resistance. Dietary composition may independently affect insulin resistance. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Regular exercise increases the number of capillaries surrounding muscle fibers and also increases the skeletal muscle fiber composition that favors insulin-mediated glucose disposal (Utriainen et al., 1996). Bouts of exercise stimulate translocation of GLUT-4 to the plasma membrane and increase glucose transport in skeletal muscle (Thorell et al., 1999). The signal that mediate exercise-induced GLUT-4 recruitment differs from those that mediate insulin-induced recruitment, in that insulin receptor expression and PI-3-kinase activity is not required for the exercise effect (Lund, Holman, Schmitz, &amp; Pedersen, 1995; Wojtaszewski et al., 1999). Instead, activation of the 5-AMP-activated kinase may have a role (Hayashi, Hirshman, Kurth, Winder, &amp; Goodyear, 1998). Exercise-induced production of NO and subsequent production of cyclic GMP may be involved in the regulation of glucose transport in muscle, independent of the effects of NO on vasodilatation (Young, Radda, &amp; Leighton, 1997). X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Bradykinin may also play a role in exercise-induced glucose transport, since it is released from muscle during exercise and, in cells expressing bradykinin receptors, it stimulates GLUT-4 translocation (Kishi et al., 1998). Muscle has high levels of bradykinin receptors, and as with the glucose uptake stimulated by exercise, bradykinin-stimulated glucose uptake is not blocked by inhibitors of PI-3 kinase (Kishi et al., 1998). XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The beneficial effect of exercise on insulin activity has recently been confirmed in the IRAS (Mayer-Davis et al., 1998). There is some evidence that implementation of dietary modification and regular exercise is feasible and is an effective modality for prevention of diabetes. In a Swedish non-randomized study (Eriksson &amp; Lindgarde, 1991), a 6-year intervention with diet and exercise advice resulted in 50% reduction in the incidence of diabetes in middle-aged men who volunteered to participate in the intervention group compared to those who were not willing to participate and thus served as controls. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Pan et al. (1997) reported on the marked decline in cumulative incidence of diabetes among subjects with IGT in the City of DaQing in China after 6 years of intervention with either a diet, exercise, or combined diet and exercise program. The incidence of diabetes was 67.7% in the control group compared with 43.8% in the diet group, 41.1% in the exercise group, and 46% in the diet plus exercise group. Interestingly, the intervention was equally successful in normal weight and obese people. The incidence of new diabetes was exceptionally high in this study where randomization was made by the clinic and not by the individual. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The Finnish Diabetes Prevention Study included lifestyle modifications to prevent diabetes in middle-aged IGT subjects and showed feasibility of lifestyle intervention in motivated individuals (Uusitupa et al., 2000). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A similar study is being conducted in US by the NIH. The results of these studies will provide evidence for effectiveness of diet and exercise to prevent or delay the onset of diabetes in high-risk individuals. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 5.1.1 BIGUANIDES =&gt; Although the liver is the primary site of action of the biguanide drugs such as metformin, in vivo studies indicate that metformin also increases glucose uptake into peripheral tissues (Inzucchi et al., 1998). Metformin improves glycemic control in monotherapy and in combination with other hypoglycemic agents. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Metformin may also delay or prevent the onset of diabetes in high-risk individuals. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX THIAZOLIDINEDIONES (TZDs) =&gt; TZDs increase the disposal of glucose in peripheral tissues in animals and humans with insulin resistance, including subjects with type 2 diabetes (Inzucchi et al., 1998). How these agents increase insulin-mediated glucose
uptake is unclear. They appear to act as a ligand for a nuclear receptor, the peroxisomal proliferator-activated receptor-g (PPAR-g), augmenting the insulin action by enhancing insulin signaling at a post-receptor step (Lehmann et al., 1995). The effects of these agents in skeletal muscle may be direct or indirect. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Treatment of insulin-resistant rodents with TZDs restores the expression and translocation of GLUT-4 in adipocytes (Hofmann, Lorenz &amp; Colca, 1991). XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX TZDs also overcome the TNF-a-induced inhibition of insulin-stimulated glucose transport in adipocytes (Szalkowski, White-Carrington, Berger, &amp; Zhang, 1995). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In insulin-resistant rats given high-fat diets and insulin-deficient rats with streptozocin-induced diabetes, TZD treatment increases insulin-stimulated glucose uptake in muscles (Hofmann et al., 1991). TZDs do not increase the expression of GLUT-4 in rodent muscle or human muscle cells, although they do induce expression of GLUT-1 (Ciaraldi &amp; Henry, 1997). Furthermore, TZDs do not restore defective insulin-stimulated GLUT-4 translocation in muscle in insulin-resistant Zucker rats (Hirshman, Fagnant, Horton, King, &amp; Horton, 1995).</td>
</tr>
</tbody>
</table>
</div>
</div>
</body>
</html>
